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Summary 
Development of selectively targeted therapeutic agents could produce more effective 
treatments for disease via improved efficacy and reduced toxicity.  This is of 
particular importance in cardiovascular disease and cancer where current therapies 
often possess wide ranging and harmful adverse effects.  Biological agents, including 
peptides and gene delivery systems (here recombinant adenoviral vectors), can be 
improved via targeting the system towards specific cell types, tissue beds and 
organs.  This has the potential to significantly increase the therapeutic index of these 
agents. 
In cardiovascular disease, oxidative stress is implicated in disease pathogenesis.  
Potential anti-oxidant therapies have shown limited effectiveness in clinical trials 
partly due to diverse patient populations and differences in the type and strength of 
the anti-oxidants used.  Therefore, development of a targeted anti-oxidant therapy 
may potentially improve efficacy.  The reactive oxygen species superoxide (SO) is 
produced by NAD(P)H oxidase in the vasculature and reduces nitric oxide (NO) 
bioavailability, leading to endothelial dysfunction.  The anti-oxidant peptide gp91ds 
selectively inhibits assembly of NAD(P)H oxidase, thereby reducing SO production.  
Vascular-targeting peptides CRPPR and CSGMARTKC were previously identified 
by T7 phage display in mice.  These peptides retained their selectivity in another 
species as determined in the normotensive Wistar Kyoto rat (WKY) and in a model 
of human essential hypertension, the stroke-prone spontaneously hypertensive rat 
(SHRSP).  In the SHRSP, CRPPR targeted to the heart with a 17-fold increase over 
insert-less control phage and had a 58-fold increase in targeting to the aorta.  
Immunohistochemical analysis with an anti-T7 antibody showed that CRPPR-
inserted phage localised to both endothelial cells and medial smooth muscle cells.  
CSGMARTKC selectively homed to the heart (specifically the coronary vasculature) 
with a 26-fold increase over control phage.  Therefore, an efficacy study to assess 
whether linkage of gp91ds to a vascular-targeting peptide could increase the anti-
oxidant effect in the SHRSP was performed. 
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Animals were subjected to radio-telemetry recording 10 days before peptide infusion 
to continuously monitor blood pressure (BP), heart rate and activity.  Peptides were 
continuously administered at 10 mg/kg/day for 21 days by subcutaneous osmotic 
mini-pumps.  Systolic BP was determined for one week prior to treatment, followed 
by three weeks of study duration before sacrifice.  Systolic BP showed a progressive 
rise from 177.6 ± 1.1 mmHg to 200.6 ± 0.7 mmHg in those groups receiving 
CSGMARTKC-gp91ds, HIV-tat-gp91ds (to allow entry to all cells), gp91ds alone 
and the control animals.  This systolic BP increase, which is characteristic of the 
SHRSP animal model, was completely prevented in animals receiving CRPPR-
gp91ds (systolic BP 187.5 mmHg ± 5.2, * p < 0.001 vs. other treatment groups and 
control group).  CRPPR-gp91ds, CSGMARTKC-gp91ds and gp91ds alone showed 
significantly improved NO bioavailability, determined by ex vivo large vessel 
myography, whereas HIV-tat-gp91ds treated animals continued to show impaired 
endothelial function, characteristic of the SHRSP.  Therefore, the anti-oxidant 
therapy alone shows improvement in NO bioavailability.  However, when the anti-
oxidant peptide was targeted with CRPPR, a significant improvement in NO 
bioavailability and attenuation of the time-dependent and progressive increase in 
systolic BP in the SHRSP was observed.  This demonstrates the potential of 
targeting biologically active peptides to defined cells in vivo. 
A related but alternative approach to targeting was to utilise adenoviral vectors.  
Recently, the interaction between adenovirus (Ad) 5 and the blood coagulation factor 
X (FX) was shown to be pivotal for liver transduction.  FX binds directly to the 
hexon of Ad5 and this interaction leads to hepatocyte transduction in vivo.  Vectors 
based on the sub-species B Ads, including Ad35, are in development for cancer gene 
therapy as the Ad35 fiber uses the membrane glycoprotein CD46 as a high affinity 
cellular receptor instead of the coxsackie and adenovirus receptor (CAR), the 
primary receptor for the Ad5 fiber.  CD46 is up-regulated in many cancers.  
Previously, it was shown that FX binds to Ad35 and, based on this, the Ad35:FX 
interaction was investigated in detail using Ad5, Ad35 and a range of chimeric 
Ad5/Ad35 vectors: the pseudotype Ad5/f35, which contains the hexon and penton of 
Ad5 with the Ad35 fiber (f), Ad5/p35/f35, which has the Ad5 hexon and the penton 
(p) and fiber of Ad35, and Ad35/f5, the reverse pseudotype.  By electron 
cryomicroscopy at 31Å resolution, FX was observed bound to the Ad35 hexon.  The 
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ability of the chimeric vectors and Ad35 to bind FX was analysed by surface 
plasmon resonance (SPR).  SPR analysis revealed that Ad5, Ad35 and the chimeric 
Ad5/Ad35 vectors all bound to FX.  Both the Ad5 and Ad35 pseudotypes have FX 
binding affinities akin to other vectors possessing the same hexon, with vectors 
containing the Ad5 hexon having an approximately ten-fold higher affinity for FX 
than those vectors containing the Ad35 hexon. 
In CHO-CD46 cells, the presence of FX had no significant effect on binding by 
vectors containing Ad35 fibers (Ad5/f35, Ad5/p35/f35 and Ad35).  However, the 
presence of FX significantly inhibited transduction by Ad5/f35, Ad5/p35/f35 and 
Ad35 by 2.7-, 1.9- and 2.2-fold, respectively, in CHO-CD46 cells.  This inhibition of 
transduction by FX could be prevented by the addition of the FX binding protein, X-
bp.  This suggests that FX limits a post-binding or post-internalisation mechanism(s) 
that leads to cellular transduction by vectors containing the Ad35 fiber. 
Vectors were intravenously administered to CD46 transgenic mice in the presence 
and absence of X-bp to assess vector targeting in vivo.  Localisation of the luciferase 
expressing vectors was visualised by whole-body bioluminescence and transgene 
expression was quantified by luciferase assay.  Vector genome (VG) accumulation 
was also quantified by qPCR.  Ad5 selectively targeted to the liver as expected in the 
CD46 transgenic mice, an effect significantly inhibited by X-bp.  Liver accumulation 
by all other vectors was substantially lower that that for Ad5 and X-bp significantly 
further reduced liver vector accumulation by Ad5/f35, Ad5/p35/f35, Ad35 and 
Ad35/f5.  This suggests that FX binding to both Ad5 and Ad35 hexon mediates liver 
accumulation and that this can be, at least partially, reduced by inhibition of the 
virus:FX interaction by X-bp.  In the absence of X-bp, Ad5/f35 and Ad5/p35/f35 
exhibited high levels of lung vector accumulation with 5.6x105 and 5.7x105 
VG/50ng of total DNA isolated, respectively.  Ad5 demonstrated very poor lung 
targeting.  Pre-administration of X-bp significantly reduced genome accumulation in 
lung by Ad5/f35 and Ad5/p35/f35 1.9- and 6.6-fold, respectively.  However, lung 
transduction by Ad35 was significantly enhanced by 1.6-fold in the presence of X-
bp.  Additionally, in vivo Ad35 had an increased lung:liver ratio in the presence of 
X-bp indicating accumulation of this vector in the lung after the removal of the FX 
interaction.  Therefore, due to its selective lung targeting ability and low 
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seroprevalence development of a vector based on Ad35, which had been modified to 
ablate the interaction with FX, would be a highly useful tool to selectively target 
CD46 and tumours in vivo by intravascular administration. 
In summary, selective targeting of an anti-oxidant peptide to the vasculature has led 
to a significant enhancement in the efficacy of the anti-oxidant peptide gp91ds.  By 
targeting defined cells in vivo, this anti-oxidant has increased potential effectiveness 
compared to alternative anti-oxidant therapies.  Additionally, administration of a 
variety of Ad35-based vectors has led to increased understanding of the requirements 
needed for the generation of a successfully targeted Ad35 vector.  Together this 
helps to identify the potential requirements for development of more appropriate 
treatments for cardiovascular disease and cancer. 
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1.1 General introduction 
There is a continual need for identification and testing of new and more effective 
treatments for many diseases due to the lack of optimal pharmacological 
interventions.  This is of particular importance in cardiovascular disease and cancer, 
due to the sheer number of patients affected by these conditions and as the developed 
therapies often have wide ranging and harmful adverse effects.  Selective targeting 
of therapeutic agents is a potential method of reducing their delivery to non-target 
cells and organs. 
Biological agents, including peptides and gene delivery systems (recombinant 
adenoviral vectors) have potential utility in disease treatment.  However, their 
efficacy is limited.  Therefore, optimisation by targeting such agents to specific cell 
types, tissue beds or organs may improve efficacy and therapeutic indices. 
1.2 Cardiovascular disease 
Cardiovascular disease refers to all diseases which affect the heart and circulatory 
system and includes hypertension, coronary heart disease, angina, myocardial 
infarction (MI) and stroke.  Although there have been many significant advances in 
treatment options and medications available to help to control symptoms and reduce 
the risk of further problems, cardiovascular disease is the most common cause of 
death in the UK (www.bhf.org.uk).  29% of men and 23% of women suffer a 
premature death due to cardiovascular disease (www.heartstats.org.uk).  This has led 
to the need to develop more effective treatments for specific aspects of 
cardiovascular disease. 
Hypertension is a chronic medical condition in which the blood pressure (BP) is 
elevated.  Hypertension can be classified as either essential (primary) or secondary 
hypertension.  Essential hypertension has no single clear medical cause and accounts 
for over 90% of hypertension cases (Carretero and Oparil, 2000, Oparil et al., 2003).  
However, there are several risk factors which have been shown to contribute to the 
development of essential hypertension, including smoking, obesity, high alcohol 
consumption, lack of exercise and high salt intake.  Secondary hypertension occurs 
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due to another condition, such as kidney disease or tumours of the adrenal medulla 
and adrenal cortex, which produces hypertension due to increased secretion of 
catecholamines or steroids, respectively.  Persistent hypertension increases the risk 
of stroke, MI and heart failure (Carretero and Oparil, 2000). 
In the 2002 World Health Organisation (WHO) World Health Report 
(www.who.int/whr/2002/en/whr02_en.pdf), hypertension was identified as the 
second most important cause of death and disability in developed countries.  In 
Scotland, 33% of men have a BP over 140/90 mmHg and a 20 mmHg increase in 
systolic BP or 10 mmHg increase in diastolic BP in patients aged 40-69 years 
doubles the risk of death (www.heartstats.org).  Hypertension causes the smooth 
muscle cells (SMCs) in the media of resistance arteries to proliferate, reducing the 
lumen diameter and further increasing peripheral resistance.  The rise in systolic BP 
also increases the work load of the left ventricular myocytes in the heart and this can 
lead to cardiac hypertrophy, where the cardiac myocytes increase in length and width 
in order to thicken the wall of the heart to normalise ventricular wall tension.  This 
remodelling causes the ventricles of the heart to become stiff, leading to impaired 
filling and diastolic dysfunction.  Over time the abnormal reduction in myocardial 
contractility caused by cardiac hypertrophy can predispose the individual to heart 
failure. 
The National Institute for Health and Clinical Excellence (NICE) guidelines for the 
treatment of hypertension in the UK have been published (www.nice.org.uk/ 
nicemedia/pdf/HypertensionGuide.pdf).  Hypertensive patients are commonly 
treated with one or more of the following antihypertensive medicines: angiotensin 
converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, calcium-
channel blockers, diuretics and beta-blockers.  ACE inhibitors reduce the formation 
of angiotensin II and aldosterone, which leads to reduced vascular tone and 
extracellular fluid volume and thus reduced BP.  Angiotensin II receptor antagonists 
and calcium-channel blockers act as vasodilators to widen resistance arteries, 
reducing peripheral resistance.  Diuretics increase water and salt excretion, thereby 
reducing extracellular fluid, blood volume and BP.  Beta-blockers reduce cardiac 
output and hence reduce BP.  However, high doses of antihypertensive drugs are 
often not effective during chronic administration and can cause side effects.  The 
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adverse effects produced by antihypertensives include a dry cough produced in 
response to ACE inhibitors, fatigue and cold peripheries due to beta-blockers and, 
headaches with treatment by calcium-channel blockers. 
The therapeutic benefit of the available agents for treating cardiovascular disease 
could be substantially enhanced by targeting them towards specific areas of the 
cardiovascular system.  In addition, cardiovascular disease has now been shown to 
have a considerable genetic influence.  Therefore, biological agents capable of 
delivering functional genes to correct mutations which lead to cardiovascular 
disorders could be highly effective tools at preventing the morbidity and mortality 
produced by cardiovascular diseases. 
1.2.1 Oxidative stress 
Oxidative stress is produced by an imbalance between the generation and removal of 
reactive oxygen species (ROS), which leads to the presence of excessive ROS.  ROS 
are reactive chemical entities and can be classified as either free radicals or non-
radical derivatives.  Free radicals possess one or more unpaired electrons and these 
include the superoxide anion (SO or O2-), the hydroxyl radical (HO.) and nitric oxide 
(NO).  Hydrogen peroxide (H2O2) and peroxynitrite (ONOO-) are not free radicals 
but contribute to oxidative stress as they also have the ability to oxidise other 
molecules.  The production of one ROS has the potential to produce many others due 
to radical chain reactions (Cai and Harrison, 2000).  At low concentrations, ROS act 
as signalling molecules and are involved in many cellular processes, including cycle 
regulation (Harris and Levine, 2005), proliferation (Harris and Levine, 2005, Kobori 
et al., 2007), cell growth (Frazier et al., 2007), differentiation (Riou et al., 2001) and 
apoptosis (Harris and Levine, 2005, Su et al., 2006).  However, at high 
concentrations, ROS elicit a plethora of harmful and toxic effects, in particular, ROS 
are key mediators that contribute to inflammation and atheroma (Cai and Harrison, 
2000). 
Production of ROS at levels exceeding the handling capacity of the endogenous anti-
oxidant defence mechanisms leads to oxidation of biological macromolecules, 
including DNA, protein, carbohydrates and lipids (Cai and Harrison, 2000).  
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Oxidative stress has been implicated in the pathogenesis of many cardiovascular 
diseases, including hypertension, atherosclerosis, diabetes mellitus, MI and heart 
failure (Cai and Harrison, 2000, Griendling et al., 2000, Neunteufl et al., 2000, 
Schachinger et al., 2000, Berry et al., 2001, Heitzer et al., 2001, Gokce et al., 2002, 
Madamanchi et al., 2005a, Madamanchi et al., 2005b). 
Possibly the most important ROS in the vasculature is SO.  The major source of SO 
are the membrane-bound enzymes nicotinamide adenine dinucleotide (phosphate) 
(NADH/NAD(P)H) oxidases in vascular and cardiac tissues (Figure 1.1) (Cai and 
Harrison, 2000).  These enzymes are thought to be responsible for the excessive 
generation of SO seen in many cardiovascular diseases as they primarily control the 
redox state of blood vessels and the myocardium (Griendling et al., 2000).  
NAD(P)H oxidase catalyses the reduction of molecular oxygen, using NADH or 
NADPH as the electron donor, producing SO at the cell surface (Berry et al., 2001). 
NAD(P)H + 2O2 → NAD(P)+ + H+ + 2O2- 
Functional NAD(P)H oxidases have been shown to be present in the endothelium 
(Gorlach et al., 2000), vascular smooth muscle (Rajagopalan et al., 1996, Laursen et 
al., 1997) and adventitia (Rey et al., 2002).  In the vasculature, several isoforms of 
NAD(P)H oxidases are present.  The membrane bound subunit gp91phox or Nox2 is 
expressed in endothelial cells (ECs) and the adventitia (Gorlach et al., 2000, Rey et 
al., 2002), Nox1 is expressed in vascular smooth muscle cells (VSMCs) (Lassegue et 
al., 2001) and Nox4 is expressed throughout the vessel wall (Sorescu et al., 2002) 
(Figure 1.1).  In the vasculature, NAD(P)H oxidase is active during conventional 
metabolism to produce SO, which is used by cells as an endogenous signalling 
molecule at low levels.  In response to endogenous agonists, for example, 
angiotensin II and tumour necrosis factor-α (TNF-α), activation of NAD(P)H 
oxidase is sustained.  This continuous production of SO has been shown in both rat 
VSMCs (Griendling et al., 1994) and in human tissues (Berry et al., 2000). 
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Figure 1.1 – NAD(P)H oxidase-related ROS generation and ROS 
degradation in the vasculature. 
NAD(P)H, nicotinamide adenine dinucleotide phosphate; ROS, reactive oxygen 
species; SOD, superoxide dismutase; NO, nitric oxide; GPx, glutathione peroxidase; 
eNOS, endothelial NO synthase.  Adapted from (Higashi et al., 2009). 
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To maintain the redox balance, an endogenous anti-oxidant defence system is also 
present in the vasculature and this includes the enzymes superoxide dismutase 
(SOD), glutathione peroxidase (GPx) and catalase (Figure 1.1).  There are three 
isoforms of SOD to scavenge any excess SO.  These are; two intracellular forms, 
manganese SOD (MnSOD) and copper/zinc SOD (CuZnSOD), which are found in 
the mitochondria and cytoplasm, respectively (Figure 1.1), with a third extracellular 
form that is found in the extracellular space associated with heparan sulphate 
proteolycans (HSPGs).  SOD rapidly dismutates SO into H2O2, which is 
subsequently eliminated by GPx and catalase to water (Figure 1.1). 
1.2.2 Oxidative stress and endothelial dysfunction 
Increased oxidative stress due to excessive production and reduced removal of ROS 
is associated with the development of many vascular disease states, such as 
hypertension (Cai and Harrison, 2000, Griendling et al., 2000, Berry et al., 2001, 
Madamanchi et al., 2005a, Madamanchi et al., 2005b).  SO is produced by 
NAD(P)H oxidase in the vasculature in response to angiotensin II or increased wall 
stretch (Griendling et al., 2000) (Figure 1.2).  Under physiological conditions, SO 
can react with the vasodilator NO producing ONOO- (Harrison, 1997) (Figure 1.2).  
As the reaction between SO and NO is three times faster than the interaction of SO 
with SOD (Thomson et al., 1995), the balance between oxidative and anti-oxidative 
systems can quickly change.  Production of SO by NAD(P)H oxidases has been 
implicated in contributing to a condition called endothelial dysfunction, as the 
combination of SO with NO leads to reduced NO bioavailability (Rajagopalan et al., 
1996, Laursen et al., 1997, Wang et al., 1998a, Di Wang et al., 1999, Gorlach et al., 
2000, Mollnau et al., 2002, Rey et al., 2002) (Figure 1.2).  Endothelial dysfunction 
occurs when the native endothelium-dependent vasorelaxation to NO is significantly 
impaired (Griendling et al., 2000). 
Endothelial dysfunction was first shown in hypercholesterolemic rabbits (Minor et 
al., 1990).  Endothelium-dependent relaxation was severely impaired (Minor et al., 
1990), suggesting a lack of endothelium-derived relaxing factor (EDRF, an 
alternative name for NO).  However, the levels of NO and NO oxidation products in 
the vessels were increased 3-fold (Minor et al., 1990).  Additionally, endothelial 
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nitric oxide synthase (eNOS) could be activated by acetylcholine (Minor et al., 
1990), indicating that the signalling pathway for producing relaxation in the vessels 
was intact.  This effect on NO bioavailability was shown to be due to SO as 
treatment of hypercholesterolemic rabbits with polyethylene-glycolated-SOD 
enhanced endothelium-dependent vascular relaxation (Mugge et al., 1991).  No 
effect of SOD treatment was seen in control rabbits (Mugge et al., 1991).  Therefore, 
NO bioavailability is partly dependent on levels of SO, the hydroxyl radical has also 
been shown to possibly interact with NO (Pieper et al., 1997). 
The effects of SO can also be increased due to eNOS uncoupling in the vasculature 
(Figure 1.2).  In eNOS uncoupling, lack of the substrate L-arginine or the essential 
cofactor and electron transfer molecule tetrahydrobiopterin (BH4), causes eNOS to 
deviate from its coupled state where it produces NO.  Instead, eNOS transfers 
electrons to molecular oxygen, reducing it and producing SO and H2O2.  
Additionally, degradation of BH4 by ROS (including ONOO-, SO and H2O2) can 
down-regulate eNOS (Kuzkaya et al., 2003).  Oxidation of BH4 by ONOO- can also 
initiate eNOS uncoupling, further increasing endothelial dysfunction (Laursen et al., 
2001) (Figure 1.2).  Therefore, endothelial dysfunction leads to increased 
endothelium-dependent vasoconstriction, increased vascular peripheral resistance 
and, ultimately, can lead to increased BP.  If this reduction in endothelium-
dependent vasodilatation occurs in the coronary circulation, it can lead to 
cardiovascular remodelling, increased adverse cardiovascular events and increased 
cardiovascular mortality (Figure 1.2) (Cai and Harrison, 2000, Schachinger et al., 
2000, Suwaidi et al., 2000). 
The generation of SO during reperfusion injury after MI exacerbates the damage 
produced to ischaemic areas of the heart.  MI is caused by coronary artery 
obstruction and the resultant ischaemia produces an area of damaged or dead muscle, 
an infarct.  When blood flow is restored to the infarct, the molecular oxygen 
contained within the blood is converted to SO by NAD(P)H oxidase (Bauersachs et 
al., 1999).  This burst of SO produced during reperfusion activates many 
intracellular signalling pathways, causing cellular damage/apoptosis and cardiac 
hypertrophy (Griendling et al., 2000). 
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Figure 1.2 – Oxidative stress-induced endothelial dysfunction. 
Adapted from Cai and Harrison (Cai and Harrison, 2000). 
 
 
1.3  Clinical trials of anti-oxidants 
With evidence indicating towards increased oxidative stress being responsible for a 
variety of human cardiovascular diseases, there has been a severe lack of effective 
anti-oxidants in clinical trials with respect to the primary outcomes and morbidity. 
The anti-oxidant vitamin ascorbic acid (vitamin C) has been shown to increase NO 
bioavailability and restore endothelium-dependent vasodilatation in patients with 
increased oxidative stress due to coronary artery disease, essential hypertension and 
hypercholesterolaemia (Levine et al., 1996, Ting et al., 1997, Taddei et al., 1998, 
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Gokce et al., 1999, Hornig, 2002).  However, other clinical trials have had mixed 
results.  The Cambridge Heart Antioxidant Study (CHAOS) randomly assigned 
patients to 400 or 800 IU/day of a natural α-tocopherol (RRR-AT) or placebo 
(Stephens et al., 1996).  The RRR-AT-treated group showed a significant reduction 
in cardiovascular deaths and non-fatal MI (Stephens et al., 1996).  This study used 
higher doses of vitamin E than other unsuccessful clinical trials (reviewed in 
(Heinecke, 2001)).  In the Secondary Prevention with Antioxidants of 
Cardiovascular Disease in End Stage Renal Disease (SPACE) study, haemodialysis 
patients with pre-existing cardiovascular disease were administered with either 800 
IU/day of RRR-AT or a placebo (Boaz et al., 2000).  The treated group had a 
significant reduction in primary cardiovascular disease endpoints (Boaz et al., 2000).  
However, many other anti-oxidant clinical trials have failed for a variety of reasons, 
including, perhaps, diverse patient populations, inappropriate clinical endpoints and 
the variation in the type and dose of the anti-oxidants used.  Natural RRR-AT is 
more potent than synthetic all rac α-tocopherol and other natural forms of α-
tocopherol (Brigelius-Flohe and Traber, 1999), potentially altering the efficacy of 
the trial.  Additionally, the redox reactions in vivo are complex and occasionally 
treatment with anti-oxidants and can lead to a paradoxical increase in oxidant 
generation.  The anti-oxidant β-carotene can act as an oxidant under certain 
conditions (Burton and Ingold, 1984), leading to an increased risk of ischemic heart 
disease (Rapola et al., 1997).  Also, high doses of vitamin C increased free radical-
induced DNA damage in healthy volunteers (Podmore et al., 1998).  However, this 
does not contraindicate the role of ROS as a key mediator of vascular oxidative 
stress.  Therefore, it is important to further increase understanding of the basic 
biology and pathology of ROS and develop more effective anti-oxidant therapies.  
Increased efficacy of anti-oxidant therapies could potentially be achieved by 
selectively targeting anti-oxidants in vivo to particular sites which are relevant in the 
pathogenesis of diseases related to oxidative stress. 
1.4 Anti-oxidant peptide 
Although there is evidence linking NAD(P)H oxidase and oxidative stress, there is a 
lack of effective inhibitors targeting this oxidase which do not inhibit other flavin-
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containing enzymes (Riganti et al., 2004).  The anti-oxidant peptide gp91ds 
(sequence CSTRIRRQL) selectively inhibits NAD(P)H oxidase by preventing the 
interactions of its subunits, specifically the interaction between the membrane bound 
gp91phox subunit and the cytosolic oxidase subunit p47phox, reducing vascular SO 
production (Rey et al., 2001).  This competitive antagonist peptide is a potent 
inhibitor of SO formation in cell-free human neutrophil assays with a half maximal 
inhibitory concentration (IC50) of 3µM (DeLeo et al., 1995, DeLeo and Quinn, 
1996). 
The anti-oxidant peptide gp91ds was linked to a peptide derived from human 
immunodeficiency virus-1 transactivation tat protein (HIV-tat, sequence 
RKKRRQRRR) (Frankel and Pabo, 1988, Green and Loewenstein, 1988).  The HIV-
tat peptide is derived from the viral coat of HIV and mediates cell entry of the anti-
oxidant peptide, allowing it to be internalised into every cell (Fawell et al., 1994).  
The HIV-tat system had been previously used to enable efficient delivery of 
conjugated, biologically active peptides after intravenous delivery (Kim et al., 1997, 
Cardarelli et al., 2007).  Pre-incubation of aortic rings with the peptide gp91ds-tat 
(RKKRRQRRR-CSTRIRRQL) 30 minutes before angiotensin II stimulation, 
significantly prevented angiotensin II-induced SO production in vitro (Rey et al., 
2001).  Additionally, co-infusion of angiotensin II and gp91ds-tat significantly 
inhibited SO production in ex vivo mouse aortic rings, compared to aortic rings from 
angiotensin II-infused animals (Rey et al., 2001).  Co-infusion of angiotensin II and 
gp91ds-tat significantly attenuated angiotensin II-induced hypertension in mice (Rey 
et al., 2001).  In vivo administration of the gp91ds-tat peptide into salt-induced 
hypertensive rats has also been shown to reduce the production of aortic SO (Zhou et 
al., 2006).  The reduced SO production in the presence of gp91ds-tat inhibited the 
development of endothelial dysfunction in the aorta of these inducibly-hypertensive 
animals but did not significantly reduce the systolic BP in the treated group (Zhou et 
al., 2006).  The gp91ds-tat peptide also did not reduce systolic BP in the 
normotensive Sprague-Dawley rat (Jacobson et al., 2003). 
The importance of the influence of the gp91phox subunit-containing or Nox2 form of 
NAD(P)H oxidase on BP has been shown as knockout mice deficient in Nox2 have a 
significantly reduced basal BP compared to wild-type mice (Wang et al., 2001).  
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Infusion of angiotensin II produced similar increases in BP in both the knockout and 
wild-type mice but angiotensin II only increased SO production two-fold in aortic 
rings from wild-type mice (Wang et al., 2001).  This indicates an essential role in 
vivo of gp91phox and NAD(P)H-derived SO in both regulation of basal BP and 
angiotensin II-induced hypertension (Wang et al., 2001).  However, targeted over-
expression of Nox2 in ECs did not alter the basal BP of Nox2-transgenic mice 
(Bendall et al., 2007).  There was a significant increase in total NAD(P)H oxidase 
activity in lysates from the left ventricle and intact aorta but this did not result in any 
effect on BP (Bendall et al., 2007).  This suggests that there are other compensatory 
mechanisms involved which prevent the significant increase in SO production in the 
endothelium from leading to a significant increase in basal BP level. 
As significant evidence indicates that increased oxidative stress is responsible for a 
variety of human cardiovascular diseases, it is critical to develop more effective anti-
oxidant therapies.  The gp91ds peptide has excellent potential as a selective blocker 
of SO formation and, thereby, oxidative stress in vivo.  An enhanced reduction of 
oxidative stress could be achieved by targeting the anti-oxidant treatments.  
Therefore, a vascular targeting anti-oxidant peptide was developed, the efficacy of 
which was compared to the non-targeted gp91ds-tat peptide in an animal model of 
human essential hypertension and stroke, the stroke-prone spontaneously 
hypertensive rat (SHRSP). 
1.5 The stroke-prone spontaneously hypertensive 
rat (SHRSP) 
The spontaneously hypertensive rat (SHR) was generated from Wistar Kyoto 
(WKY) rats, selectively bred for high BP without any dietary or environmental 
stimuli (Okamoto and Aoki, 1963).  A sub-strain of the SHR with exceptionally high 
BP and increased susceptibility to stroke was subsequently selectively bred and 
designated as SHRSP.  As in humans, BP in the SHRSP increases with age whilst 
the reference strain remains normotensive throughout its lifespan (Davidson et al., 
1995, Clark et al., 1996).  In line with human essential hypertension, there is severe 
concentric left ventricular hypertrophy (LVH, assessed by echocardiography with 
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post-mortem validation) with approximately 10-20% of male SHRSP from 
University of Glasgow colonies developing spontaneous strokes, either ischaemic or 
haemorrhagic in origin. 
Research into the genetic basis of essential hypertension has been performed on the 
SHRSP and quantitative trait loci (QTL) have been identified linked to BP (on 
chromosomes 2 and 3), stroke (chromosome 5) and LVH (chromosome 14).  
Microarray gene expression profiling was performed for the QTLs on chromosome 2 
and has identified oxidative stress related genes (McBride et al., 2003, McBride et 
al., 2005).  The SHRSP has an increased infarct volume following middle cerebral 
artery occlusion compared to the WKY, a trait with very strong genetic 
determination (Jeffs et al., 1997, Gratton et al., 1998). 
Importantly, endothelial dysfunction due to increased generation of SO and relative 
NO deficiency can also be reversed using both gene-based and pharmacological 
approaches (Alexander et al., 1999, Dowell et al., 1999, Alexander et al., 2000, 
Fennell et al., 2002, Miller et al., 2005), thus defining oxidative stress as a key 
mediator of endothelial dysfunction in the SHRSP.  As in man, oxidative stress and 
resulting endothelial dysfunction is accelerated with ageing in the SHRSP (Hamilton 
et al., 2001). 
Concentric LVH, both in the SHRSP and in human essential hypertension, is 
associated with increased susceptibility to MI.  Moreover, it has been shown that the 
progression of left ventricular dysfunction is more pronounced, the greater the extent 
of initial LVH (Dominiczak et al., 1996). 
Therefore, the SHRSP is a well-characterised and well-established animal model of 
essential hypertension and endothelial dysfunction (McBride et al., 2005).  The 
SHRSP has greater than normal vascular SO production (Berry et al., 2001) and 
increased levels of uncoupled eNOS.  The resultant excess of SO in the SHRSP 
reduces NO bioavailability, impairing vascular relaxation and increasing BP (Kerr et 
al., 1999).  As the SHRSP exhibits increased SO production and hypertension, it has 
been chosen as the in vivo model for the investigation of effects of vascular targeting 
anti-oxidant peptides on BP and endothelial function. 
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1.6 Gene therapy 
Gene therapy is best defined as the introduction of a gene into an organism in order 
to treat an inherited disorder or other disease caused by either a loss- or gain-of-
function mutation in a gene.  The application of gene therapy has been used in 
monogenic diseases, such as cystic fibrosis and Duchenne’s muscular dystrophy, 
where replacement of a non-functional gene with the wild-type gene should restore a 
normal phenotype.  Additionally, the potential of gene therapy to provide novel 
treatments for diseases currently lacking suitable therapies or cures has led to its use 
for the treatment of cancer.  However, before the full potential of gene therapy for 
the treatment of wide ranging diseases and conditions can be reached, there are 
numerous limitations which need to be overcome.  The vector chosen for each gene 
therapy application needs to be developed to allow efficient and selective targeting to 
the required cell types, to prevent gene transfer to non-target tissues and organs, 
thereby improving the therapeutic indices.  The therapeutic gene must ideally be 
expressed at the correct physiological level and expressed for a suitable duration to 
provide a benefit to the patient, which may vary from lifelong expression to a short 
burst of expression.  The ability to provide long-term therapeutic effects by sustained 
gene expression within relevant cell types has limited the clinical efficacy of many 
gene therapy trials performed to date. 
Up to March 2009, there have been 1537 gene therapy trials approved worldwide 
with 12% of the trials being performed in the UK (http://www.wiley.co.uk/ 
genetherapy/clinical/).  The majority of clinical trials (66.1%) have used viral vectors 
(http://www.wiley.co.uk/genetherapy/clinical/).  Gene therapy clinical trials have 
been performed for a variety of diseases, including 64.6% of trials for cancer gene 
therapy, 8.9% for the treatment of cardiovascular disease, 8.1% for the treatment of 
monogenic diseases, 7.9% for infectious diseases, 1.8% for neurological diseases 
and 1.1% for the treatment of ocular diseases (http://www.wiley.co.uk/ 
genetherapy/clinical/).  The first disorder to be treated by gene therapy was 
adenosine deaminase-deficient (ADA) severe combined immunodeficiency (SCID).  
This disease results in the accumulation of toxic metabolites due to the inability to 
metabolise purines.  Patients were treated by ex vivo administration of a classical 
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retroviral vector containing the wild-type ADA gene to T-lymphocytes removed 
from the patient.  The cells were transduced, selected and expanded ex vivo before 
being returned to the patient and expression of the wild-type ADA gene could still be 
detected in 20% of the lymphocytes from one patient more than 10 years later (Muul 
et al., 2003).  This demonstrates the potential of gene therapy at the clinical level. 
There have also been several successful clinical trials for the treatment of X-linked 
SCID (SCID-X1), an inherited disorder in which patients have a loss-of-function 
mutation in the common cytokine receptor γ chain gene (γc), leading to defective 
cytokine signalling and resulting in dysfunctional B-cells and lack of T-cells and 
natural killer (NK) cells of the immune system.  This condition is also known as 
“boy in the bubble” syndrome as sufferers are extremely vulnerable to infectious 
diseases due to a crippled adaptive immune system.  Based on efficacious pre-
clinical data (Candotti et al., 1996, Cavazzana-Calvo et al., 1996, Hacein-Bey et al., 
1996, Stephan et al., 1996, Taylor et al., 1996, Hacein-Bey et al., 1998, Whitwam et 
al., 1998, Lo et al., 1999, Soudais et al., 2000), clinical studies were initiated.  In 
two clinical studies, CD34+ bone marrow stem cells were removed from patients and 
transduced ex vivo by a retroviral vector, the transgene of which was the wild-type 
version of the mutated γc cytokine receptor gene (Cavazzana-Calvo et al., 2000, 
Gaspar et al., 2004, Cavazzana-Calvo et al., 2005).  After 4 months, the 18 treated 
infants had newly developed functional NK and T-cells, which were present within 
the normal ranges for the majority of the patients.  Reconstitution of the immune 
system was variable but apparent in all patients.  However, 2-6 years after gene 
therapy, four of the patients have developed treatment-related leukaemia due to 
insertional mutagenesis by the retroviral gene therapy vector, leading to expression 
of endogenous proto-oncogenes (Hacein-Bey-Abina et al., 2003, Howe et al., 2008).  
These studies demonstrated outstanding data but highlighted the risk involved for the 
patients.  The risk/benefit ratio of retroviral gene therapy for patients with no match 
for a bone marrow donor requires careful ethical consideration until safer vectors are 
developed and tested. 
Adenoviral-based gene therapy systems are the most commonly used vector for 
clinical trials with viral vectors, representing 24% of all clinical trials approved to 
date (http://www.wiley.co.uk/genetherapy/clinical/).  These gene therapy advances 
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have been broadly overshadowed by the death 10 years ago of a patient in a clinical 
trial to treat ornithine transcarbamylase (OTC) deficiency (Raper et al., 2003).  OTC 
deficiency is an inborn error of urea synthesis, which affects the ability of the body 
to excrete ammonia and results in seizures and mental retardation in sufferers.  A 
first generation adenovirus was generated carrying the functional OTC gene, a 
similar vector to one which corrected the metabolic defect in OTC deficient sparse 
fur mice (Morsy et al., 1996, Ye et al., 1996) and had “an acceptable safety profile” 
in mice and non-human primates (Yang et al., 1994, Ye et al., 1997, Nunes et al., 
1999, Raper et al., 2003).  The vector was administered by infusion into the right 
hepatic artery in a dose escalation study.  Jesse Gelsinger was the most severely 
affected subject and was the second patient to receive the highest dose used in the 
clinical trial.  He suffered jaundice and an altered mental status approximately 18 hrs 
after administration of the vector and died 98 hours after administration due to a 
profound and uncontrollable systemic inflammatory response syndrome, 
disseminated intravascular coagulation and multiple organ system failure.  In fact, all 
11 patients in the trial had immune responses to the vector and there was no 
therapeutic benefit demonstrated (Raper et al., 2002). 
Subsequent discussions into this trial have pointed to deaths in monkeys after 
administration of the vector, inadequate information given to the patients regarding 
the risks and benefits of the treatment and the inclusion criteria of the trial, as Jesse 
Gelsinger was included when he displayed high ammonia levels, as potential reasons 
for the unsuccessful outcome (www.fda.gov).  This clinical trial highlighted the 
fundamental lack of understanding surrounding basic aspects of adenovirology at 
that point.  The host:vector interaction, which determined adenoviral fate in terms of 
biodistribution and transduction profiles, and also the host immune response 
generated to adenoviral vectors required greater definition.  In addition, there are 
significant difficulties in conducting clinical trials due to variation in patient 
response to new agents, relevance of animal species in pre-clinical studies and 
variation in levels of pre-existing immunity to Ad5 in the human population.  
Therefore, much of the research produced in the aftermath of the death of Jesse 
Gelsinger has been to increase the understanding of the gene therapy vectors 
themselves. 
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1.7 Adenoviruses 
Adenoviruses (Ads) are common human pathogens of which there are 51 human 
serotypes divided into six sub-species (A to F) based on their phylogenic origin, 
haeagglutination properties in a variety of species and their oncogenicity in rodents 
(Figure 1.3).  The sub-species are characterised by differences in their capsid 
structure and the primary receptor used in vitro (Table 1) (Wadell et al., 1980, 
Crawford-Miksza and Schnurr, 1996, Madisch et al., 2005).  The sub-species B Ads 
can be further sub-divided into sub-species B1 and B2 Ads (Table 1 and Figure 1.3) 
(Wadell et al., 1980, Segerman et al., 2003a).  Additionally, there is a degree of 
correlation between the sub-species of Ad and the native tissue tropism of the vector, 
leading to its clinical properties.  Sub-species B, C and E Ads cause respiratory 
disease and ocular infections, sub-species B2 Ads infect the kidneys and urinary tract 
and sub-species F Ads produce gastroenteritis (Russell, 2009).  In general, infection 
with Ads does not lead to severe diseases (Russell, 2009).  However, Ad infection in 
an immune-compromised patient (for example, an allogenic bone marrow recipient) 
tends to be invasive and can lead to increased mortality (Hierholzer, 1992, 
Flomenberg et al., 1994, Ljungman, 1997, Chakrabarti et al., 2000, Echavarria et al., 
2001, La Rosa et al., 2001, Legrand et al., 2001, Runde et al., 2001, Lankester et al., 
2002).  There is a particularly high incidence of Ad infection in immuno-suppressed 
children (Hierholzer, 1992, Flomenberg et al., 1994, Chakrabarti et al., 2000).  In 
one study, the peripheral blood of 132 paediatric patients undergoing allogenic stem 
cell transplantation for a variety of conditions was tested for the presence of Ads 
(Lion et al., 2003).  Ads were detected in the peripheral blood of 11 children, with 
the most prevalent being the sub-species C Ads which were detected in 78% of those 
infected (Lion et al., 2003).  There was a highly significant association between Ad 
infection and transplant-related mortality in the 82% of patients who died (relative 
risk 5.8, p < 0.001) (Lion et al., 2003).  Also, there are many Ads from other species 
(Jager and Ehrhardt, 2007), which are relevant to human gene therapy, especially 
vaccines. 
Ads can infect most but not all cell types and do so independently of cell division, 
having evolved sophisticated mechanisms to deliver their genome to the nucleus of 
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host cells in the absence of cell division (Russell, 2000).  Ads are under development 
for diverse gene therapy applications, especially for the treatment of cardiovascular 
disease and cancer, and for vaccination.  The wide range of applications for Ads 
reflects the ease with which they can be genetically manipulated to produce 
replication deficient adenoviral vectors and their substantial tolerance to the 
incorporation of novel targeting ligands.  The majority of gene therapy vectors used 
to date are based on Ad5 (a sub-species C Ad) as it can be grown to high titres and is 
highly efficient at transducing non-dividing cells. 
 
 
Figure 1.3 – Phylogenetic tree for human Ads. 
Phylogenetic depiction of human Ads generated by parsimony analysis of fiber knob 
amino acid sequences.  Number of each Ad is indicated on the right with sub-species 
designations A, BI, BII, C, D, E, FL (long fiber of sub-species F virus) and FS (short 
fiber of sub-species F virus).  Amino acid diversity is shown below the tree.  
Adapted from Havenga et al. (Havenga et al., 2002). 
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Sub-species Serotype
A 12, 18, 31
B1 3, 7, 16, 17
B2 11, 14, 34, 35, 50
C 1, 2, 5, 6
D 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, 42-49, 51
E 4
F 40, 41
 
Table 1 – Sub-species of human Ads. 
 
 
1.7.1 Structure of adenoviruses 
Ads are non-enveloped viruses which are 70-90 nm in diameter and have a double-
stranded linear 36 kb DNA genome.  The genome is enclosed within the icosahedral 
virion capsid which consists of three major exposed protein components – hexon, 
penton and fiber proteins (Figure 1.4A).  The majority of the capsid consists of 240 
trimeric hexon capsomers, which form 20 triangular faces, and associate with 12 
pentameric penton bases.  The structure of each Ad also contains 12 fiber proteins, 
which consists of the fiber shaft and knob.  The fibers project away from the virion 
surface and are attached to the capsid by the penton base (Figure 1.4A).  The fiber 
shaft of all human Ad serotypes has an N-terminal tail with a variable number of 
repeating sequences before the large C-terminal globular knob domain.  Each repeat 
of the repeating sequence is encoded by 15-20 amino acids and is one of the defining 
characteristics between the sub-species with the sub-species B Ads having the 
shortest fibers (consisting of 5.5 repeats) whereas the sub-species C Ads have 22 
repeats in their fibers. 
The hexon proteins of the Ad capsid form into a trimeric structure and are the major 
site of Ad antigenicity (Norrby, 1969, Gall et al., 1996).  Hypervariable regions 
(HVRs) are present within the surface exposed area of the hexon protein and these 
HVRs differ between Ad sub-species and serotypes (Crawford-Miksza and Schnurr, 
1996).  In some, but not all, Ads the penton base of the Ad capsid contain a triple 
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amino acid motif (arginine-glycine-aspartic acid – RGD) on a surface exposed loop 
(Wickham et al., 1993).  The RGD motif binds to and activates cell surface integrins 
leading to virus uptake via clathrin-coated endocytosis, in the case of Ad5 (Wickham 
et al., 1993, Wang et al., 1998b). 
1.7.2 Mechanism of human adenoviral infection in vitro 
The mechanism of Ad5 infection in vitro is well characterised.  The fiber protein of 
Ad5 binds to the coxsackie virus and adenovirus receptor (CAR) as its primary 
attachment receptor to infect cells in vitro (Figure 1.4B) (Bergelson et al., 1997, 
Tomko et al., 1997).  CAR is a 46 kDa transmembrane glycoprotein with two 
extracellular immunoglobulin-like domains (D1 and D2).  CAR is ubiquitously 
expressed (Defer et al., 1990) and is a component of tight junctions.  The D1 domain 
of CAR forms trans homodimers between molecules of the protein located on 
adjacent cells (van Raaij et al., 2000) and it is through this interaction that CAR 
serves as a cell-cell adhesion molecule (Honda et al., 2000).  The mouse homologue 
of CAR also functions as a receptor for Ads (Bergelson et al., 1998). 
To investigate the interaction between sub-species C Ads and CAR, CAR-expressing 
cell lines were developed (Bergelson et al., 1997, Tomko et al., 1997).  One study 
used CAR-negative NIH 3T3 cells for transfection with a plasmid expressing CAR 
(Tomko et al., 1997).  Ad5 transgene expression was only seen in NIH 3T3 cells 
transfected with CAR cDNA as control NIH 3T3 cells were completely refractory to 
transduction by Ad5 (Tomko et al., 1997).  CHO cells were also transfected with 
CAR cDNA and cell surface expression of CAR was detected by the anti-CAR 
antibody RmcB and immunoprecipitation (Bergelson et al., 1997).  Ad2 and isolated 
Ad2 fibers bound specifically to CHO-CAR cells with the same affinity and cellular 
attachment by the Ad2 virus was prevented in the presence of Ad2 fibers and 
recombinant Ad5 knob domains (Bergelson et al., 1997).  Transgene expression by 
Ad5 was increased 100-fold in CHO-CAR cells, compared to control cells 
(Bergelson et al., 1997).  These studies demonstrated that CAR is responsible for 
fiber-mediated attachment to cells by Ad2 and Ad5.  Ad5 can also use the CAR 
receptor for interaction with red blood cells of some species (Nicol et al., 2004, 
Carlisle et al., 2009, Subr et al., 2009). 
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Figure 1.4 – Model of Ad5 infectivity in vitro. 
(A) Major capsid proteins of adenovirus.  (B) In vitro Ad5 uses the coxsackie virus 
and adenovirus receptor (CAR) as its primary attachment receptor to infect cells and 
this promotes interaction between the penton base and integrins for cell 
internalisation. 
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Ad5 binds to CAR by the knob domain as transduction by Ad5 can be efficiently 
inhibited by ablation of the CAR interaction by mutation of the knob, addition of 
anti-knob antibodies or the presence of recombinant knob protein (Henry et al., 
1994, Nicklin et al., 2005).  The interaction between the Ad5 fiber knob and soluble 
CAR has been shown to be a high affinity interaction with a dissociation constant of 
14.8 nM (Kirby et al., 2000, Kirby et al., 2001).  Resolution of the crystal structure 
of the Ad5 fiber knob bound to CAR revealed that the interface involved in the fiber 
knob:CAR interaction overlapped with the areas of CAR involved in CAR 
homodimer formation (van Raaij et al., 2000).  The Ad5 fiber knob binds to CAR 
with almost 100-fold higher affinity than the interaction between CAR molecules to 
form homodimers, which has a dissociation constant of 16 µM (Freimuth et al., 
1999, van Raaij et al., 2000). 
The interaction between the Ad5 fiber knob and CAR then promotes cell 
internalisation of the vector through engagement of αvβ3/5 integrins with the RGD 
motif in the penton base (Figure 1.4B) (Wickham et al., 1993).  Binding of the 
penton base to the integrin receptors occurs due to a flexible hinge region in the Ad5 
fiber (Chiu et al., 2001).  Modification of the Ad5 fiber shaft to a short-shafted fiber 
from the sub-species B Ads hindered infection by these vectors (Shayakhmetov and 
Lieber, 2000), indicating that the presence of the hinge region in the Ad5 fiber shaft 
is crucial for cellular transduction. 
CAR is a transmembrane protein with a C-terminal cytoplasmic domain and this 
cytoplasmic domain of the receptor contains putative phosphorylation sites, possibly 
indicating the potential of CAR to produce intracellular signalling.  However, 
deletion of this cytoplasmic domain does not effect infection by Ads (Wang and 
Bergelson, 1999, Kirby et al., 2000).  Recently, the cytoplasmic tail of CAR has 
been shown to activate p44/42 mitogen-activated protein kinase (MAPK) (Farmer et 
al., 2009).  Activation of p44/42 MAPK was required for efficient infection by Ad5 
through the CAR infection pathway as activation of this kinase enzyme, by Ad5 
binding to CAR, induces CAR:CAR interaction in cis (in comparison to native CAR 
dimerisation interaction which occurs in trans (van Raaij et al., 2000)) and clustering 
of CAR at the cell membrane (Farmer et al., 2009).  p44/42 MAPK activation also 
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promotes integrin activation, resulting in increased cell adhesion (Farmer et al., 
2009). 
Following integrin engagement, the virion is internalised into endosomes by 
receptor-mediated endocytosis (Maxfield and McGraw, 2004).  Ad5 infection was 
shown to be mediated by endocytosis via clathrin-coated pits by using dynamin to 
prevent the formation of clathrin-coated vesicles (Wang et al., 1998b).  Once 
internalised, acidification of the endocytic vessel occurs due to vacuolar H+-ATPase 
activity.  At pH 6.0, dissociation of the penton base and fiber from the virion occurs.  
Disassembly of the fiber occurs first, possibly mediated through interaction between 
the RGD motif in the penton and αvβ3/5 integrins (Wickham et al., 1993).  At low 
pH, a change in the conformation of the penton protein occurs exposing hydrophobic 
regions (Medina-Kauwe, 2003).  Binding of the penton to integrins inside the 
acidified endomome (Bai et al., 1993) causes dissociation of the penton base from 
the viral capsid to occur (Greber et al., 1993, Seth, 1994a) and signals endosomal 
lysis by protein kinase C and a viral protease (Medina-Kauwe, 2003).  This lysis of 
the endosomal membrane results in escape of virion into the cytosol (Seth, 1994b, 
Miyazawa et al., 2001).  Ad5 rapidly escapes into the cytosol within three to 15 
minutes after internalisation (Greber et al., 1993, Greber et al., 1996, Leopold et al., 
1998, Miyazawa et al., 1999).  Inhibition of endosome acidification results in 
retention of Ad in endosomes and decreased transgene expression (Greber et al., 
1993, Leopold et al., 1998). 
Following escape from the endosome, the virion binds to microtubules for migration 
through the cytosol (Leopold et al., 1998, Suomalainen et al., 1999, Leopold et al., 
2000, Suomalainen et al., 2001, Mabit et al., 2002).  Ads interact with cytoplasmic 
dynein, a molecular motor which drives motility along microtubule filaments 
towards the nucleus of the cell (Kelkar et al., 2004).  During this period protein IX (a 
capsid stabilisation protein) dissociates from the virion capsid (Greber et al., 1993).  
Ads dissemble from the microtubles before arriving at the microtubule organising 
centre (Suomalainen et al., 2001, Bailey et al., 2003).  At the nuclear membrane, 
interaction of the virus with nuclear pore complexes leads to hexon dissociation 
(Greber et al., 1993, Greber et al., 1997, Martin-Fernandez et al., 2004).  The viral 
genome then enters the nucleus through binding to the nuclear pore protein 
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CAN/Nup214 (Trotman et al., 2001).  Ad DNA is imported using the nuclear pore 
complex receptor CAN/Nup214 and histone H1 (Trotman et al., 2001).  The 
genomes of Ads do not integrate into the cellular DNA and are maintained 
episomally.  Most Ad gene therapy vectors have deleted genes encoding early phase 
proteins required for the replication of viral DNA to ensure that they are replication-
deficient. 
1.7.3 Mechanism of human adenoviral infection after 
systemic administration in vivo 
The basic mechanism of Ad5 infection in vitro is well established.  However, the 
mechanism of Ad5 infection in vivo after systemic delivery is less clear.  Following 
intravascular administration, a substantial proportion of the vector is rapidly cleared 
by Kupffer cells, resident phagocytotic macrophage cells in the liver and part of the 
innate (non-antigen-specific) immune system (Figure 1.5) (Lieber et al., 1997, 
Worgall et al., 1997).  This interaction does not contribute to Ad5-mediated 
transduction (Mullbacher et al., 1989, Yang et al., 1994).  Accumulation of Ad5 in 
Kupffer cells leads to rapid Kupffer cell death, within ten minutes of vector 
administration in mice, due to loss of membrane integrity (Manickan et al., 2006).  
The dead Kupffer cells gradually disappear from the liver (Schiedner et al., 2003, 
Manickan et al., 2006), which results in increased transduction of the liver and other 
organs.  The remaining Ad5 selectively accumulates within and transduces the 
hepatocytes of the liver (Huard et al., 1995, Connelly, 1999, Parker et al., 2006, 
Waddington et al., 2007, Kalyuzhniy et al., 2008, Waddington et al., 2008). 
Many attempts have been made to retarget Ad vectors to reduce uptake by the liver 
and spleen and selectively target alternative sites to allow treatment of diseased 
tissues.  The ability to selectively target treatment sites could increase the safety and 
efficiency of the vectors and also increase the therapeutic index, as a reduced dose of 
the vector would be required.  As Ads use an airborne infection mechanism 
naturally, the cellular interactions with the capsid and subsequent entry pathways by 
modified Ad vectors in the artificial blood-borne environment needs to be fully 
elucidated before Ads can be effectively used as gene therapy vectors. 
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Figure 1.5 – Interactions of Ad5 after intravascular administration. 
Following intravascular administration, Ad5 interacts with red blood cells (RBC), 
platelets, complement proteins, blood coagulation factors (including FX) and 
antibodies.  Some of these interactions lead to subsequent binding to a variety of 
receptors, including HSPGs and LRP.  A substantial proportion of the Ad5 is rapidly 
cleared by Kupffer cells.  Generated by Dr. S.A. Nicklin, University of Glasgow, 
UK. 
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1.7.4 Adaptive tropism by fiber modification 
The majority of attempts to retarget Ad5 away from the liver and spleen involved 
modification of the fiber and/or penton proteins of the viral capsid.  The alterations 
to the fiber broadly included either mutation of the Ad5 fiber or pseudotyping 
(replacement of the Ad5 fiber protein with a fiber from another Ad) (reviewed by 
Nicklin et al. (Nicklin et al., 2005)).  Initial studies focused on residues in the fiber 
knob domain which had been identified as critical for binding to CAR (Bergelson et 
al., 1997, Roelvink et al., 1999).  In vitro, a CAR-binding ablated vector (AdKO1) 
reduced infectivity by 99% relative to non-modified Ad5 (Jakubczak et al., 2001).  
Modification of these residues to ablate the interaction between the fiber knob and 
CAR, either singularly or in combination with deletion of the RGD motif in the 
penton base, ablated the in vitro tropism of the vectors but there was no difference in 
liver transduction in C57BL/6 mice (Alemany and Curiel, 2001, Smith et al., 2002, 
Martin et al., 2003).  There was also no difference in liver sequestration by AdKO1, 
AdPD1 (ablated αv-integrin interaction) and Ad5 one hour after systemic 
administration of the vectors in mice (Di Paolo et al., 2009b).  However, other 
studies have shown that CAR ablation in combination with deletion of the RGD 
motif results in a significant reduction in liver targeting in mice (Einfeld et al., 2001, 
Koizumi et al., 2003). 
Investigation into the differences between in vitro and in vivo transduction profiles 
by modified vectors has also been performed in rats.  Five days after infusion of 
vectors into WKY rats pre-treated with a protocol to block Ad clearance by Kupffer 
cells, AdKO1 or AdPD1 did not produce different levels of liver transduction in 
comparison to control Ad5 (Nicol et al., 2004).  However, WKY rats infused with 
AdKO1PD1, an Ad5 vector with ablated CAR and αv-integrin binding sites, showed 
a 99% reduction in liver transduction compared to Ad5 (Nicol et al., 2004).  In 
addition to the clear species differences for these vectors between mice and rats, 
there was also a difference between rat strains.  In Brown Norway and Sprague-
Dawley rats, AdKO1PD1 mediated a modest 30% reduction in liver transduction, 
indicating an important strain-strain variation exists (Nicol et al., 2004).  Although 
AdPD1 vectors show reduced liver targeting in some studies, the further use of 
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vectors with αv-integrin binding ablated vectors (AdPD1 or Ad5∆RGD) as a gene 
therapy vector is probably limited. 
In vitro, Ad5∆RGD showed a 60% reduction in internalisation at five minutes and 
overall significantly slower internalisation kinetics compared to Ad5 (Shayakhmetov 
et al., 2005a).  The kinetics of endosomal escape by Ad5∆RGD was also shown to 
be significantly slower compared to Ad5 (Shayakhmetov et al., 2005a).  Therefore, 
Ad5 requires the ability to bind integrins for efficient internalisation and endosomal 
escape to produce efficient cellular transduction.  Consequently, low levels of 
transduction are likely with AdPD1/Ad5∆RGD and the use of this vector for gene 
therapy applications is limited.  However, the RGD motif has been shown to partly 
mediate liver sequestration of intravenously administered Ad5 (Di Paolo et al., 
2009b).  Interactions of the RGD motif and liver sinusoidal ECs and hepatocytes 
leads to virus retention in the space of Disse (Di Paolo et al., 2009b).  Recently, the 
RGD motif of Ad5 was also shown to be partly responsible for activation of the 
innate immune system in mice (Di Paolo et al., 2009a).  After systemic 
administration, Ad5 binds to β3 integrins on splenic macrophages triggering 
production of interleukin-1α (IL-1α) (Di Paolo et al., 2009a).  Production of IL-1α 
was significantly reduced in mice administered with Ad5∆RGD (Di Paolo et al., 
2009a).  Therefore, to prevent certain aspects of the liver sequestration and the anti-
viral response in vivo, RGD motif-deleted vectors are required but their use will 
reduce viral uptake and activity. 
The inconsistencies in the data involving ablation of the CAR and/or αv-integrin 
interaction with Ad5 outlined above led to investigation into a putative HSPG 
binding site in the Ad5 fiber shaft as identified by competition analysis with heparin 
(Dechecchi et al., 2000, Dechecchi et al., 2001).  The HSPG-binding motif, 
designated by four consecutive amino acids lysine-lysine-threonine-lysine (KKTK) 
in position 91-94 amino acids in the fiber shaft, is only present in the sub-species C 
Ads.  Mutation of this KKTK sequence to glycine-alanine-glycine-alanine (GAGA) 
significantly reduced liver transduction by 1000-fold in mice (Smith et al., 2003b) 
and 57% in rats (Nicol et al., 2004).  Additionally, the mutation of the HSPG 
interaction significantly reduced liver infectivity in non-human primates in vivo 
(Smith et al., 2003a).  Moreover, liver transgene expression by a vectors with the 
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KKTK mutation (designated AdS*) could be significantly reduced further in 
combination with KO1 and KO1PD1, producing a 99% reduction in liver 
transduction (Nicol et al., 2004).  Further research into the AdS* mutant led to the 
conclusion that AdS* had a reduced ability to internalise and traffic to the nucleus of 
the infected cell (Bayo-Puxan et al., 2006, Kritz et al., 2007).  This was due to the 
KKTK motif occurring in the hinge region of the Ad5 fiber and mutation of this 
produced an inflexible fiber.  Although, the vector could still efficiently bind to the 
cell surface, it was unable to interact with integrins as is necessary to mediate 
cellular transduction and, as a result, is non-longer considered a viable gene therapy 
vector candidate (Bayo-Puxan et al., 2006, Kritz et al., 2007). 
1.7.5 Adaptive tropism by modification of the HI loop 
As CAR- and integrin-binding ablated vectors still displayed high levels of liver 
tropism, an alternative site for mutagenesis, to increase the selective targeting 
capacity of Ad vectors, was sought.  Many vector targeting studies focussed on 
exosites of the knob domain, of which the HI loop of the knob domain is the most 
exposed.  Insertion of peptide sequences into the HI loop appear not to effect the 
overall structure of the fiber shaft or knob domain and, as the HI loop is on the 
surface of the viral capsid, the inserted peptide sequence is accessible.  Insertion of 
the integrin-binding RGD sequence into the HI loop developed a vector which 
transduced cells by a CAR-independent mechanism (Dmitriev et al., 1998). 
The combination of insertion of a targeting peptide into the HI loop of the vector and 
ablation of CAR binding led to the development of several Ad vectors which 
selectively targeted ECs (Nicklin et al., 2001, Nicklin et al., 2004) and VSMCs 
(Work et al., 2004) in vitro.  After identification of a novel human EC-binding 
peptide by phage display (Nicklin et al., 2000), a mutant AdKO1 vector was 
developed with the EC targeting peptide sequence SIGYPLP inserted into the HI 
loop (Nicklin et al., 2001).  Inclusion of the SIGYPLP peptide sequence in the 
AdKO1 vector (AdKO1SIG), increased transduction of human umbilical vein 
endothelial cells (HUVECs) and human aortic endothelial cells (HAECs) by 4.7- and 
8.0-fold, respectively, compared to AdKO1 (Nicklin et al., 2001).  Transduction by 
AdKO1SIG was not significantly different from AdKO1 in VSMCs and a hepatocyte 
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carcinoma cell line, HepG2 (Nicklin et al., 2001).  Therefore, SIGYPLP-mediated 
selective gene transfer to ECs from different vascular beds, with little tropism for 
other cell types.  However, when AdKO1 vectors containing peptide sequences 
selectively targeted for HUVECs, and which produced similar levels of transduction 
of HUVECs as control Ad5, were administered systemically in vivo into mice it 
resulted in high levels of liver transduction equivalent to control Ad5 (Nicklin et al., 
2001).  For one of the peptide-modified AdKO1 vectors, there was a modest increase 
in transduction of abdominal aorta/vena cava (Nicklin et al., 2001), suggesting 
improved (but not efficient) retargeting of the vector. 
Identification of peptides which selectively targeted VSMCs could lead to the 
targeting of therapeutic genes chosen to prevent late vein graft failure, which is 
caused by restenosis or reocclusion of the artery lumen and is a common side effect 
following coronary artery bypass grafting and angioplasty.  VSMCs require high 
viral titres to achieve transduction by Ad5 due to the low expression of CAR by 
these cells (Havenga et al., 2001).  To improve the transduction efficacy by Ad 
vectors in VSMCs, the peptide sequence EYHHYNK was inserted into the HI loop 
of AdKO1 (AdEYH) (Work et al., 2004).  EYHHYNK selectively targets VSMCs, 
as identified by phage biopanning on human saphenous vein (HSV) SMCs, but did 
not target HSVECs (Work et al., 2004).  AdEYH significantly enhanced 
transduction of HSVSMCs and with a significant reduction in transgene expression 
in HSVECs compared to control Ad5 (Work et al., 2004). 
1.7.6 Adaptive tropism by pseudotyping 
Identification of different primary cellular receptors used by Ad viruses and the 
variation in tropism compared to Ad5 led to the development of pseudotype Ad 
vectors.  Fiber-pseudotype vectors have the hexon and penton from Ad5 with either 
the full fiber protein or only the fiber knob domain from another Ad.  The fibers of 
the alternative serotypes showed differences to Ad5 in their lack of a CAR binding 
site but also had differences in the rigidity of the fiber, the length of the fiber shaft 
and/or the presence of the putative HSPG binding domain.  It was hoped that 
development of pseudotype vectors with a different infection profile in vitro to Ad5 
would display an alternative tropism in vivo. 
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The majority of research into pseudotype vectors has centred on use of the fiber from 
sub-species B Ads.  The sub-species B Ads use the membrane glycoprotein CD46 as 
their cellular receptor and not CAR (Gaggar et al., 2003).  Therefore, cells which are 
relatively refractive to infection by Ad5 due to low or no CAR expression, for 
example SMCs, ECs and many cancer cells, should be efficiently transduced by a 
sub-species B pseudotype vector via CD46 engagement.  This has led to the 
development of many novel vectors including Ad5/f35, a pseudotype vector 
consisting of the entire Ad5 virion but with the Ad35 fiber.  This vector efficiently 
transduced haematopoietic cells, which are refractory to Ad5 transduction 
(Shayakhmetov et al., 2000), thereby providing proof of principle of this technology.  
“Pseudotype libraries” were subsequently developed to allow screening on cell lines 
to determine the most efficient fiber for transduction (Havenga et al., 2001, Havenga 
et al., 2002). 
Pseudotype vectors Ad5/f19p and Ad5/f37 demonstrated a striking reduction in 
hepatic transduction in mouse, rat and human hepatocytes in vitro (Denby et al., 
2004).  These vectors which contain fibers from the sub-species D Ads Ad19p and 
Ad37, demonstrated less than 1% of the transgene expression achieved by Ad5 
(Denby et al., 2004).  Both Ad5/f19p and Ad5/f37 vectors produced equivalent and 
significantly enhanced transduction in HUVECs and HSVSMCs, respectively, 
compared to Ad5 (Denby et al., 2004).  At one hour after systemic delivery of 
Ad5/f19p and Ad5/f37 in WKY rats, there was 63% and 55% reduction in liver 
accumulation by the vectors compared to Ad5, respectively, with no detectable 
vector genomes present five days post-infusion (Denby et al., 2004).  Ad5 genomic 
DNA was still present five days after delivery of the vector (Denby et al., 2004).  
Importantly, Ad5/f19p and Ad5/f37 produced significantly less liver transduction 
than Ad5 (Denby et al., 2004).  Therefore, the markedly reduced tropism for 
hepatocytes demonstrated in vitro by Ad5/f19p and Ad5/f37 vectors remained after 
systemic delivery in vivo. 
As the pseudotype Ad5/f19p demonstrated significantly reduced liver transduction 
(Denby et al., 2004), it has been further developed to selectively retarget this vector 
to specific cell types.  Phage display in WKY rats identified two peptides, 
HTTHREP (HTT) and HITSLLS (HIT), which selectively target to the kidney 
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(Denby et al., 2007).  Each of these peptides was then inserted into the HI loop of 
the Ad5/f19p fiber and the vectors were administered to WKY rats.  The peptide-
modified vectors produced a significantly higher level of kidney transduction 
compared to both Ad5 and the control Ad5/f19p vector, which had no peptide 
insertion (Denby et al., 2007).  Moreover, the peptide-modified vectors transduced 
different groups of cells within the kidney; the glomerulus was transduced by 
Ad5/f19p-HIT, whereas Ad5/f19p-HTT selectively transduced tubular epithelial 
cells (Denby et al., 2007).  Transduction by either vector was not detected in any 
non-target organ, including the liver (Denby et al., 2007).  Therefore, after 
intravenous administration, the peptide-modified Ad5/f19p vectors produced 
efficient and selective transduction of the kidneys.  However, most pseudotype 
vectors showed liver transduction after systemic delivery in vivo, consistent with 
Ad5. 
1.7.7 Interaction of adenoviruses with other blood 
components and blood cells 
Human complement component C3 from plasma has been shown to bind to Ad5 
(Jiang et al., 2004) (Figure 1.5).  In complement C3 knockout mice, a low dose Ad5 
(2.3x109 virus particles(VP)/mouse) produced a 99-fold reduction in hepatocyte 
transduction three days after administration of the vector, in comparison to transgene 
expression in non-transgenic control mice (Zinn et al., 2004).  However, this was not 
reproducible at higher doses of Ad5.  A dose of 1.5x1011 VP/mouse produced no 
significant difference in liver transduction between complement C3 knockout mice 
and wild-type mice (Kiang et al., 2006).  The acute inflammatory response to 
systemic delivery of Ad was significantly reduced in complement C3 knockout mice 
(Kiang et al., 2006).  The toxicity resulting from injection of Ad5 is characterised by 
complement activation, cytokine release with the consequent vascular damage 
leading to a systemic inflammatory response which can be fatal to the host (Schnell 
et al., 2001, Lozier et al., 2002, Morral et al., 2002, Raper et al., 2003). 
The Ad5 fiber has also been shown to interact with human erythrocytes (Nicol et al., 
2004, Carlisle et al., 2009, Subr et al., 2009) and platelets (Hofherr et al., 2007, 
Othman et al., 2007, Stone et al., 2007b) (Figure 1.5).  Ad5 agglutinates rat and 
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human but not mouse erythrocytes, an effect which does not occur in CAR binding 
ablated vectors indicating involvement of the knob domain (Nicol et al., 2004).  
Human erythrocytes were shown to express CAR and Ad5 bound to 90% of red 
blood cells suspended in phosphate buffered saline (PBS) (Carlisle et al., 2009).  
Binding by Ad5 was prevented in the presence of excess Ad5 fiber protein or an 
anti-CAR antibody (Carlisle et al., 2009), indicating that the interaction between 
erythrocytes and Ad5 is CAR-dependent.  In plasma, addition of the anti-CAR 
antibody reduced binding of Ad5 to erythrocytes by less than 25% (Carlisle et al., 
2009), indicating other mechanisms of Ad5 binding occur in plasma.  The 
complement receptor (CR1) is also present on human erythrocytes and binds Ad5 in 
the presence of complement and antibodies (Carlisle et al., 2009).  In transgenic 
mice which express CAR on their erythrocytes, the circulation time of Ad5 was 
extended and liver transduction was significantly reduced (Carlisle et al., 2009).  
Therefore, sequestration of Ad5 by erythrocytes restricts Ad5 infection, an effect 
which could be seen in humans after either natural exposure to Ad5 or during its use 
as a gene therapy vector.  Coating the Ad5 capsid with hydrophilic polymers has 
been shown to decrease the interaction between Ad5 and erythrocytes from 95% 
binding by Ad5 to 25% by Ad5 coated with the polymer (Subr et al., 2009). 
After intravenous delivery, Ad5 activated platelets and induced platelet-leukocyte 
aggregation formation in mice (Othman et al., 2007).  This suggests a direct 
interplay between Ad-platelet interaction in blood and subsequent thrombocytopenia, 
activation of coagulation, endothelial activation and leukocyte infiltration.  In 
humans, 78% of platelets express CAR (Othman et al., 2007), suggesting that human 
platelets would sequester a large number of CAR-binding Ad vector particles after 
systemic administration.  Additionally, the interaction of Ad vectors and platelets 
results in vector sequestration by the hepatic reticuloendothelial system (Stone et al., 
2007b).  Ad5 bound to over 95% of platelets in mice with subsequent accumulation 
in the liver sinusoids and interaction with Kupffer cells for degradation (Stone et al., 
2007b).  This would lead to an overall reduction in the concentration of Ad5 
reaching its intended target, decreased transduction of target cells and reduced 
circulation time (Lyons et al., 2006).  As higher doses may be required to produce 
efficacy, dose limiting toxicities would become relevant.  Additionally, as Ad5 
interacts with human but not murine erythrocytes (Nicol et al., 2004) and 98% of Ad 
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genomes associated with erythrocytes taken from clinical trial patients (Lyons et al., 
2006), this highlights the need for utilisation of appropriate animal models which 
accurately and reliably predict the interaction of Ad vectors in humans. 
1.7.8 Role of blood factors in liver tropism 
For gene therapy applications, the goal has been delivery of the vector by minimally 
invasive intravenous administration with selective gene transfer to the required cell 
type.  However, after intravenous administration Ad5 selectively transduces the 
liver, as discussed in Section 1.7.3.  This tissue tropism does not appear to correlate 
with CAR expression levels and cellular localisation and cannot be redirected by the 
ablation of CAR binding (Smith et al., 2003a, Smith et al., 2003b, Nicol et al., 2004, 
Nicklin et al., 2005), indicating that the presence of or binding to CAR is not 
necessary for tissue transduction in vivo.  CAR expression is also restricted to tight 
junctions between cells (Cohen et al., 2001), which makes it difficult to correlate 
selective hepatocyte transduction after systemic delivery of Ad vectors in vivo if 
CAR is used as the primary receptor.  Additionally, ablation of the integrin-binding 
RGD motif in the penton base was also largely unsuccessful (Nicklin et al., 2005).  
This suggested that alternative pathways exist which define liver tropism in vivo. 
The first convincing study to further investigate the mechanism of Ad5 infection in 
vivo demonstrated that factors in the blood were capable of influencing hepatocyte 
transduction (Shayakhmetov et al., 2005b).  Ad5 and a CAR-binding ablated vector, 
Ad*F, produced equivalent levels of liver transduction in the presence of blood in 
vivo (Shayakhmetov et al., 2005b).  However, when the liver was excluded from the 
circulation using an in situ perfusion model (to allow delivery of the vector in the 
absence of blood), there was a significant reduction in liver transduction by Ad*F 
but not by Ad5 (Shayakhmetov et al., 2005b).  This indicated that liver transduction 
in vivo was mediated by two mechanisms, one which was CAR-mediated and 
another CAR-independent mechanism mediated by blood factors.  After injection of 
competing ligands (which included polymerised bovine serum albumin (BSA) to 
saturate the scavenger receptor SR-BI, asialofetuin to saturate the asialoglycoprotein 
receptor, human low density lipoprotein (LDL) to saturate the LDL receptor and 
lactoferrin to saturate LDL receptor-related protein (LRP) as well as HSPGs) for 
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cellular receptors present in the liver, it was determined that Ad vectors could use 
either HSPGs or LRP as receptors in the presence of blood factors as transgene 
expression by Ad*F was reduced 50-fold (Shayakhmetov et al., 2005b) (Figure 1.5).  
Additionally, infusion of heparinase I (an enzyme which selectively cleaves highly 
sulphated polysaccharide chains preventing cell surface expression of functional 
HSPGs) into wild-type mice before administration of the vectors significantly 
reduced liver transduction by both Ad5 and Ad*F (Shayakhmetov et al., 2005b).  
This indicates that, in the presence of blood factors, these vectors use HSPGs as their 
cellular receptors.  Tandem mass spectrometry and slot blot assays were used to 
identify blood factors which bind to the fiber knob domain of Ad5.  Human 
coagulation factor IX (FIX) and complement binding protein (C4BP) bind to the 
Ad5 fiber knob and addition of the physiological concentration of these proteins 
returns Ad*F transduction levels in cultured hepatocytes to that of Ad5 
(Shayakhmetov et al., 2005b).  Mouse livers perfused with Ad*F in the presence of 
FIX, increased transduction by Ad*F to levels comparable with Ad5 and addition of 
coagulation factor X (FX) did not improve transgene expression by Ad*F 
(Shayakhmetov et al., 2005b).  However, there was no significant difference in liver 
transduction by Ad*F in wild type and FIX knockout mice (Shayakhmetov et al., 
2005b).  This suggests that there is some influence by other blood factors for 
transduction by Ad5 vectors in vivo or possible compensatory mechanisms are 
activated due to the deficiency of FIX. 
1.7.9 FX is responsible for liver transduction 
Further work investigating the influence of the vitamin K-dependent blood 
coagulation factors (FVII, FIX, FX and protein C [PC]) on Ad5 liver transduction 
led to the finding of a direct, calcium-dependent interaction between Ad5 and FX 
(Parker et al., 2006).  FVII, FIX, FX and PC are homologous serine proteases which 
are synthesised in the liver and circulate in the plasma as inactive zymogens.  They 
are activated by proteolytic cleavage as part of the coagulation cascade (Gomez and 
McVey, 2006).  Addition of physiological concentration of FIX (5 µg/ml) or FX (8 
µg/ml) significantly enhanced transduction of a hepatocyte cell line by AdKO1, a 
CAR-binding ablated mutant Ad5 (Parker et al., 2006).  However, FX was more 
efficient at enhancing transduction by AdKO1 as there was a substantial difference 
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in cellular transduction levels, particularly after a short exposure time with the vector 
(Parker et al., 2006).  Importantly, activation of FX was not required to mediate the 
enhancement in hepatocyte transduction since transduction was equivalent in the 
presence of both the latent and activated form of FX (Parker et al., 2006). 
Coagulation factors FVII, FIX, FX and PC all comprise of a four domain structure: a 
γ-carboxylated glutamic acid (Gla) domain, an epidermal growth factor-like (EGF1) 
domain, an EGF2 domain and a globular active site containing a serine protease (SP) 
domain (Gla-EGF1-EGF2-SP) (Figure 1.6).  Addition of physiological concentration 
of FVII, FIX, FX and PC significantly enhanced transduction by AdKO1 in a 
hepatocyte cell line, whereas the non-homologous coagulation factors FXI and FXII 
did not (Parker et al., 2006).  This suggests a common approach is responsible for 
the enhancement of hepatocyte transduction in the presence of FVII, FIX, FX and 
PC. 
 
 
Figure 1.6 – Structure of FX. 
FX shares homology with FVII, FIX, FX and PC as all comprise of a four domain 
structure: a γ-carboxylated glutamic acid (Gla) domain, an epidermal growth factor-
like (EGF1) domain, an EGF2 domain and a serine protease (SP) domain (Gla-
EGF1-EGF2-SP).  Green balls indicate calcium ions.  Adapted from Waddington et 
al. (Waddington et al., 2008). 
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Surface plasmon resonance (SPR) analysis was used to determine whether FX 
interacts directly with the vectors Ad5 and AdKO1.  Ad5 and AdKO1 were injected 
over a biosensor chip to which FX was covalently bound.  Association and 
dissociation of the vectors can then be determined and kinetic analysis performed.  
Both Ad5 and AdKO1 bound strongly to FX and with similar affinity constants in a 
calcium-dependent manner as addition of 3 mM ethylenediamine tetra-acetic acid 
(EDTA) was required for vector dissociation (Parker et al., 2006). 
In an ex vivo liver perfusion model, designed to investigate liver transduction by 
vectors in the absence of blood, addition of physiological concentrations of human 
FX significantly increased transduction by Ad5 and AdKO1 by 25- and 250-fold, 
respectively, to equivalent levels of liver transgene expression (Parker et al., 2006).  
This finding was contrary to previous reports using a similar in situ perfusion model 
(Shayakhmetov et al., 2005b).  To assess the effect of FX in vivo, a warfarin pre-
treatment model was developed.  Warfarin prevents the maturation and secretion of 
functional vitamin K-dependent coagulation factors, specifically by blocking the 
post-translation modification of the Gla domain by a vitamin K-dependent 
carboxylase enzyme.  The Gla domain will then not fold properly, reducing the level 
of functional FX circulating in the bloodstream (Zivelin et al., 1993).  In mice, 
injection of Ad5 and AdKO1 results in highly efficient liver transduction but pre-
treatment of these animals with warfarin, reduced liver transduction by several 
orders of magnitude due to blockade of the interaction between vitamin K-dependent 
coagulation factors and Ad (Parker et al., 2006, Waddington et al., 2007).  Pre-
infusion of FX into warfarin-treated mice rescued liver transduction by both Ad5 and 
AdKO1, thus unveiling a novel non-CAR-dependent pathway that regulates Ad5-
mediated gene transfer in vivo (Parker et al., 2006, Waddington et al., 2007).  
However, coagulation factors do not affect Kupffer cell uptake or early Ad 
accumulation (Waddington et al., 2007, Di Paolo et al., 2009b) and warfarin pre-
treatment also does not ablate Kupffer cell capacity to trap blood-borne Ad vectors 
(Waddington et al., 2007, Di Paolo et al., 2009b), indicating that coagulation factors 
play a pivotal role in the selective transduction of hepatocytes but are not involved in 
sequestration of Ad vectors by Kupffer cells. 
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SPR was also used to show that FX can bind directly to Ad5 vectors pseudotyped 
with the fibers from various sub-species D Ads (Parker et al., 2007).  The addition of 
physiological concentrations of FX significantly increased both binding and 
transduction by Ad5/f17, Ad5/f24, Ad5/f30, Ad5/f33, Ad5/f45 and Ad5/f47, all 
fibers from sub-group D Ads, in a hepatocyte cell line, HepG2 (Parker et al., 2007).  
Transduction by these sub-species D pseudotype vectors was not significantly 
effected by the addition of FVII and FIX, in contrast to Ad5 and AdKO1/Ad*F, 
suggesting potential differences in the fiber-coagulation factor interactions 
(Shayakhmetov et al., 2005b, Parker et al., 2006, Parker et al., 2007).  However, 
consistent with Ad5 and AdKO1/Ad*F, the addition of FX seems to direct the sub-
species D pseudotype vectors through HSPGs for transduction in vitro (Parker et al., 
2007).  FX-mediated transduction by Ad5/f17, Ad5/f24, Ad5/f30, Ad5/f33, Ad5/f45 
and Ad5/f47 was significantly reduced in the CHO-pgsA745 cell line, compared to 
CHO-K1 cells (wild-type CHO cells) (Parker et al., 2007).  CHO-pgsA745 cells 
have been genetically modified to be deficient in HSPG polymerisation and, 
therefore, have no cell surface HSPG expression.  This provides further evidence 
that after interaction with FX, Ad5 and sub-species D pseudotyped Ads use HSPGs 
as their predominant cellular receptor system.  However, this interaction probably 
does not occur using the putative HSPG binding motif KKTK (identified in the Ad5 
fiber shaft), as this is not present in fibers from the sub-species D Ads and AdS* 
vectors, which have a mutated KKTK motif, and both these groups of vectors bind 
FX (Kritz et al., 2007).  Taken together, these data suggest the presence of a 
common FX binding site on the fibers from sub-species C and D Ads or the fiber 
protein is not responsible for binding FX. 
In vivo experiments in mice also demonstrated that liver transduction by Ad5/f47 
was substantially reduced by warfarin pre-treatment (Waddington et al., 2007).  
Therefore, in vivo coagulation factors affect Ad vectors with sub-species D fibers 
(Ad5/f47) as well as those with sub-species C fibers (Ad5).  These studies indicated 
that CAR plays little or no role in hepatocyte transduction after systemic delivery of 
Ad vectors (Shayakhmetov et al., 2005b, Parker et al., 2006, Kritz et al., 2007, 
Parker et al., 2007, Waddington et al., 2007).  Additionally, as coagulation factors 
are not responsible for the early sequestration of vectors by Kupffer cells, strategies 
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which deplete Kupffer cells may be required to increase the bioavailability of the 
vector. 
1.7.10 Determination of FX binding site on adenoviral 
vectors 
SPR analysis determined that FX did not bind to the fiber of Ad5 as Ad5 vectors 
with the knob domain deleted, fiber shaft deletions (Li et al., 2006) or a completely 
fiberless Ad5 vector (Von Seggern et al., 1999) all bound FX (Waddington et al., 
2008).  Cell binding by these fiber mutant Ad5 vectors was significantly enhanced in 
the presence of FX (Waddington et al., 2008), suggesting that FX binds to an 
alternative Ad5 capsid protein and not the fiber. 
By use of purified Ad5 hexon protein, it was determined by SPR that FX bound to 
the Ad5 hexon in a direct calcium-dependent, high affinity manner (Waddington et 
al., 2008).  SPR analysis of FX mutants containing different components of the FX 
four domain structure (Gla-EGF1-EGF2-SP) demonstrated that the Gla domain of 
FX was required for binding to Ad5 (Waddington et al., 2008).  This was also 
confirmed in vivo as a Gla-domainless FX variant failed to rescue Ad5-mediated 
liver transduction in the vitamin K-dependent coagulation factor-ablated warfarin 
mouse model (Waddington et al., 2008). 
By electron cryomicroscopy (cryo-EM), it was possible to determine that FX binds 
within a central cavity formed by the trimeric hexon proteins of Ad5 and involves 
interaction with the Ad5 hexon HVRs (Kalyuzhniy et al., 2008, Waddington et al., 
2008).  A novel mutant Ad5 vector Ad5HVR48 (Roberts et al., 2006), which is the 
complete Ad5 vector with only the amino acids in the all the HVRs swapped from 
Ad5 to those from Ad48, was used to ascertain the importance and relevance of this 
putative hexon:FX interaction.  By SPR, Ad48 and Ad5HVR48 did not bind FX and 
FX did not enhance cellular binding or transduction by either Ad48 or Ad5HVR48 in 
a number of cell lines (Waddington et al., 2008).  In vivo, Ad5HVR48 produced a 
600-fold reduction in liver transduction in comparison to Ad5 after systemic 
administration of the vectors (Waddington et al., 2008).  In vivo, fiber-dependent 
transduction of the Ad5HVR48 vector and Ad5 was tested by intramuscular injection 
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into the mouse hind limb to confirm that the Ad5HVR48 vector was viable in vivo 
(Waddington et al., 2008).  Transgene expression by Ad5HVR48 was not 
significantly different to Ad5 (Waddington et al., 2008), thereby demonstrating that 
Ad5 can utilise alternate virion proteins for transduction when placed into different 
environments.  This also suggests that fiber has no role in binding to FX as 
Ad5HVR48 has the Ad5 fiber and does not bind FX with a substantial reduction in 
liver tropism. 
To further assess the interaction of Ad5 and FX, an inhibitor was utilised.  X-bp is a 
29 kDa protein isolated from Deinagkistrodon acutus (the hundred pace snake) 
which binds with high affinity to human and murine FX (Atoda et al., 1998).  X-bp 
blocks the FX-Gla domain-Ad5 interaction and pre-incubation of X-bp with FX in 
vitro totally abolished the FX-mediated enhancement in Ad5 transduction 
(Waddington et al., 2008).  Furthermore, X-bp pre-incubated with FX before 
administration to warfarinised mice, prevented FX rescue of liver transduction by 
Ad5 (Waddington et al., 2008).  Additionally, in non-warfarinised mice the presence 
of X-bp substantially reduced Ad5 liver transduction (Waddington et al., 2008).  The 
binding of FX to the Ad5 hexon proteins in vivo promotes the interaction of the Ad5-
FX complex with cellular HSPGs via the serine protease domain of FX (Waddington 
et al., 2008).  Therefore, it is the use of HSPGs as receptors for the Ad5-FX 
complex, and not CAR via a direct engagement, which leads to liver transduction 
after systemic administration in vivo (Waddington et al., 2008). 
Investigation of the other Ad serotypes found that although the sub-species D 
pseudotype Ads bind FX (Parker et al., 2007), the sub-species D Ads did not 
(Waddington et al., 2008).  The sub-species D pseudotype Ad5/f47 was also 
sensitive to warfarin pre-treatment in vivo (Waddington et al., 2007), suggesting that 
binding of FX to the Ad5 hexon leads to efficient liver targeting and is dominant 
over any other effects produced by the fiber.  The majority of previous studies to 
retarget the virus to alternate cells and organs have focused on fiber by creating and 
using pseudotype vectors (Havenga et al., 2002, Parker et al., 2007).  However, the 
role of hexon in dictating Ad biodistribution is now clear and is an increasingly 
relevant target for Ad modification. 
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1.7.11 Hexon modification to prevent FX binding 
Previous research into retargeting of Ad5 liver tropism by modification of the hexon 
protein focussed on hexon HVR 5 (HVR5) as there was low structural constraint on 
the insertion of proteins into this area of the capsid (Vigne et al., 1999).  Hexon 
modification to include a ligand specific for αv integrins in HVR5 (AdHRGD) 
increased transduction of human VSMCs, which are naturally refractory to infection 
by Ad5 as they do not express CAR (Vigne et al., 1999).  In mice, AdHRGD 
produced a 98% reduction in liver transduction after systemic administration of the 
vector, compared to control Ad5 (Vigant et al., 2008).   
Ad vectors have also been generated with hexon proteins from other Ad serotypes 
(Ostapchuk and Hearing, 2001, Alba et al., 2009).  The HVR5 of Ad5 was swapped 
for the HVR5 of Ad2 (another sub-species C Ad, producing AdHAd2) and the sub-
species D Ads Ad19 (AdHAd19) and Ad30 (AdHAd30) (Vigant et al., 2008).  After 
intravenous delivery to mice, these three HVR5 mutant vectors produced 
significantly reduced liver transgene expression (Vigant et al., 2008).  Importantly, 
the HVR5 swap from Ad5 to Ad2, a sub-species C vector which has strong liver 
tropism as a full serotype vector, did not rescue the reduction in liver transduction 
compared to control Ad5.  AdHRGD and AdHAd2 bound FIX and FX as efficiently 
as control Ad5 (Vigant et al., 2008).  Whereas, AdHAd19 and AdHAd30 had 
strongly impaired binding of FIX and binding to FX was also decreased, although to 
a lesser degree (Vigant et al., 2008).  However, the addition of FX did not 
significantly enhance transduction in vitro by any of the HVR5 modified vectors 
(Vigant et al., 2008).  This suggests that HVR5 of the hexon protein is responsible 
for binding to FX. 
Therefore, it was known that the HVRs were important in FX binding as hexon 
modified vectors, including Ad5HVR48 and AdHRGD, showed reduced FX binding 
(Vigant et al., 2008, Waddington et al., 2008).  However, it was not known exactly 
which of the seven HVRs present in the hexon protein were required for the 
interaction with FX.  Cryo-EM images at 40 Å resolution suggested that the FX 
density was in close proximity to HVR3, HVR5 and HVR7 of Ad5 (Kalyuzhniy et 
al., 2008).  High resolution cryo-EM images at less than 26 Å identified the HVR5 
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and HVR7 domains as areas potentially key for FX binding (Waddington et al., 
2008).  Putative contact residues involved in FX binding were determined in the 
hexon protein and the amino acid residue glutamic acid (E) in position 451, which is 
conserved in all Ad serotypes that bind FX but is replaced by glutamine (Q) in Ads 
that do not bind to FX (Waddington et al., 2008, Alba et al., 2009). 
For further interrogation into the precise HVRs involved in binding FX, Ad5 vectors 
were engineered which contained the HVRs of Ad5 exchanged for the HVRs of 
Ad26, a sub-species D Ad which does not bind FX (Waddington et al., 2008, Alba et 
al., 2009).  Ad5 vectors were produced with the HVR5 swapped [Ad5HVR5(Ad26)], 
HVR7 swapped [Ad5HVR7(Ad26)] and both HVR5 and HVR7 swapped 
[Ad5HVR5+7(Ad26)] for that of Ad26 (Alba et al., 2009).  SPR analysis showed 
that Ad5HVR5(Ad26) had substantially reduced FX binding, whereas FX binding to 
Ad5HVR7(Ad26) and Ad5HVR5+7(Ad26) was completely abolished, equivalent to 
Ad26 (Alba et al., 2009).  In vitro, binding and transduction of SKOV-3 cells was 
significantly reduced by all three vectors (Alba et al., 2009).  The addition of 
physiological concentrations of FX did not affect binding and transduction by 
Ad5HVR7(Ad26) and Ad5HVR5+7(Ad26), whereas Ad5HVR5(Ad26) was affected 
by the presence of FX but this was reduced compared to control Ad5 (Alba et al., 
2009).  In vivo, all vectors showed substantially reduced liver transduction in 
comparison to Ad5 after intravenous administration in mice (Alba et al., 2009).  
Therefore, HVR5 and HVR7 of Ad5 are essential for FX binding.  However, it was 
found that the Ad5HVR5(Ad26) and Ad5HVR5+7(Ad26) mutations prevented 
maturation of the vectors as they showed reduced capacity to transduce cells via the 
fiber-dependent CAR-binding pathway in vitro (Alba et al., 2009). 
To prevent alteration of the integrity of the virus capsid proteins, point mutations of 
the amino acid residues in HVR5 and HVR7 of the Ad5 hexon, thought to be 
directly involved in binding to FX, were performed.  In combination with the point 
mutations to the HVRs and alone, the amino acid E451 (which is in HVR7) was 
changed to Q, the residue present in all non-FX binding serotypes (Alba et al., 
2009).  Modification of key amino acids in HVR7 completely ablated FX binding 
and the E451Q mutation showed decreased binding to FX (Alba et al., 2009).  All 
point mutations demonstrated reduced in vitro cell binding and transduction, and 
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liver transduction in vivo was also markedly reduced compared to Ad5 (Alba et al., 
2009).  Therefore, this study ascertained not only the regions of the Ad5 hexon 
which bound FX but determined specific amino acid residues responsible for this 
interaction. 
1.7.12 Host immune reactions 
After administration of Ad vectors, a variety of anti-viral host immune reactions are 
produced.  Recognition of viral components by host pattern-recognition receptors 
(PRRs) induces the anti-viral innate immune response (Janeway and Medzhitov, 
2002).  Kupffer cells in the liver and other macrophages rapidly sequester the vectors 
(Lieber et al., 1997, Worgall et al., 1997) (Figure 1.5).  Additionally, macrophages 
in the spleen can trigger an IL-1α-mediated response to vectors containing the RGD 
motif (Di Paolo et al., 2009a). 
There is a broad prevalence of Ad5-specific neutralising antibodies in the population 
(Christ et al., 1997, Sprangers et al., 2003, Vogels et al., 2003, Sumida et al., 2005, 
Abbink et al., 2007, Parker et al., 2009).  These are naturally occurring antibodies 
associate with the virus capsid and prevent transduction in vivo (Kuriyama et al., 
1998, Stallwood et al., 2000, Sprangers et al., 2003).  Interaction with neutralising 
antibodies then leads to rapid clearance of the virus (Christ et al., 1997).  Therefore, 
the adaptive immune system poses a barrier to the use of gene therapy vectors.  
Polyethylene glycol (PEG) and the hydrophilic polymer HPMA have been used to 
coat the adenoviral capsid to physically shield the vector from being recognised by 
both antibody-mediated and innate immune system but this has led to a reduction in 
the efficiency of transduction by the vector (Croyle et al., 2005, Eto et al., 2005, 
Mok et al., 2005, Carlisle et al., 2009).  However, one study has shown that PEG 
modification of Ad5 prevented interaction of the vector with platelets and blood 
cells, attenuating the threat of thrombocytopenia, coagulation and spenomegaly seen 
with control Ad5, and did not show a reduction in liver transduction in mice 
(Hofherr et al., 2007). 
Ad5 also can produce an overall toxicity profile at high doses which has led to a well 
publicised fatality (Raper et al., 2003).  Activation of the immune system due to 
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interaction of Ad5 with both antibodies and the complement system can lead to 
cytokine release, resulting systemic inflammatory response syndrome which can be 
fatal to the host (Schnell et al., 2001, Lozier et al., 2002, Morral et al., 2002, Raper 
et al., 2003).  Additionally, the recently terminated STEP trial, which was a 
vaccination study in the clinic for HIV, suggested that Ad5-based strategies may 
enhance infection rates in subjects with pre-existing antibodies (Perreau et al., 2008).  
However, this has been recently refuted (Hutnick et al., 2009, O'Brien et al., 2009).  
A better understanding of the basic virus:host interactions will enable the generation 
of safer vectors more suited to intravenous administration with greatly improved 
targeting capacity and dose limiting toxicities. 
1.7.13 Future of gene therapy with adenoviruses 
Although the mechanism of infection by Ad5 in vitro and in vivo is now known, the 
effective use of Ad5 vectors is, however, severely hampered by a number of 
problems.  Local delivery of Ad vectors often eliminate or substantially restrict the 
dissemination of the vector to distant, non-target sites as the vector has not been 
exposed to the bloodstream.  However, leakage can occur and accumulation of 
vectors in other non-target organs, especially the liver, is an important constraint on 
safety (Wang et al., 2003). 
Therefore, the future of systemic, non-hepatic gene therapy should be based on Ad5 
vectors designed to block the hexon-FX interaction or focus on Ads that offer no FX 
interaction and have a low seroprevalance with respect to pre-existing antibodies in 
the human population (Roberts et al., 2006, Abbink et al., 2007).  This would allow 
intravenous administration of gene therapy vectors without liver tropism, due to the 
FX interaction, and with possibly reduced toxic effects.  Additionally, the liver de-
targeted vectors could be retargeted to selected cells and tissues, potentially realising 
one of the goals of gene therapy; the targeted and selective use of oncolytic Ads to 
eliminate metastatic disease. 
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1.8 Aims of thesis 
The principle aim of this thesis was to investigate means of producing targeted 
delivery of biological agents, which includes both peptides and gene delivery 
systems (recombinant adenoviral vectors).  This was divided into two separate 
studies: targeting an anti-oxidant to the vasculature to improve its potential and the 
investigation of the influence of blood coagulation FX on in vivo targeting by Ad35 
and chimeric Ad5/Ad35 vectors.  This was achieved through the following 
techniques: 
• In vitro and in vivo evaluation of candidate vascular and cardiac targeting 
peptides through phage display for cardiac-specific endothelial markers in the 
stroke prone spontaneously hypertensive rat (SHRSP). 
• Comparison of the benefit of vascular targeting the anti-oxidant peptide 
gp91ds in vivo in the SHRSP. 
• Evaluation of the interaction between Ad35 and blood coagulation FX. 
• Evaluation of the influence of FX on binding, internalisation, trafficking and 
transduction of Ad35 and chimeric Ad5/Ad35 vectors in vitro. 
• Evaluation of the influence of FX on specific organ targeting by Ad35 and 
chimeric Ad5/Ad35 vectors in vivo in CD46 transgenic mice. 
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2.1 Materials 
2.1.1 Chemicals 
All chemicals, unless otherwise stated, were obtained from Sigma-Aldrich (Poole, 
UK) and were of the highest grade obtainable.  All cell culture reagents were 
obtained from Gibco (Paisley, UK) unless otherwise stated.  Dulbecco’s calcium and 
magnesium free phosphate buffered saline (PBS) was obtained from Lonza (Basal, 
Switzerland).  Peptides were synthesised by and obtained from Peptide 2.0 
(Chantilly, VA, USA). 
2.2 Methods 
2.2.1 Tissue culture 
All tissue culture was performed in sterile conditions using biological safety class II 
vertical laminar flow cabinets.  Cells were grown in 37°C incubators maintained at 
5% CO2, 95% air.  Cell lines and media used are detailed in Table 2. 
2.2.2 Maintenance of established cell lines 
Cells were grown as a monolayer and media was replenished every 3-4 days.  Cells 
were routinely passaged at approximately 80% confluence to prevent overgrowth 
and loss of surface contact.  To passage, cells were washed twice in PBS and 
incubated in 3 ml of trypsin-ethylenediamine tetra-acetic acid (trypsin-EDTA, 
Gibco, Paisley, UK) for approximately 5 minutes at 37°C or until the majority of the 
cells had detached from the flask.  The action of trypsin-EDTA was then prevented 
by the addition of 5 ml complete media.  Cells were pelleted by configuration at 
1500 rpm for 5 minutes and resuspended in complete media for passaging or plating.  
Before plating cells were counted using a haemocytometer to ensure the required 
seeding density. 
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Cell Type Description Composition of Cell Culture Media Used
CHO-BC1 
CHO-BC2 
CHO-C1       
CHO-C2        
CHO-WTR
Chinese hamster ovary cells 
stably transfected with an isoform 
of human CD46 or control 
plasmid (gift from Prof. J. 
Atkinson, Washington University 
School of Medicine, St Louis, 
MO, USA)
Dulbecco's Modified Eagle Medium (DMEM)/F-12 media supplemented 
with 10% (v/v) fetal calf serum (FCSPAA Laboratories, Yeovil, UK), 2 
mM L-glutamine, 1% (v/v) penicillin, 100 µg/ml streptomycin and 500 
µg/ml geneticin (G-418).
MDA-MB-435
Human breast ductal carcinoma 
cell line (National Institutes of 
Health [NIH])
RPMI 1640 media supplemented with 10% (v/v) fetal calf serum, 2 mM 
L-glutamine, 1% (v/v) penicillin, 100 µg/ml streptomycin, 250 µg/ml 
amphotericin B (fungizone) and 0.01 mg/ml gentamicin.
RGE
Rat glomerular endothelial cell 
line (Deutsche Sammlung von 
Mikrooganismen and Zellkulluren 
GmbH [DSMZ, Braunschweig, 
Germany])
DMEM supplemented with 10% (v/v) fetal calf serum, 2 mM L-
glutamine, 1% (v/v) penicillin and 100 µg/ml streptomycin.
SKOV-3 Human ovary adenocarcinoma 
cell line (NIH)
RPMI 1640 media supplemented with 10% (v/v) fetal calf serum, 2 mM 
L-glutamine, 1% (v/v) penicillin, 100 µg/ml streptomycin, 250 µg/ml 
amphotericin B (fungizone) and 0.01 mg/ml gentamicin.
T-47D Human breast ductal carcinoma 
cell line (NIH)
RPMI 1640 media supplemented with 10% (v/v) fetal calf serum, 2 mM 
L-glutamine, 1% (v/v) penicillin, 100 µg/ml streptomycin, 250 µg/ml 
amphotericin B (fungizone) and 0.01 mg/ml gentamicin.
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2.2.3 Cryo-preservation and recovery of cultured cell lines 
Cells were harvested as described above and resuspended in 2 ml complete media 
supplemented with 10% dimethyl sulphoxide (DMSO) per T-150 cell culture flask of 
cells (5% DMSO for cancer cell lines).  1 ml of the cell suspensions was aliquoted 
into cryo-preservation vials and cooled at a constant -1°C/minute to -80°C using 
isopropanol.  Vials were then stored indefinitely in liquid nitrogen.  Cryo-preserved 
cells were recovered by thawing at 37°C and then adding them drop-wise to 10 ml 
complete media.  Cells were then pelleted by configuration at 1500 rpm for 5 
minutes and resuspended in complete media and added to a T-25 cell culture flask.  
Cells were incubated overnight at 37°C and the media changed the following day. 
2.3 Determination CAR and CD46 level of cell 
lines 
The three cancer cell lines used in this study, MDA-MB-435, SKOV-3 and T-47D, 
were identified and obtained from the NCI60 database (http://dtp.nci.nih.gov).  This 
database also provides information on the relative levels of molecular targets 
expressed by these cancer cell lines.  CAR and CD46 RNA and protein expression 
levels were confirmed by TaqMan quantitative PCR (qPCR) and western blotting, 
respectively. 
2.3.1 RNA extraction 
Total RNA was extracted from the cancer cell lines using the RNeasy Mini Kit 
(QIAGEN, Crawley, UK) as per manufacture’s instructions.  Briefly, one T-150 cell 
culture flask of cells was trypsinised as described and cells were pelleted by 
configuration at 1500 rpm for 5 minutes.  600 µl buffer RLT was added to the cell 
pellet and vortexed to disrupt the cells.  Buffer RLT contains guanidine 
isothiocyanate which immediately inactivates RNases to ensure isolation of intact 
RNA.  To ensure complete homogenisation of the sample, it was also passed through 
a blunt 20-gauge needle five times.  600 µl 70% ethanol was added to the lysates to 
ensure ideal binding conditions.  700 µl of the lysate was loaded onto the RNeasy 
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Spin Column.  Samples were centrifuged at 8000 x g for 15 seconds at room 
temperature to allow the RNA to bind to the silica-gel membrane of the spin column.  
This was repeated until the entire lysate had been added to the spin column.  The 
spin column was then washed with 700 µl buffer RWT and centrifuged at 8000 x g 
for 15 seconds at room temperature.  This was followed by two wash steps with 500 
µl buffer RPE, the first wash centrifuged at 8000 x g for 15 seconds at room 
temperature and the second wash centrifuged at 8000 x g for 2 minutes at room 
temperature.  Finally the RNA was eluted in 30 µl RNase-free water by 
centrifugation at 8000 x g for 1 minute.  The eluted RNA was then passed through 
the spin column again to increase the RNA yield.  The quantity of RNA in each 
sample was quantified by NanoDrop (ND-1000 spectrophotometer [Labtech 
International, Ringmer, UK]). 
2.3.2 DNase treatment of RNA 
DNase digestion is required for RNA applications which are sensitive to DNA 
contamination (e.g. qPCR analysis).  DNase treatment of RNA samples was 
performed using the TURBO DNA-free™ (Ambion, TX, USA).  For a 40 µl RNA 
sample, 4.5 µl 10 x TURBO DNase Buffer and 1 µl TURBO DNase (2 U/µl) was 
added.  After incubation at 37°C for 30 minutes, 5 µl DNase inactivation reagent was 
added and incubated for 2 minutes at room temperature.  The sample was then 
centrifuged at 13000 rpm for 2 minutes at room temperature and supernatant kept as 
a DNA-free RNA sample, stored at - 80°C. 
2.3.3 cDNA synthesis 
One µg RNA was used to synthesis cDNA using Advantage RT-for-PCR Kit 
(Clontech, CA, USA) as per manufacture’s instructions.  Briefly, 1 µg RNA samples 
were diluted to a total volume of 12.5 µl and 1 µl random hexamer primer was 
added.  Samples were then incubated at 70°C for 2 minutes before placing the 
samples on ice.  To each RNA sample, 4 µl 5 x reaction buffer, 1 µl dNTP mix (10 
mM each), 0.5 µl recombinant RNase inhibitor and 1 µl MMLV reverse transcriptase 
was added and mixed by pipetting.  The samples were incubated at 42°C for 1 hour 
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to allow cDNA synthesis to occur and then heated to 94°C for 5 minutes to stop the 
cDNA synthesis reaction and to destroy any DNase activity. 
2.3.4 TaqMan qPCR 
TaqMan qPCR was used to quantify the relative concentration of CAR and CD46 
RNA present in each of the cancer and CHO cell lines.  This quantitative 
measurement is based on the detection of a fluorescent signal produced 
proportionally during amplification of a PCR product.  The amount of fluorescence 
released during the amplification cycle is proportional to the amount of product 
generated in each cycle and can be measured directly.  Acquisition of data occurs 
when PCR amplification is in the exponential phase.  The Power SYBR Green 
detection system (Applied Biosystems, Warrington, UK) was used.  Power SYBR 
Green PCR master mix with 300 nM CAR or CD46 primers (CAR: forward 5’-
CTCCAAAGAGCCGTACGTCC-3’ and reverse 5’-AGTCTTGGAATATCCTTC-
CATGTTG-3’, CD46: forward 5’-TTGCTGTTGATTGTACCAAGGG-3’ and 
reverse 5’-ACTGCTTGGCTAAGGGACTCAG-3’) were used to amplify CAR or 
CD46 cDNA.  The following conditions were used: denaturation – 95°C for 10 
minutes; amplification – 95°C for 15 seconds; annealing – 60°C for 1 minute 
(repeated for 50 cycles); dissociation – 95°C for 15 seconds, 60°C for 15 seconds 
and 95°C for 15 seconds.  CT values were used to ascertain the levels of CAR and 
CD46 present in the cell lines relative to each other. 
2.3.5 Western blotting 
To determine the relative expression levels of CAR and CD46 in the cancer cell 
lines, sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blotting were performed.  To separate the two isoforms of CD46, which are 
56 and 66 kDa, respectively, and CAR, which is a 46 kDa protein, reducing 
conditions and a 12% polyacrylamide gel (containing 40% (v/v) polyacrylamide 
(30%), 11.25 mM Tris pH 8.8, 0.1% (v/v) SDS, 300 µl ammonium persulphate 
(APS) and 30 µl N,N,N′,N′-tetramethylethylenediamine (TEMED)) were used. 
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Cells were harvested and lysed in 0.2% triton X-100.  Samples were also 
freeze/thawed and passed through a blunt 20-gauge needle five times to produce 
complete lysis of the cells.  Protein concentration was determined by bicinchoninic 
acid (BCA) assay (Perbio Science, Cramlington, UK) as described below (Section 
2.3.5.1).  Protein samples were diluted to the same concentration in a total volume of 
50 µl and mixed with 2 x reducing loading dye (125 mM Tris pH 6.8, 4% (v/v) SDS, 
10% (v/v) glycerol, 0.006% (w/v) bromophenol blue and 2% (v/v) β-
mercaptoethanol).  The samples were then heated to 95°C for 5 minutes before 
loading onto the gel.  40 µl rainbow ladder (Amersham Bioscience UK Ltd, 
Buckingham, UK) was also added to the gel as a marker of protein size.  Samples 
were electrophoresed at 200 V in running buffer (0.025 M Tris-HCl, 0.2 M glycine, 
0.001 M SDS) for approximately 6 hours to achieve separation of the CD46 isoforms 
on the gel. 
Proteins were transferred onto Hybond-P membrane (Amersham Bioscience UK Ltd, 
Buckingham, UK) overnight at 0.9 mAmps at 4°C in transfer buffer (0.025 M Tris, 
0.2 M glycine, 20% (v/v) methanol, 0.01% (v/v) SDS).  The membrane was then 
blocked in 10% (w/v) fat-free milk powder in TBS-T (150 mM NaCl, 50 mM Tris, 
0.1% (v/v) Tween-20) for 2 hours with shaking.  The membrane was incubated for 1 
hour at room temperature with a 1:500 dilution in blocking solution of either the 
anti-CD46 antibody (H-294 clone; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA) or the anti-CAR antibody (RmcB clone; Upstate, Lake Placid, NY, USA).  
The membrane was washed by two 5 minute washes in blocking solution before 
addition of the secondary antibodies.  A 1:2000 dilution of swine anti-rabbit 
horseradish peroxidase (HRP) antibody (Dako, Denmark) in blocking solution was 
used for the anti-CD46 membrane and a 1:1000 dilution of rabbit anti-mouse HRP 
antibody (Dako, Denmark) was used for the anti-CAR membrane.  Both secondary 
antibodies were incubated with the membrane for 1 hour at room temperature.  The 
membrane was then washed with four 15 minute washes in blocking solution with an 
addition two 15 minute washes with TBS-T.  Proteins were visualised using 
enhanced luminol-based chemiluminescent (ECL) detection system (Amersham 
Bioscience UK Ltd, Buckingham, UK) as per the manufacture’s instructions.  
Briefly, equal quantities of the two solutions from the ECL kit were mixed and 
poured onto the membrane.  After one minute, the excess ECL was drained off and 
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films were exposed for overnight to determine the presence of the CD46 or CAR 
proteins. 
2.3.5.1 Determination of protein concentration 
Protein concentrations of the cell lysates were quantified by BCA assay (Perbio 
Science, Cramlington, UK) as per the manufacture’s instructions.  A standard curve 
was generated using dilution of bovine serum albumin (BSA) ranging from 2000 
µg/ml to 25 µg/ml.  PBS was used as the blank control.  200 µl of BCA working 
reagent was added to 25 µl of the cell lysate or standard in duplicate in a 96-well 
plate.  The plate was then incubated at 37°C for 30 minutes.  The absorbance was 
measured at 570 nm using a Wallac VICTOR2 plate reader (Wallac, Turku, Finland). 
2.4 Administration of fluorescently-labelled 
peptides to RGE cells 
RGE cells were seeded in 96-well plates at a seeding density of 1x104 cells/well and 
incubated overnight at 37°C to produce 70-80% confluence.  Peptides were added to 
the cells in concentrations ranging from 1 – 100 µmol/l in 300 µl of complete media.  
Peptides were allowed to incubate with the cells at 37°C for 10 minutes.  The cells 
were washed with PBS and complete media was added so that images could be taken 
using a fluorescence microscope. 
2.5 Preparation of plasmid DNA 
An ampicillin containing agar plate was streaked with bacteria containing the 
plasmid DNA to be amplified from a glycerol stock and incubated overnight at 37°C.  
A single colony was then picked from the plate and used to inoculate a starter culture 
of 10 ml luria broth (LB) containing ampicillin.  The starter culture was incubated in 
an orbital shaker for 8 hours at 37°C and 180 rpm.  The cloudy starter culture was 
then added to 500 ml LB in a 2 l flask and incubated in an orbital shaker overnight at 
37°C and 180 rpm.  The bacterial cells were harvested by centrifugation at 6000 x g 
for 15 minutes at 4°C. 
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The plasmid DNA was extracted from the bacteria using the Plasmid Maxi Kit 
(QIAGEN, Crawley, UK) as per manufacture’s instructions.  Briefly, the bacterial 
pellet was re-suspended in 10 ml of the lysis Buffer P1.  Buffer P1 contains Tris and 
EDTA.  EDTA chelates divalent metals (primarily magnesium and calcium).  
Removal of these cations destabilises the cell membrane, producing lysis of the 
bacterial cells, and also inhibits DNases.  In addition, Buffer P1 also contained 
RNase A (a ribonuclease to degrade RNA).  10 ml of Buffer P2 was added, the 
solution mixed thoroughly by inverting 4-6 times and incubated at room temperature 
for 5 minutes.  Buffer P2 contains sodium hydroxide and SDS.  SDS is a detergent 
which produces holes in the cell membranes and sodium hydroxide loosens the cell 
walls.  This results in release of plasmid DNA and sheared cellular DNA from the 
cells.  Sodium hydroxide also denatures the DNA, producing linearisation of cellular 
DNA and separation and the strands are separated.  As plasmid DNA is circular, it 
remains topologically constrained.  10 ml of Buffer P3 was added (chilled to 4°C), 
the solution mixed thoroughly by inverting 4-6 times and incubated on ice for 20 
minutes.  Buffer P3 was a neutralisation buffer containing potassium acetate and 
allows precipitation of genomic DNA, proteins, cell debris and KDS (combination of 
acetate and SDS).  The circular plasmid DNA is also allowed to renature.  The 
solution was then centrifuged at 20000 x g for 30 minutes at 4°C and the supernatant 
containing the plasmid DNA was removed.  A QIAGEN-tip 500 was equilibrated by 
addition of 10 ml Buffer QBT.  The column was allowed to empty by gravity flow.  
The supernatant was applied to the anion-exchange QIAGEN-tip and allowed to 
enter the resin by gravity flow where the plasmid DNA selectively binds under low-
salt and pH conditions.  The QIAGEN-tip was then washed twice with 30 ml Buffer 
QC, which was a medium-salt wash to remove RNA, proteins, metabolites and other 
low-molecular-weight impurities.  The plasmid DNA was then eluted from the 
QIAGEN-tip by addition of 15 ml Buffer QF, a high-salt buffer.  As DNA is 
negatively charged, the addition of salt masks the charges and allows DNA to 
precipitate.  The plasmid DNA was then concentrated and desalted by isopropanol 
precipitation.  10.5 ml of isopropanol was added to the plasmid DNA and 
centrifuged immediately at 15000 x g for 30 minutes at 4°C.  The supernatant was 
then removed, the pellet washed by addition of 5 ml 70% (v/v) ethanol and 
centrifuged at 15000 x g for 10 minutes.  The supernatant was removed and the 
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pellet air-dried for 5-10 minutes.  The plasmid DNA was then re-dissolved in 200 µl 
TE buffer before quantification of yield by NanoDrop. 
2.6 Transfection methods 
Transfection of peptide receptor plasmids into RGE cells was performed using either 
Lipofectamine™ 2000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA) or 
FuGENE® 6 Transfection Reagent (Roche Applied Science, Indianapolis, IN, USA) 
as per the manufacture’s instructions and briefly described below.  Transfection 
procedures were optimised in RGE cells using an enhanced green fluorescent protein 
(eGFP) expression plasmid, which would allow determination of transfected cells 
after viewing with a fluorescence microscope. 
2.6.1 Transfection optimisation using Lipofectamine™ 
2000 
Lipofectamine™ 2000 reaction complexes were generated with a DNA (µg) to 
Lipofectamine™ 2000 (µl) ratio of 1:1, 1:2, 1:3 and 1:4 in Opti-MEM® I serum free 
media.  2 µg DNA was diluted in 50 µl of Opti-MEM® I serum free media and 
mixed gently by pipetting.  In a separate Eppendorf, 2, 4, 6 or 8 µl Lipofectamine™ 
2000 was diluted in 50 µl of Opti-MEM® I serum free media and incubated at room 
temperature for 5 minutes.  The diluted DNA and diluted Lipofectamine™ 2000 
were combined and incubated at room temperature for 20 minutes.  Lipofectamine™ 
2000 only, DNA only and no transfection complex controls were also performed. 
2.6.2 Transfection optimisation using FuGENE® 6 
FuGENE® 6 reaction complexes were generated with a DNA (µg) to FuGENE® 6 
(µl) ratio of 1:1, 2:3, 1:2 and 2:9 in Opti-MEM® I serum free media.  2 µg DNA was 
diluted in 20 µl of Opti-MEM® I serum free media and mixed gently by pipetting.  
In an Eppendorf, 2, 3, 6 or 9 µl FuGENE® 6 was diluted in 100 µl of Opti-MEM® I 
serum free media and incubated at room temperature for 5 minutes.  The media must 
be added to the tubes first to prevent interaction between the plastic tube and 
FuGENE® 6.  The diluted DNA and diluted FuGENE® 6 were combined and 
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incubated at room temperature for 45 minutes.  FuGENE® 6 only, DNA only and no 
transfection complex controls were also performed. 
2.6.3 Transfection of RGE cells 
RGE cells were seeded in 12-well plates at a seeding density of 1.5x105 cells/well 
and incubated overnight at 37°C to produce 70% confluence.  Transfection protocol 
was performed with receptor expression plasmids.  Cells were washed with PBS and 
500 µl Opti-MEM® I serum free media was added to each well.  The transfection 
reagent and plasmid DNA reaction mixtures were added to individual wells and 
mixed by gently by rocking the plate back and forth.  After 4-6 hours, 2 ml complete 
media was added to the cells.  The cells were then left overnight before the media 
was changed and 48 hours after addition of transfection reagent reaction mixture the 
presence of transgene expression was determined.  Subsequent transfection 
experiments were performed with a 1:1 ratio of DNA to Lipofectamine™ 2000. 
2.6.3.1 Administration of fluorescent-labelled peptides to transfected 
RGE cells 
RGE cells were seeded in 96-well plates at a seeding density of 1x104 cells/well and 
incubated overnight at 37°C to produce 70-80% confluence.  50 µM peptides were 
added to the cells in 300 µl of complete media.  Peptides were allowed to incubate 
with the cells at 37°C for 10 minutes.  The cells were washed with PBS and 
complete media was added so that images could be taken using a fluorescence 
microscope. 
2.7 Production of adenoviruses 
2.7.1 Production of full serotype adenoviruses 
Full serotype recombinant adenoviral vectors Ad5 and Ad35 were obtained from 
Crucell (Leiden, Netherlands) as part of a materials transfer agreement and were 
used to produce high titre stocks in house (Table 3).  Low passage 293 cells were 
grown to 80-90% confluence before infection with a multiplicity of infection (MOI) 
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of approximately 1 plaque forming unit (pfu)/cell.  After 3-4 days the cytopathic 
effect of the vector caused the cells to detach from the tissue culture flask.  The 
media containing the cells was collected and the cells were harvested by 
centrifugation at 2000 rpm for 10 minutes at room temperature.  The supernatant was 
discarded and the pellet resuspended in 8 ml of PBS.  An equal volume of Arklone P 
(trichlorotrifluoroethane) was added and after inversion of the falcon tube for 10 
seconds and gentle shaking for 5 seconds, the solution was centrifuged at 3000 rpm 
for 10 minutes at room temperature.  The top aqueous layer was removed and stored 
at -80°C until purification by CsCl gradient 
2.7.2 Production of pseudotype adenoviruses 
Pseudotype recombinant adenoviral vectors Ad5/f35 and Ad5/p35/f35 were obtained 
from Crucell as part of a materials transfer agreement and were used to produce high 
titre stocks in house in the same way as above, however, with the addition of 4 µg/ml 
polybrene in the media (Table 3).  Ad35/f5 was produced in PER.C6 cells and was 
obtained from Crucell as part of a materials transfer agreement (Table 3). 
 
 
Virus Transgene Cell type and conditions for production Original production
Ad5 Luciferase 293 cells Crucell (Leiden, Netherlands)
Ad5.eGFP Enhanced green fluorescent protein (eGFP) 293 cells Crucell
Ad5/f35 Luciferase 293 cells + 4 µg/ml polybrene Crucell
Ad5/f35.eGFP eGFP 293 cells + 4 µg/ml polybrene Crucell
Ad5/p35/f35 Luciferase 293 cells + 4 µg/ml polybrene Crucell
Ad35 Luciferase 293 cells Crucell
Ad35.eGFP eGFP 293 cells Crucell
Ad35/f5 Luciferase PER.C6 cells Crucell
 
Table 3 – Virus transgene and production conditions. 
All viruses were originally obtained from Crucell (Leiden, Netherlands) as part of a 
materials transfer agreement and were used to produce high titer stocks in house. 
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2.8 Adenovirus purification 
Centrifugation on CsCl density gradients was used to purify and concentrate crude 
adenoviral stocks.  Ultra-clear centrifuge tubes (Beckman Coulter Ltd, 
Buckinghamshire, UK) were sterilised with 70% ethanol and then washed with 
sterile water.  A CsCl gradient was produced by sequentially layering 2 ml of CsCl 
with a density of 1.45 g/cm3, 3 ml of CsCl with a density of 1.32 g/cm3 and 2 ml 
40% glycerol.  The crude adenoviral supernatant was then added to the top of the 
gradient and the remaining space was filled with PBS.  The tube was loaded into a 
rotor and centrifuged at 25000 rpm for 1.5 hours at 4°C with maximum acceleration 
and zero deceleration.  Following centrifugation, a band containing the complete 
adenovirus can be seen between the two CsCl layers.  This was removed by piercing 
the tube below the virus band using a 21 gauge needle and removing the band in the 
minimum volume and taking care to prevent disruption of the other bands.  Extracted 
virus was transferred to a Slide-A-Lyzer Dialysis Cassette (molecular weight cut-off 
of 10000) (Perbio Science UK Ltd., Northumberland, UK) for dialysis after 
hydration of the cassette for 1 minute in dialysis solution.  The virus was dialysed in 
2 l of 0.01 M Tris pH 8 / 0.001 M EDTA for 2 hours, after which the buffer was 
replaced and dialysis repeated overnight.  The buffer was changed and supplemented 
with 10% (v/v) glycerol and dialysis was continued for a further 2 hours.  The virus 
was then removed from the cassette, aliquoted and stored at -80°C. 
2.9 Determination of adenoviral particle titres 
Particle titre of all adenoviral vectors was calculated based on the protein content of 
the virus stock using a Micro BCA assay kit (Pierce, Rockford, IL, USA).  Briefly, 
eight BSA standards ranging from 200 µg/ml to 0.5 µg/ml were prepared in PBS and 
150 µl of each and 150 µl of PBS as the blank was pipetted in duplicate into a 96-
well plate.  1, 3 and 5 µl of virus were added in duplicate and each well was made up 
to a total volume of 150 µl with PBS.  150 µl of BCA working reagent was added to 
each well and the plate incubated at 37°C for 2 hours.  The absorbance was 
measured at 570 nm using a Wallac VICTOR2 plate reader (Wallac, Turku, Finland).  
Background absorbance was subtracted from the sample and standards and the 
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amount of protein present in each virus was then calculated from the standard curve.  
The virus particle titre was then calculated using the established formula: 1 µg 
protein = 1x109 viral particles (VP) (Von Seggern et al., 1998). 
2.10 Infection of cells with adenovirus 
2.10.1 Adenovirus binding 
Cells were seeded in 24-well plates at a seeding density of 2x105 cells/well and 
incubated overnight at 37°C to produce 90-100% confluence.  Cells were transferred 
to ice-cold serum-free media ± 8 µg/ml FX (1 IU/ml, Cambridge Biosciences, 
Cambridge, UK) or serum-free media + FX and FX binding protein, X-bp (15 
µg/ml).  X-bp was pre-incubated with FX for 30 min before adding to cells.  Virus 
was diluted in PBS and added at 1000 VP/cell in triplicate and cells were incubated 
at 4°C for 1 hour.  The cells were then washed in ice-cold PBS and the wells were 
scraped to remove the cells in 500 µl PBS into a 1.5 ml Eppendorf.  The cell 
suspension was then centrifuged at 13000 rpm for 5 minutes at room temperature to 
allow the cells to pellet.  Supernatant was then removed and the pellet was 
resuspended in 200 µl PBS. 
2.10.1.1 DNA extractions 
Viral and total genomic DNA was isolated from each well of the adenoviral cell 
binding experiment using the QIAamp DNA Mini Kit (QIAGEN, Crawley, UK) as 
per manufacturer’s instructions.  Briefly, 20 µl proteinase K and 200 µl buffer AL 
was added to each of the 200 µl resuspended cell samples and vortexed.  Buffer AL 
contains chaotropic salts which allow the nucleic acids to be adsorbed onto the 
silica-gel membrane of the QIAamp Spin Column as the chaotropic salts remove 
water from hydrated molecules in solution.  Polysaccharides and proteins do not 
adsorb and are removed.  Samples were incubated at 56°C for 10 minutes.  200 µl 
100% ethanol was added to the samples, mixed and then the complete sample was 
loaded onto a QIAamp Spin Column.  Samples were centrifuged at 6000 x g for 1 
minute at room temperature to allow the DNA to adsorb onto the silica-gel 
membrane of the spin column.  The spin column was then washed with 500 µl buffer 
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AW1 and centrifuged at 6000 x g for 1 minute at room temperature, followed by a 
second wash step with 500 µl buffer AW2 and centrifuged at 16000 x g for 3 
minutes at room temperature.  Finally the DNA was eluted in 50 µl nuclease-free 
deionised water by centrifugation at 6000 x g for 1 minute.  The quantity of DNA in 
each sample was quantified by NanoDrop (ND-1000 spectrophotometer [Labtech 
International, Ringmer, UK]). 
2.10.1.2 TaqMan qPCR 
TaqMan qPCR was used to quantify the number of virus genome particles remaining 
bound to the cells from the cell-binding experiment.  The Power SYBR Green 
detection system (Applied Biosystems, Warrington, UK) was used.  Power SYBR 
Green PCR master mix with 300 nM luciferase primers, forward (5’-
GCCCGCGAACGACATTTATAA3’) and reverse (5’-
CGCAGTATCCGGAATGATTTG-3’), were used to amplify luciferase DNA.  The 
conditions used were described previously (Section 2.3.4).  A luciferase 
quantification standard curve was produced from serial dilutions of Ad5 (102-107 
VP).  50 or 100 nanograms (ng) total DNA was used in each reaction and total 
adenoviral genomes were calculated using the SDS 2.3 software. 
2.10.2 Adenovirus internalisation 
Cells were seeded in 24-well plates at a seeding density of 2x105 cells/well and 
incubated overnight at 37°C to produce 90-100% confluence.  Cells were transferred 
to ice-cold serum-free media ± FX.  Virus was diluted in PBS and added at 1000 
VP/cell in triplicate and cells were incubated at 4°C for 1 hour.  Cells were then 
incubated at 37°C for 1 hour to allow internalisation of the vectors.  The cells were 
then washed in glycine (0.2 M glycine, pH 2.2) for 10 min of ice, which was 
neutralised with 1 M Tris, pH 8.  The cells were then washed in ice-cold PBS and the 
wells were scraped to remove the cells in 500 µl PBS into a 1.5 ml Eppendorf.  The 
cell suspension was then centrifuged at 13000 rpm for 5 minutes at room 
temperature to allow the cells to pellet.  Supernatant was then removed and the pellet 
was resuspended in 200 µl PBS.  Viral and total genomic DNA was isolated as 
described above and qPCR was preformed. 
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2.10.3 Adenovirus transduction 
Cells were seeded in 96-well plates at a seeding density of 4x104 cells/well and 
incubated overnight at 37°C to produce 70-80% confluence.  Cells were transferred 
to serum-free media ± 8 µg/ml FX or serum-free media + FX and 15 µg/ml X-bp.  X-
bp was pre-incubated with FX for 30 min before adding to cells.  Virus was diluted 
in PBS and added at 1000 VP/cell in triplicate and cells were incubated at 37°C for 3 
hours.  The cells were washed with PBS and complete media was added.  Cells were 
incubated at 37°C for 72 hours. 
2.10.3.1 Transgene quantification 
Expression of luciferase transgene was quantified using Luciferase Assay System 
(Promega, Madison, WI, USA) and recombinant luciferase protein (Promega, 
Madison, WI, USA) was used a standard.  Briefly, cells were washed with PBS and 
50 µl 1 x Reporter Lysis Buffer (5 x Reporter Lysis Buffer stock solution, Promega, 
Madison, WI, USA) was added.  To ensure complete lysis of the cells, the plate was 
also freeze/thawed.  10 µl of each sample was transferred to a white 96-well plate 
and 90 µl 1 x Reporter Lysis Buffer was added to each well.  Standard curves of 
recombinant luciferase ranging from 0-100 pg/ml and 0-1 pg/ml were produced and 
100 µl of each dilution was added in duplicate.  Luciferase Assay Buffer was added 
to Luciferase Assay substrate and 100 µl was then added to each well.  
Luminescence was measured using a Wallac VICTOR2 plate reader.  Luciferase 
activity was then normalised to total protein content of the samples determined by 
BCA assay producing relative light units per milligram protein (RLU/mg protein). 
2.10.3.2 Transduction in the presence of anti-CD46 antibody 
Cells were seeded in 96-well plates at a seeding density of 4x104 cells/well and 
incubated overnight at 37°C to produce 70-80% confluence.  Cells were transferred 
to serum-free media ± either 1 µg/ml MEM258 mouse anti-human CD46 antibody 
(AbD Serotec, Oxford, UK) or 100 µg/ml mouse immunoglobulin G (IgG) 1 control 
(Dako, Denmark) 30 min before addition of the virus.  Virus was diluted in PBS and 
added at 1000 VP/cell in triplicate and cells were incubated at 37°C for 3 hours.  The 
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cells were washed with PBS and complete media was added.  Cells were incubated 
at 37°C for 72 hours.  Expression of the luciferase transgene was then quantified and 
normalised to total protein content. 
2.10.4 Labelled vectors 
Labelled adenoviral vectors were produced using the Alexa Fluor® 488 Microscale 
Protein Labeling Kit (Invitrogen, Carlsbad, CA, USA) as per manufacture’s 
instructions.  Briefly, the quantity of vector required was determined by the 
following calculation, where MW is the molecular weight: 
([(µg protein/protein MW) x 1000] x dye:protein molar ratio)   =   µl of dye required 
Concentration of the dye provided in the kit (11.3 nmol/µL) 
The molecular weight of an Ad is 150x106 Da and the volume of the dye provided in 
the kit was 9 µl.  To produce a sufficient percentage of labelled to non-labelled 
vectors, the dye:protein molar ratio attempted was 100%.  After calculation, this 
meant that 152550 µg of protein was required for the labelling reaction.  As 1 µg 
protein = 1x109 VP using the established formula (Von Seggern et al., 1998), this 
meant that 6.1x1014 VP were required for each labelling reaction.  The volume of 
each vector required for addition to the labelling reaction was then calculated by: 
6.1x1014/viral titre per µl 
The calculated volume of vector, including a 20% excess, was transferred to a Slide-
A-Lyzer Dialysis Cassette (molecular weight cut-off of 10000) (Perbio Science UK 
Ltd., Northumberland, UK) for dialysis after hydration of the cassette for 1 minute in 
dialysis solution.  The virus was dialysed in 2 l of PBS pH 7.4 overnight to remove 
the glycerol in which the vector was stored.  The vector was removed from the 
cassette and the calculated volume of vector was added to the reaction tube 
(Component C) supplied by the kit.  A 1 M sodium bicarbonate solution (pH 8.3) 
was prepared by addition of 1 ml of deionised water was added to the vial of sodium 
bicarbonate (Component B).  A 1/10 volume of 1 M sodium bicarbonate was added 
to the reaction tube and mixed by pipetting up and down several times.  Immediately 
before use, 10 µl of deionised water was added to one vial of Alexa Fluor® 488 TFP 
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ester (Component A) and pipetted up and down to ensure the contents of the vial 
were completely dissolved.  9 µl of the reactive dye solution was added to the 
reaction tube and was mixed thoroughly by pipetting up and down several times.  
The reaction mixture was incubated at room temperature for 15 minutes in the dark. 
The labelled vector was then transferred to a new dialysis cassette (molecular weight 
cut-off of 10000) for dialysis after hydration of the cassette for 1 minute in dialysis 
solution.  The virus was dialysed in 2 l of 0.01 M Tris pH 8 / 0.001 M EDTA for 2 
hours, then the buffer was changed and supplemented with 10% (v/v) glycerol and 
dialysis was continued for a further 2 hours.  The dialysis was performed in the dark.  
The virus was then removed from the cassette, aliquoted and stored at - 80°C 
wrapped in tin foil to protect from the light. 
2.10.4.1 Cell trafficking with labelled vectors 
SKOV-3 cells were seeded in 6 well plates at 5x105 cells/well on coverslips and 
incubated overnight at 37°C to produce approximately 50% confluence.  Cells were 
transferred to serum-free media ± 8 µg/ml FX.  Virus was diluted in PBS and added 
at 10000 VP/cell in duplicate and cells were incubated at 4°C for one hour.  The cells 
were then either immediately washed in PBS and fixed in 4% paraformaldehyde for 
5 minutes at room temperature or fixed after incubation at 37°C for 15 minutes, one 
hour or three hours.  The coverslips were then removed from the plates and mounted 
cell side down on slides in ProLong® Gold Antifade Reagent with DAPI to 
counterstain the nuclei of the cells.  The mounting agent was allowed to set 
overnight before viewing on the confocal microscope. 
2.11 Surface plasmon resonance (SPR) 
SPR analysis was performed using a Biacore T100 (GE Healthcare, Little Chalfont, 
UK) as described (Parker et al., 2006).  Briefly, virus was biotinylated using sulfo-
NHS-LC-biotin (Pierce, Rockford IL) according to the manufacturer’s instructions.  
Virus was covalently immobilized onto the flowcell of a streptavidin biosensor chip 
(SA, Biacore) according to the manufacturer’s instructions.  Immobilisation of the 
virus by biotinylation was chosen as it can be controlled to give a very low 
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incorporation of biotin, with hopefully only 1-2 molecules per virus particle.  The 
immobilisation densities of the viruses were: Ad5 – 400 response units (RU), 
Ad5/f35 – 132 RU, Ad5/p35/f35 – 198 RU, Ad35 – 198 RU and Ad35/f5 – 310 RU. 
FX in 10 mM HEPES pH 7.4; 150 mM NaCl; 5 mM CaCl2; 0.005% Tween 20 was 
passed over the chip at a flow rate of 30 µl/min.  Sensorchips were regenerated 
between FX application by injection of 10 mM HEPES pH 7.4; 150 mM NaCl; 3 
mM EDTA; 0.005% Tween 20.  Kinetic analysis was performed in triplicate using 
FX concentrations in the range 108 to 0.05 µg/mL and analysed using Biacore T100 
Evaluation software using either a 1:1 or heterogenous ligand model.  Non-specific 
binding was determined by examination of FX binding to a flow cell with no virus 
immobilised.  FX showed no non-specific binding to the flow cell over the range of 
FX concentrations used. 
Immobilisation of FX on the chip, instead of immobilisation of the virus, was 
attempted but this method only yielded binding data due to the 240 binding sites for 
FX on the virus particle.  The avidity of this interaction is so tight that no 
dissociation of FX from the virus particle was detected.  Therefore, for determination 
of association rate, dissociation rate and equilibrium dissociation constants the virus 
particle was immobilised on the chip. 
2.12 Phage methods 
Phage experiments were carried out using T7Select415-b phage display system 
(Novagen, EMD Biosciences, Darmstadl, Germany), which used the T7 capsid 
protein to display peptides on the surface of the phage.  All candidate peptide-phage 
and a non-recombinant control phage (with no peptide insertion) were obtained as a 
gift from Professor E. Ruoslahti (Burnham Institute, Santa Barbara, CA, USA).  
Candidate peptides had been isolated by three rounds of selection on ex vivo murine 
heart cells, followed by three rounds of selection in vivo (Zhang et al., 2005).  All 
phage amplification and titration was performed using Escherichia coli strain BL21 
(Novagen, EMD Biosciences, Darmstadl, Germany). 
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2.12.1 Amplification of phage 
Phage were amplified using the liquid lysate amplification protocol as described in 
the Novagen T7 Select system manual.  Briefly, a single BL21 colony was picked 
from a freshly streaked plate and amplified overnight in 25 ml M9LB (1.25 ml 20x 
M9 salts [20 g/l NH4Cl, 60 g/l KH2PO4, 120 g/l NaH2PO4.7H2O], 0.5 ml 20% 
glucose, 25 µl 1M MgSO4, 25 ml LB) in an orbital shaker at 37°C and 180 rpm.  5 
ml of the overnight culture was added to 500 ml LB in a 2 l flask and incubated for 
approximately 3 hours at 37°C in an orbital shaker at 180 rpm.  The absorbance of 
the culture was read at intervals until the optical density reached 600 nm (OD600) 
0.5-1.0.  Separately, 50 µl phage was added to 5 ml of the overnight culture and 
grown until lysis had occurred.  This was then added to the 500 ml culture and was 
incubated with shaking at 37°C for 1-3 hours until cell lysis had occurred as 
determined by an OD600 of less than 0.5.  10% (v/v) 5 M NaCl was added to the 
culture, which was then centrifuged at 8000 x g for 10 minutes to remove cell debris.  
The supernatant was transferred to a sterile bottle for polyethylene glycol (PEG-
8000) precipitation. 
2.12.2 Purification of phage 
1/6th volume of 50% (v/v) PEG-8000 was added to the supernatant and thoroughly 
mixed before incubating at 4°C overnight.  The supernatant was then centrifuged at 
3185 x g for 30 minutes at 4°C.  The pellet was resuspended in 2 ml TBS and 
transferred to microcentrifuge tubes where 1/6th volume of 20% PEG-8000/2.5M 
NaCl was added to the phage and left overnight at 4°C.  The phage was centrifuged 
for 30 minutes at 12600 x g and 4°C and the pellet resuspended in 1 ml TBS and left 
on ice for 1 hour prior to centrifugation for 10 minutes at 12600 x g and 4°C.  The 
pellet was resuspended in 1 ml 0.02% NaN3 and left at room temperature for 20 
minutes before a further centrifugation of 10 minutes at 12600 x g and 4°C.  
Supernatants were then pulled and stored at 4°C. 
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2.12.3 Determination of phage titre 
To determine the titre of the phage stocks produced, a single BL21 colony was 
picked from a freshly streaked plate and amplified overnight in 25 ml LB 
supplemented with 5 ml M9 salts, 2 ml 20% glucose and 0.1 ml 1 M MgSO4 in an 
orbital shaker at 37°C and 180 rpm.  The culture was diluted to an OD600 of 
approximately 1.  LB plates were pre-warmed in a 37°C incubator and serial 
dilutions of phage were made in LB (10-6 to 10-9).  Agar tops (10 g/l bactrotyptone, 5 
g/l yeast extract, 1 g/l MgCl.6H2O, 7 g/l agarose) were melted and 3 ml aliquots 
made and placed in a 50°C water bath.  250 µl of culture was added to 20 µl of each 
dilution of phage and incubated together for 10 minutes at room temperature.  This 
was then added to an aliquot of agar top and poured onto an LB plate.  Once set 
plates were inverted and left at room temperature overnight.  The number of plaques 
at each dilution were counted and used to calculate an average titre for the phage 
stock using the formula: 
Phage titer (pfu/ml) = Number of plaques x dilution factor x 50 
2.12.4 Extraction of phage from tissues 
Phage was also extracted from approximately 25 mg of tissue from selected organs.  
Tissues were placed into 2 ml microcentrifuge tubes containing 1 ml ice cold 
DMEM-PI (DMEM supplemented with 1% (w/v) BSA, 1 mM 
phenylmethanesulfonyl fluoride (PMSF), 1 µg/ml leupeptin, 2 µg/ml aprotinin).  
Tissues were homogenised in a Tissuelyser (QIAGEN, Crawley, UK) by performing 
two 3 minutes runs at 25 Hz.  Leupeptin, PMSF and aprotinin inhibit proteases, 
serine proteases and trypsin, respectively, preventing degradation of proteins in the 
homogenate.  66 µl of 1% non-ident P40 (NP40) was added to each homogenate and 
incubated on ice for 5 minutes to disrupt the cyotplasmic membrane of the cells.  
This was followed by the addition of 20 µl 1% NaN3 and samples were stored at 4°C 
for up to 5 days before titration. 
Chapter 2 – Materials and Methods 
66 
2.13 Preparation of osmotic mini-pumps 
The 2ML4 osmotic mini-pumps (Alzet, CA, USA) were filled as per manufacture’s 
instructions.  Briefly, the reservoir of the mini-pumps was required to be 90% filled 
to ensure optimum operating efficiency and the concentration of the peptide solution 
depended on the weight of the rat and the release rate of the mini-pump.  Animals 
were administered 10 mg/kg/day peptide and the pumps were filled with enough 
peptide for 29 days of administration to ensure over 90% filling.  Peptides were 
diluted to a 350 mg/ml stock solution in DMSO for storage and the required further 
dilution with deionised water was calculated from the formula: 
Mass delivery rate (µg/hour) = concentration of peptide (µg/µl) x volume delivery 
rate (µl/hour) 
Therefore, for a 225 g rat, required administration rate = 2.25 mg/day 
(2.25 mg/day x 29 days) / 350 mg/ml = 186.4 µl peptide + 1658 µl dH20 
Mini-pumps were filled the day before implantation and incubated overnight at 37°C 
in isotonic saline to ensure that the pumping rate had reached a steady state before 
implantation. 
2.14 Animal models 
All animals were housed under controlled environmental conditions.  Temperature 
was maintained at ambient temperature with 12 hours light/dark cycles.  Mice and 
rats were fed standard chow (rat and mouse No.1 maintenance diet, Special Diet 
Services) and water was provided ad libitum.  All experiments were carried out in 
accordance with the Animals (Scientific Procedure) Act, 1986.  Administration of 
Ad vectors into mice was performed under the project license held by Dr. S.N. 
Waddington (Royal Free and University College Medical School, London, UK), 
Licence No. 70/6906.  Administration of phage and peptides into rats was performed 
under the project license held by Prof. A.F. Dominiczak (University of Glasgow, 
UK), Licence No. 60/2874.  CD46 transgenic mice were generated by back-crossing 
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an established CD46 transgenic line onto white MF1 mice.  Both CD46 transgenic 
mice and control MF1 mice were used for the in vivo experiments.  Male SHRSP 
were obtained from the Glasgow colony by brother-sister mating (Dominiczak et al., 
1993) 
2.14.1 Administration of adenovirus 
In vivo adenoviral work was performed in CD46 transgenic mice 25-30 g.  Mice 
were anaesthetised and injected with 5x1010 VP/mouse via lateral tail vein injection.  
X-bp treated animals were injected with 4.8 mg/kg X-bp 30 minutes before injection 
of Ad. 
2.14.1.1 Quantification of adenoviral accumulation and transgene 
expression 
Mice were subject to whole body bioluminescence quantification (IVIS Spectrum; 
Caliper Life Sciences, Hopkinton, MA, USA) 48 hours post-Ad administration and 
were sacrificed after 72 hours for tissue analysis.  Tissue homogenates were 
produced from 25 mg tissue (10 mg spleen) using TissueLyser II (QIAGEN, 
Crawley, UK).  Luciferase expression analysis was then performed on the tissue 
homogenates and normalised to total protein content.  DNA was also isolated from 
tissue homogenates using QIAamp DNA mini kit (QIAGEN, Crawley, UK).  50 ng 
of total DNA was subject to qPCR analysis as described above. 
2.14.2 Administration of phage 
In vivo phage work was performed in 12-week male SHRSP rats.  Rats were 
anaesthetised by isofluorane (3%).  All rats received 5x1010 pfu phage via femoral 
vein injection which was left to circulate for 5 minutes.  Blood samples were taken 
by cardiac puncture before rats were perfused through the heart with heparinised 
saline and organs were removed and snap frozen. 
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2.14.3 Administration of peptides 
For the in vivo anti-oxidant study, rats were implanted with radio-telemetry probes 
under isofluorane anaesthesia at 10 weeks of age.  Under isofluorane anaesthesia, 
animals were implanted with 2ML4 osmotic mini-pumps at 12 weeks of age to 
deliver the peptides continuously for 3 weeks.  At 15 weeks of age, the animals were 
sacrificed under terminal isofluorane anaesthesia; blood was immediately drawn 
from the heart and stored in EDTA before being snap frozen in liquid NO2 for SO 
measurement by EPR.  The descending thoracic aorta was isolated and removed to 
study endothelial function.  Internal carotid arteries and selected organs were taken 
for further study.  Throughout procedures and subsequent analysis, animal breeding 
numbers were used to identify SHRSP, and not treatment groups, to ensure a blinded 
study. 
2.15 Determination of blood pressure changes 
Radio-Telemetry Monitoring of Blood Pressure and Heart Rate The Dataquest IV 
telemetry system (Data Sciences International) was used for measurement of systolic 
pressure, diastolic pressure, mean arterial pressure, heart rate, and motor activity, as 
previously described (Davidson et al., 1995).  Briefly, the monitoring system 
consists of a transmitter (radio frequency transducer model TA11PA), receiver 
panel, consolidation matrix, and personal computer with accompanying software.  
Before the device was implanted, calibrations were verified to be accurate within 3 
mm Hg.  SHRSP rats at 10 weeks of age were anesthetised with isofluorane and the 
flexible catheter of the transmitter was surgically secured in the abdominal aorta just 
below the renal arteries and pointing upstream (against the flow).  The transmitter 
was sutured to the abdominal wall.  Rats were housed in individual cages after the 
operation.  Each cage was placed over the receiver panel which was connected to the 
computer for data acquisition.  The rats were unrestrained and free to move within 
their cages.  Haemodynamic data were sampled every 5 minutes for 10 seconds.  
Blood pressure and heart rate takes up to 7 days to stabilise post-operatively 
(Davidson et al., 1995).  Therefore, mini-pumps were implanted two weeks later and 
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telemetry data were collected for one week prior to implantation of the mini-pumps 
and for the 21 days on treatment. 
2.16 Echocardiography (ECHO) 
Trans-thoracic ECHO was carried out by Dr. K. Gilday (University of Glasgow, 
UK).  Briefly, it was performed using an ACUSON Sequoia C512 ultrasound system 
(Siemens, Germany) with a linear array transducer at a frequency of 15 MHz.  
Echocardiography was performed on a lightly anesthetized animal (1.25% to 1.5% 
isoflurane in 1.5 litres/min O2) placed in the left lateral decubitus position on a 
heated pad.  Non-invasive acquisitions of 2-D guided M-mode images at a depth of 
20 mm were recorded at the tip of the papillary muscles.  The thickness of the 
posterior and anterior walls of the left ventricle (LV) chamber and the LV chamber 
diameter during systole and diastole were measured in a short axis view using the 
leading edge to leading edge convention.  All parameters were measured over at least 
three consecutive cardiac cycles.  Pulse-wave velocity was used to measure the 
velocity of blood through the mitral valve and to qualitatively examine the valve for 
evidence of mitral valve regurgitation. 
2.16.1 Formulae used in ECHO assessments 
Ejection fraction was defined as follows: EF = [(LVEDV - LVESV) / LVESD x 
100], where LVEDV is left ventricular end diastolic volume and LVESV is left 
ventricular end systolic volume.  Fractional shortening was derived from: FS = 
[(LVEDD - LVESD) / LVEDD x 100], where LVEDD is left ventricular end 
diastolic diameter and LVESD is left ventricular end systolic diameter.  Cardiac 
output was derived from: CO = [(ESV - EDV) x HR], where HR is heart rate.  
Change in interventricular septal wall thickness (ISWT) was measured using the 
formula [(AWTs - AWTd) / AWTs x 100], where AWT is anterior wall thickness, s 
is systole and d is diastole. 
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2.17 Myography 
2.17.1 Large vessel myography 
Thoracic aorta was cleaned of connective tissue and cut into 2 mm rings, which were 
mounted in large vessel 5 ml myograph baths containing Krebs buffer maintained at 
37°C and oxygenated with 95% O2, 5% CO2.  After pre-treatment with potassium-
buffered Krebs and stimulatory dose of phenylephrine (PE), cumulative 
concentration-response curves to PE (1 nmol/l to 10 µmol/l) were constructed, first 
in the absence and again after washout in the presence of 100 µmol/l N-nitro-L-
arginine methyl ester (L-NAME) to inhibit eNOS.  Response to PE was expressed as 
percentage of maximum contraction produced during the first PE curve.  The 
increase in tension in the presence of L-NAME provided a measure of the effect of 
NO on basal tone. 
Other sections of the thoracic aorta were also used to perform cumulative 
concentration-response curves to apocynin (10 µmol/l to 1 mmol/l) directly after a 
cumulative concentration-response curve to PE (1 nmol/l to 10 µmol/l) was 
constructed.  Apocynin (also known as 4′-Hydroxy-3′-methoxyacetophenone or 
acetovanillone) inhibits NAD(P)H oxidase and can act an anti-oxidant.  Response to 
apocynin was expressed as percentage of maximum contraction produced during the 
first PE curve. 
2.17.2 Small vessel myography 
Third order mesenteric resistance arteries were dissected from connective tissue and 
stored overnight at 4°C before use.  Segments (approximately 2 mm in length) were 
mounted as ring preparations in Krebs buffer maintained at 37°C and oxygenated 
with 95% O2, 5% CO2 on two stainless steel wires on a four-channel small vessel 
myograph (Danish MyoTechnology, Aarhus, Denmark).  One wire was attached to a 
force transducer and the other to a micrometer.  Following a 30 minute rest period, 
vessels were set to a normalised internal diameter (L1) to achieve optimal 
contraction.  Internal diameter was calculated using the following equation: 
L1=0.0*L100, (where L100 was determined using the LaPlace equation, P=T/r (P is 
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effective pressure, T is wall tension and r is the internal radius).  After further 60 
min, contractile responses to 10 µmol/l KCl were examined, followed by washout.  
A cumulative concentration response curve to PE (1 nmol/l to 30 µmol/l) was 
performed first in the absence and again after washout, in the presence of 100 µmol/l 
L-NAME.  The increase in tension in the presence of L-NAME provided a measure 
of the effect of NO on basal tone. 
2.18 Electron paramagnetic resonance (EPR) 
Oxidative stress status was assessed by analysing SO release from heparinised whole 
blood taken by cardiac puncture at sacrifice.  Blood was kept on ice and processed 
within one hour.  SO levels were detected by EPR (e-scan R; Bruker BioSpin 
GmbH, Rheinstetten Germany) with the spin probe 1-hydroxy-3-carboxy- 2,2,5,5-
tetramethylpyrrolidine (CPH; Noxygen, Elzach, Germany) added to a final 
concentration of 500 µmol/l.  Blood was then incubated at 37°C for 30 minutes 
before being snap frozen in liquid nitrogen.  SO levels were then measured in the 
snap frozen samples and the rate of SO production was calculated as counts per 
minute.  Instrument settings were: centre field of 3392 G, modulation amplitude of 
5.08 G, sweep time of 10.49 s, sweep width of 120 G and 10 scans. 
2.19 Histology 
Tissues were excised and immediately fixed in 10% formalin overnight and then 
transferred to PBS.  Tissues were then paraffin embedded and single tissue sections 
of 6 µm thickness mounted onto a salinised glass slide, which were heated for 3 
hours at 65°C, then overnight at 40°C. 
2.19.1 Slide salinisation 
Blank glass slides were placed in a solution of 2% 3-amino-propyltriethoxysaline 
(APES) in 100% acetone for 30-60 seconds.  Slides were then rinsed twice in 100% 
acetone, followed by two rinses in deionised water before being left to air dry in an 
oven overnight at 37°C. 
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2.19.2 Immunohistochemistry 
Paraffin was removed from the sections by two 7 minute washes in Histoclear 
(Thermo Fisher Scientific, UK).  Sections were rehydrated by passing through an 
alcohol gradient 100%, 95% and 70% ethanol for 7 minutes each.  After washing 
slides in deionised water for 5 minutes, endogenous peroxide activity was quenched 
by incubating slides in 0.3% (v/v) methanol-hydrogen peroxide for 30 minutes at 
room temperature.  Slides were then washed twice in deionised water for 5 minutes.  
Antigen unmasking was then performed in 10 mM sodium citrate, pH 6.0 for 15 
minutes at 95-100°C.  Slides were then washed twice in deionised water for 5 
minutes.  Immunohistochemistry was performed using Vectastain avidin and 
biotinylated horseradish peroxidase complex (ABC) rabbit IgG kit (Vector 
Laboratories, UK).  Sections were incubated in blocking solution (goat serum) for 1 
hour at room temperature in a humidified chamber.  The primary anti-T7 antibody 
(Chemicon, CA, USA) and the negative control rabbit IgG antibody (Dako, 
Denmark) were diluted to 0.01 mg/ml in blocking solution.  Antibodies were 
incubated on the sections overnight at room temperature in a humidified chamber.  
Slides were washed three times in PBS for 5 minutes each.  The secondary 
Vectastain avidin and biotinylated goat anti-rabbit IgG antibody was diluted 1:200 in 
blocking solution and incubated on the slides for 30 minutes at room temperature.  
Slides were then washed three times in PBS for 5 minutes each.  The avidin and 
biotinylated horseradish peroxidase complex (ABC) was then incubated on the slides 
for 30 minutes at room temperature, followed by three washes in PBS of 5 minutes 
each.  Slides were then incubated with DAB chromagen solution (3,3-
diaminobenzidine, hydrogen peroxide and nickel solution) (Vector Laboratories, 
UK) for 5 minutes.  Slides were washed in deionised water for 5 minutes then nuclei 
were counterstained by incubation with Harris haematoxylin for 30 seconds.  Slides 
were washed in running water and dehydrated by incubation in 70%, 95% and 100% 
ethanol, followed by Histoclear for 7 minutes each.  Finally, slides were mounted 
using Histomount (National Diagnostics, GA, USA).  Nuclei appeared blue/purple 
and areas to which the primary antibodies bound appear brown. 
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2.19.3 Immunofluorescence 
After the removal of paraffin and rehydration of slides as described above, 
endogenous peroxide activity was quenched by incubating slides in 0.3% (v/v) 
methanol-hydrogen peroxide for 30 minutes at room temperature.  Slides were then 
washed twice in deionised water for 10 minutes.  Antigen unmasking was performed 
by incubating the sections in proteinase K solution (20 µg/ml proteinase K [Roche 
Applied Science, Indianapolis, IN, USA], 2.5 mM Tris pH 8.0 / 0.05 mM EDTA) for 
20 minutes at 37°C.  Slides were then removed from the incubator and left for 20 
minutes at room temperature.  Slides were washed twice in PBS for 5 minutes and 
then washed twice in TBS (150 nM NaCl, 50 nM Tris pH 7.4) 0.0025% (v/v) Triton 
X-100.  Sections were incubated in 10% goat serum in TBS for 30 minutes at room 
temperature in a humidified chamber.  The primary anti-GFP antibody (Abcam, 
Cambridge, UK) and the negative control rabbit IgG antibody (Invitrogen, Carlsbad, 
CA, USA) were diluted to 0.5 µg/ml in 1% goat serum in TBS.  Antibodies were 
incubated on the sections for one hour at room temperature.  Slides were washed 
twice in TBS 0.0025% (v/v) Triton X-100 for 5 minutes each.  The fluorescent 
Alexa Fluor® 488 secondary goat anti-rabbit IgG antibody (Invitrogen, Carlsbad, 
CA, USA) was diluted 1:750 in 1% goat serum in TBS and incubated on the slides 
for 30 minutes at room temperature.  Slides were then washed three times in TBS for 
5 minutes each and mounted in ProLong® Gold Antifade Reagent with DAPI to 
counterstain the nuclei of the cells.  The mounting agent was allowed to set 
overnight before viewing on the confocal microscope. 
2.19.4 Haemotoxylin and eosin (H&E) staining 
After the removal of paraffin and rehydration of slides as described above, slides 
were stained in Harris haemotoxylin for 2 minutes.  Slides were washed in running 
water for 5 minutes and then placed in eosin for two minutes, before a further 5 
minutes wash in running water.  Slides were dehydrated and then mounted in 
Histomount.  Nuclei appeared blue/purple whereas cytoplasm was stained pink. 
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2.19.5 Picro-sirius red staining 
After the removal of paraffin and rehydration of slides as described above, slides 
were incubated in Sirius red F3B dissolved in 0.1% (w/v) saturated picric acid for 90 
minutes at room temperature in the dark.  Slides were washed twice with 0.01 N HCl 
for 3 minutes each, followed by two washes in deionised water for 3 minutes each.  
Slides were dehydrated and then mounted in Histomount.  Collagen was stained 
various shades of red. 
2.19.6 Masson’s trichrome staining 
Masson’s Trichrome staining was performed using the kit obtained from Sigma-
Aldrich (Poole, UK).  Briefly, after the removal of paraffin and rehydration of slides 
as described above, slides were incubated in Bouin’s solution overnight at room 
temperature.  Slides were washed under running water until the yellow colour was 
removed.  Sections were stained for 5 minutes in Weigert’s Iron Haematoxylin 
solution (Weigert’s Iron Haematoxylin solution was prepared by mixing equal parts 
of Solution A (1% haematoxylin in ethanol) and Solution B (1.2% (w/v) ferric 
chloride and 1% (v/v) hydrochloric acid)).  Slides were then washed in running 
water for 5 minutes.  Slides were stained in Biebrich Scarlet-Acid Fuchsin (0.9% 
Biebrich scarlet, 0.1% acid fuchsin, 0.1% acetic acid) for 5 minutes and then rinsed 
in deionised water.  Slides were placed in Working Phosphotungstic/Phospho-
molybdic Acid Solution (1 volume 10% Phosphotungstic Acid, 1 volume 10% 
Phosphomolybdic Acid with two volumes deionised water) for 5 minutes and then in 
Aniline Blue Solution (2.4% Aniline Blue and 2% acetic acid) for 5 minutes.  
Sections were washed in 1% acetic acid for two minutes before they were 
dehydrated and mounted in Histomount.  Cell nuclei appear black, cytoplasm and 
muscle fibres appear red and collagen was stained blue. 
2.20 Statistical analysis 
All results are expressed as mean ± stardard error of the mean (SEM).  In vitro 
experiments were performed in triplicate on at least three independent occasions and 
analysis was by unpaired Student’s t test.  Comparisons between myography curves 
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in the individual groups were performed using an unpaired Student’s t test for the 
area under the curve.  Comparison between EPR blood SO production by the 
different groups was performed using an unpaired Student’s t test. 
2.20.1 In vivo statistical analysis 
In vivo experiments were performed with at least four mice per group in the Ad 
study and six SHRSP per group for the anti-oxidant study.  Comparison between 
groups for the radio-telemetry data was performed by repeated measures analysis of 
variance (ANOVA), as described previously (Davidson et al., 1995).  Comparison 
between treatment groups and control animals for the ECHO data was performed by 
one-way ANOVA with a Dunnett’s post-test. 
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3.1 Introduction 
Evidence indicates that increased oxidative stress is responsible for a variety of 
human cardiovascular diseases.  Therefore, it is critical to develop more effective 
anti-oxidant therapies.  Enhanced reduction of oxidative stress could be achieved by 
using targeted anti-oxidant treatments.  Specific proteins have been found to be 
restricted to highly defined regions of the vasculature, particularly within organs.  
Previously ECs have been shown to differentially express markers in various organs 
and disease states (Garlanda and Dejana, 1997, Ghitescu et al., 1997, Thorin and 
Shreeve, 1998, Ruoslahti and Rajotte, 2000, Ribatti et al., 2002, Oh et al., 2004).  
Exploitation of this differential expression of proteins on the cell surface of ECs has 
led to the identification of peptides that selectively target specific areas of the 
vasculature. 
Screening with phage-displayed peptide libraries and cDNA libraries has previously 
led to the discovery of tissue-specific peptides, including peptides that target the 
heart (Zhang et al., 2005), brain, kidneys, lungs, breast, prostate (Rajotte and 
Ruoslahti, 1999, Ruoslahti and Rajotte, 2000, Essler and Ruoslahti, 2002), muscle 
(Samoylova and Smith, 1999), fat (Kolonin et al., 2004) and venous circulation 
(Nicklin et al., 2000).  Both ex vivo and in vivo phage display was performed to 
identify peptides which selectively targeted ECs of the coronary vasculature and 
chambers of the heart (Zhang et al., 2005).  Three rounds of ex vivo phage display 
were performed on ECs isolated from murine heart cell suspensions, increasing 
binding by peptide-inserted phage 230-fold over non-recombinant control phage 
(Zhang et al., 2005).  The ex vivo selected phage were then subject to selection in 
vivo in BALB/c mice based on their heart-homing capacity.  After three rounds of in 
vivo screening the heart-targeting capacity of the phage had increased to 200-fold 
greater than the control phage with low levels of phage bound in other non-target 
organs (Zhang et al., 2005). 
Following sequencing to identify the peptide inserts in the heart-targeted phage, the 
peptides were matched against a heart cDNA library expressed in a bacterial 2-
hybrid system (Zhang et al., 2005).  After exclusion of abundant cardiac muscle 
proteins (including myosin and myoglobin), six membrane or cell-surface proteins 
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were identified producing putative peptide-receptor combinations (Zhang et al., 
2005).  Cysteine-rich protein 2 (CRIP-2) was identified as the receptor for two of the 
peptide sequences, CRPPR and CGRKSKTVC, and is expressed in the vascular 
endothelium of the heart (Yu et al., 2002).  Phage displaying peptide insert 
sequences CRPPR and CGRKSKTVC targeted to the heart with 310- and 46-fold 
selectivity compared to the non-recombinant control phage, respectively (Zhang et 
al., 2005).  CPKRPR-inserted phage demonstrated 35-fold heart selectivity and 
bound to an un-annotated RIKEN expressed sequence tag (EST) (Zhang et al., 
2005).  CRSTRANPC binds to an “un-named” protein product similar to the 
mitochondrial membrane protein integral membrane protein CII-3 (MPCII-3) (Zhang 
et al., 2005).  CRSTRANPC was 22-fold more selective for the heart than the non-
recombinant control phage (Zhang et al., 2005).  The final receptor identified for 
peptides CPKTRRVPC and CSGMARTKC was the mouse homologue of the human 
bladder cancer-associated protein BC-10, a protein which is down-regulated as 
cancer develops from pre-malignant lesions in the bladder (Gromova et al., 2002).  
The peptides CPKTRRVPC and CSGMARTKC targeted the heart with a 62- and 
14-fold increase, respectively, relative to the control phage (Zhang et al., 2005).  
Receptor expression analysis by qPCR showed that CRIP-2, MPCII-3 and BC-10 
were expressed at the highest level in the heart, with much lower levels of the 
receptors present in other tissues (Zhang et al., 2005). 
Co-injection of selected phage displaying the heart-targeted peptide sequences 
(including the peptide sequences CRPPR, CRSTRANPC and CPKTRRVPC) into 
mice with fluorescein-conjugated tomato lectin to stain blood vessels identified that 
the phage were bound to the endothelium of the heart (Zhang et al., 2005).  
Importantly, none of the phage were seen to bind to the endothelium of other tissues 
(Zhang et al., 2005).  Additionally, using fluorescein-conjugated CRPPR peptide, it 
was shown that this peptide extensively co-localised with an anti-CRIP-2 antibody 
and the endothelial marker CD31 in coronary arteries, capillaries and the 
endocardium (Figure 3.1) (Zhang et al., 2005).  Therefore, heart-targeting peptides 
and their receptors in the endothelium of the cardiac vasculature are known and can 
be exploited to develop an anti-oxidant therapy that selectively targets to the areas of 
oxidative stress. 
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Figure 3.1 – CRPPR peptide co-localises with CD31 in mouse 
endocardium. 
Fluorescein-conjugated CRPPR peptide (green) co-localises with anti-CD31 
antibody (red) in the endocardium of the heart after intravenous administration in 
mice.  CD31 is an endothelial cell marker.  Adapted from Zhang et al. (Zhang et al., 
2005). 
 
 
The heart-targeting capability of CRPPR was tested in three mouse strains (BALB/c, 
FVB and C57BL/6), with a similar degree of specific cardiac homing seen in the 
different strains (Zhang et al., 2005).  Phage inserted with the peptide sequences 
CGRKSKTVC, CPKRPR, CPKTRRVPC, CRPPR, CRSTRANPC and 
CSGMARTKC have been previously administered to the normotensive WKY rat to 
investigate whether the efficiency and selectivity of the peptides extended across 
species (Shirley, 2008).  Phage recovery analysis from the major organs showed 
enhanced recovery of all six peptides from rat heart homogenates, compared to 
control insert-less phage (Shirley, 2008).  However, three of the peptides, 
CGRKSKTVC, CPKRPR and CPKTRRVPC, did not show strong selectivity for the 
heart (Shirley, 2008).  CRPPR, CRSTRANPC and CSGMARTKC retained their 
strong heart-targeting capacity with high selectivity (Shirley, 2008).  CRPPR, 
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CRSTRANPC and CSGMARTKC all demonstrated enhanced cardiac selectivity of 
over 400-fold, 2000-fold and 80-fold, respectively (Shirley, 2008).  
Immunohistochemical analysis using an anti-T7 phage antibody confirmed the 
cardiac targeting of CRPPR, CRSTRANPC and CSGMARTKC.  The histology also 
revealed that CSGMARTKC was found to primarily target the vascular endothelial 
cells, whereas T7 phage displaying the peptides CRPPR and CRSTRANPC were 
also found throughout the myocardium (Shirley, 2008). 
The phage inserted with the most selective and effective heart-targeting peptide 
sequences in the WKY rat (CRPPR, CRSTRANPC and CSGMARTKC) were tested 
in the SHRSP, a disease model of human essential hypertension.  The peptides which 
remained selective for the cardiac vasculature in the SHRSP (CRPPR and 
CSGMARTKC) were linked to the anti-oxidant peptide gp91ds (Rey et al., 2001) to 
develop a novel vascular-targeting anti-oxidant peptide.  The effect of this vascular-
targeting anti-oxidant therapy on BP and endothelial function in the SHRSP was 
then assessed. 
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3.2 Results 
3.2.1 In vitro internalisation of targeting peptides in a rat 
endothelial cell line 
The ability of the peptides to bind to and internalise into cells in vitro was assessed 
using a rat glomerular endothelial (RGE) cell line.  RGE cells provide a model of rat 
endothelial cells and have been used previously with success (Nicol et al., 2009).  
The heart-targeting peptides CRPPR, CSGMARTKC and CRSTRANPC were 
previously identified by ex vivo and in vivo phage display (Zhang et al., 2005) and 
their selectivity for the cardiac vasculature was maintained in WKY rats (Shirley, 
2008).  The targeting peptides and the HIV-tat peptide were linked to a fluorescein 
(FITC) label to allow visualisation by fluorescence microscopy.  1 – 100 µmol/l of 
the peptides were added to 1x104 RGE cells/well and internalisation of the peptides 
by the cells was determined by the presence of the green FITC-labelled peptide after 
the cells were washed. 
At 1-10 µmol/l of the peptides, there was no clear internalisation observed by any of 
the heart-targeting peptides (Figure 3.2).  However, the HIV-tat peptide internalised 
into a small number of RGE cells (Figure 3.2).  CRSTRANPC and HIV-tat peptides 
both effectively internalised at 50 µmol/l, with the HIV-tat peptide present in a 
greater number of the cells (Figure 3.2).  CRPPR and CSGMARTKC were also 
internalised by the RGE cells at 50 µmol/l concentration but at a lower level (Figure 
3.2).  At 100 µmol/l of the peptides, there was considerable internalisation by all four 
peptides, with the HIV-tat peptide again producing the highest level of 
internalisation (Figure 3.2).  However, 100 µmol/l of peptide also produced cell 
death, resulting in reduced cell numbers at this concentration (Figure 3.2).  As the 
targeting peptides can internalise into the RGE cells, this suggests that there was 
some expression of their receptors.  The visually most effective peptide 
internalisation at each of the concentrations was produced by the HIV-tat peptide 
(Figure 3.2).  For further experiments, 50 µmol/l of the peptides was used as this 
concentration of peptide produced internalisation into the RGE cells without high 
levels of cell death. 
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Figure 3.2 – Internalisation of peptides in RGE cells. 
Peptides were added to 1x104 RGE cells/well in concentrations ranging from 1 – 100 
µmol/l.  Peptides were incubated with the cells at 37°C for 10 minutes.  The cells 
were then washed and internalisation of the peptides by the cells was determined by 
the presence of the green FITC-labelled peptide after the cells were washed.  
Visualisation of the FITC-label was ascertained by fluorescence microscopy and 
arrows indicate cells with internalised peptides.  Scale bar = 50 µm, magnification x 
10. 
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3.2.2 Transfection of RGE cells with plasmids containing 
the putative receptors for each peptide 
To attempt to increase internalisation of the peptides in RGE cells, cells were 
transfected with the putative receptors for each peptide (discussed in Section 3.1).  
RGE cells are derived from the glomerular endothelium and, therefore, may not 
express the necessary receptors for the heart-targeting peptides.  However, Figure 3.2 
does suggest some presence of receptors for two of the peptides.  The transfection 
procedure was optimised in RGE cells using an eGFP expression plasmid and two 
transfection reagents, Lipofectamine™ 2000 and FuGENE® 6.  The ratio of 
transfected to non-transfected cells in each condition was determined by 
fluorescence microscopy. 
Lipofectamine™ 2000 reaction complexes were generated with a DNA (µg) to 
Lipofectamine™ 2000 (µl) ratio of 1:1, 1:2, 1:3 and 1:4 in Opti-MEM® I serum free 
media, with 2 µg DNA being used for each complex.  Complexes were incubated 
with the RGE cells for 4-6 hours and 48 hours after transfection images were taken 
(Figure 3.3).  Over 90% of the cells transfected with a 1:1 ratio of Lipofectamine™ 
2000 and DNA expressed eGFP (Figure 3.3).  Increasing concentrations of 
Lipofectamine™ 2000 increased the transfection efficiency slightly but substantially 
increased cell death as Lipofectamine™ 2000 was toxic to the RGE cells (Figure 
3.3). 
A similar optimisation experiment was performed with FuGENE® 6, with reaction 
complexes with a DNA (µg) to FuGENE® 6 (µl) ratio of 1:1, 2:3, 1:2 and 2:9 in 
Opti-MEM® I serum free media.  Approximately 10% of RGE cells were 
transfected with a 1:1 FuGENE® 6 to DNA ratio (Figure 3.4).  Increasing the ratio 
to 2:3 and 1:2, significantly increased the transfection efficiency but the toxicity of 
the transfection reagent was producing some cell death at these concentrations 
(Figure 3.4).  At the highest concentration of FuGENE® 6 (ratio 2:9), over 70% cell 
death was observed with no transfection of the remaining cells (Figure 3.4). 
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Figure 3.3 – Transfection optimisation using Lipofectamine™ 2000. 
Transfection was optimised in RGE cells using an eGFP expression plasmid to allow 
determination of transfected cells after viewing by fluorescence microscopy.  
Lipofectamine™ 2000 reaction complexes were generated with a DNA (µg) to 
Lipofectamine™ 2000 (µl) ratio of 1:1, 1:2, 1:3 and 1:4 in Opti-MEM® I serum free 
media.  Lipofectamine™ 2000 and DNA only controls were produced, in addition to 
a complete un-transfected control.  Images were taken 48 hours after transfection and 
light-field images show the presence of cells (top) with the presence of eGFP 
expression shown below. Scale bar = 50 µm, magnification x 10. 
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Figure 3.4 – Transfection optimisation using FuGENE® 6. 
Transfection was optimised in RGE cells using an eGFP expression plasmid to allow 
determination of transfected cells after viewing by fluorescence microscopy.  
FuGENE® 6 reaction complexes were generated with a DNA (µg) to FuGENE® 6 
(µl) ratio of 1:1, 2:3, 1:2 and 2:9 in Opti-MEM® I serum free media.  FuGENE® 6 
and DNA only controls were produced, in addition to a complete un-transfected 
control.  Images were taken 48 hours after transfection and light-field images show 
the presence of cells (top) with the presence of eGFP expression shown below. Scale 
bar = 50 µm, magnification x 10. 
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Subsequent transfection experiments were performed with a 1:1 ratio of DNA to 
Lipofectamine™ 2000.  The lowest dilution of this transfection reagent produced 
greater than 90% transfection of the RGE cells in the absence of visual cell death.  
Expression plasmids containing the sequences for the putative receptors for CRPPR, 
CSGMARTKC and CRSTRANPC, called CRIP-2, BC-10 and MPCII-3 
respectively, were transfected into RGE cells.  After the cells were incubated for 48 
hours to allow expression of the transfected receptors to occur, 50 µmol/l of each of 
the peptides were added and incubated with the cells at 37°C for 10 minutes after 
which images were taken by fluorescence microscopy to visualise internalisation of 
the FITC-labelled peptides by transfected and control cells. 
RGE cells were transfected with the expression plasmid for the putative receptor for 
the peptide CRPPR, CRIP-2 (Zhang et al., 2005) (Figure 3.5) .  The HIV-tat peptide 
effectively internalised into the transfected cells, however, lower levels of 
internalisation were observed for the other peptides (Figure 3.5).  Transfection with 
the CRIP-2 expression plasmid did not enhance internalisation by the CRPPR 
peptide (Figure 3.5).  RGE cells were also transfected with a BC-10 expression 
plasmid, the putative receptor for the CSGMARTKC peptide (Zhang et al., 2005) 
(Figure 3.6).  HIV-tat effectively internalised and CRSTRANPC also internalised 
into the transfected RGE cells (Figure 3.6), similar to the levels of internalisation 
seen in the non-transfected cells (Figure 3.2).  Transfection of the BC-10 expression 
plasmid into the RGE cells did not enhance internalisation by CSGMARTKC 
(Figure 3.6).  Finally, RGE cells were transfected with the MPCII-3 expression 
plasmid, the putative receptor for the peptide CRSTRANPC (Zhang et al., 2005) 
(Figure 3.7).  Again, HIV-tat produced high levels of internalisation in the 
transfected RGE cells; whereas the other peptides produced internalisation only in a 
few transfected cells (Figure 3.7). 
Taken together, these data suggest that transfection of RGE cells with the expression 
plasmids for the putative receptors for the heart-targeted peptides did not 
significantly enhance internalisation of the peptides.  The peptides did achieve low 
levels of internalisation into RGE cells, either transfected or non-transfected, but in 
all cases, the highest level of internalisation was produced by the HIV-tat peptide.  
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Based on this, it was concluded that RGE cells were not a suitable model system and 
consequently, in vivo experiments were progressed. 
 
 
HIV-tat CRPPR CRSTRANPCCSGMARTKC
 
Figure 3.5 – Transfection of RGE cells with CRIP-2 expression plasmid. 
RGE cells transfected with the CRIP-II expression plasmid, the putative receptor for 
the peptide CRPPR.  Transfected cells were incubated with 50 µmol/l peptide at 
37°C for 10 minutes.  The cells were then washed and internalisation of the peptides 
by the cells was determined by the presence of the green FITC-labelled peptide after 
the cells were washed.  Visualisation of the FITC-label was ascertained by 
fluorescence microscopy and arrows indicate cells with internalised peptides.  Scale 
bar = 50 µm, magnification x 10. 
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HIV-tat CRPPR CRSTRANPCCSGMARTKC
 
Figure 3.6 – Transfection of RGE cells with BC-10 expression plasmid. 
RGE cells transfected with the BC-10 expression plasmid, the putative receptor for 
the peptide CSGMARTKC.  Transfected cells were incubated with 50 µmol/l peptide 
at 37°C for 10 minutes.  The cells were then washed and internalisation of the 
peptides by the cells was determined by the presence of the green FITC-labelled 
peptide after the cells were washed.  Visualisation of the FITC-label was ascertained 
by fluorescence microscopy and arrows indicate cells with internalised peptides.  
Scale bar = 50 µm, magnification x 10. 
 
HIV-tat CRPPR CRSTRANPCCSGMARTKC
 
Figure 3.7 – Transfection of RGE cells with MPCII-3 expression plasmid. 
RGE cells transfected with the MPCII-3 expression plasmid, the putative receptor 
for the peptide CRSTRANPC.  Transfected cells were incubated with 50 µmol/l 
peptide at 37°C for 10 minutes.  The cells were then washed and internalisation of 
the peptides by the cells was determined by the presence of the green FITC-labelled 
peptide after the cells were washed.  Visualisation of the FITC-label was ascertained 
by fluorescence microscopy and arrows indicate cells with internalised peptides.  
Scale bar = 50 µm, magnification x 10. 
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3.2.3 Assessment of phage displaying peptides after in 
vivo administration in the SHRSP 
As discussed above, peptide sequences which targeted the cardiac vasculature were 
identified in the mouse by phage display technology (Zhang et al., 2005).  Six phage 
inserted with the peptide sequences CGRKSKTVC, CPKRPR, CPKTRRVPC, 
CRPPR, CRSTRANPC and CSGMARTKC have been previously administered to 
the normotensive WKY rat to confirm the efficiency and selectivity of the peptides 
extended across species (Shirley, 2008).  Phage recovery analysis from the major 
organs showed enhanced recovery of all six peptides from rat heart homogenates 
compared to control insert-less phage (Shirley, 2008).  However, three of the 
peptides did not show strong selectivity for the heart, whereas CRPPR, 
CRSTRANPC and CSGMARTKC showed strong heart targeting with high 
selectivity (Shirley, 2008).  Therefore, the phage with the most selective and 
effective heart-targeting peptide sequences (CRPPR, CRSTRANPC and 
CSGMARTKC) were tested in the SHRSP, a disease model of human essential 
hypertension.  Co-localisation of phage in the heart and non-target organs was 
determined in the SHRSP, which included the aorta.  Animals were intravascularly 
infused with 5x1010 pfu and the major organs recovered (n = 3 per group).  Phage 
containing the peptide sequence CRSTRANPC showed no selective targeting to the 
heart in the SHRSP (Figure 3.8A).  CRPPR targeted to the heart with a 17-fold 
increase over the control phage and further showed a 58-fold increase in targeting to 
the aorta (Figure 3.8B).  CSGMARTKC displayed selective targeting for the heart 
with 26-fold greater homing to the heart than the control phage (Figure 3.8C). 
Immunohistochemical analysis of major organs was performed with an anti-T7 
antibody to determine the cell specific targeting within organs by the phage 
displaying each of the peptide sequences.  Antibody detection was performed using 
DAB chromagen solution and sections were counterstained with Harris 
haematoxylin.  Therefore, the nuclei appear blue/purple and areas to which the 
primary antibodies bound appear brown (Figure 3.9). 
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Figure 3.8 – Targeting capacity of peptide-inserted phage in SHRSP. 
Recovery of T7 phage which displayed the cardiac endothelial homing peptides 
CRSTRANPC (A), CRPPR (B) and CSGMARTKC (C) from SHRSP animals 
intravenously infused with 5x1010 pfu of indicated phage.  Data represented as fold 
change in comparison to control insert-less phage in liver, spleen, brain, kidney, 
lung, muscle, aorta and heart (n = 3/group). 
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Figure 3.9 – Immunohistological analysis of targeting capacity of 
peptide-inserted phage in SHRSP. 
Immunohistological analysis of vascular targeting with an anti-T7 antibody or IgG 
control antibody was performed on sections of heart, aorta, muscle, brain and kidney 
from SHRSP intravenously infused with 5x1010 pfu of peptide-inserted T7 phage.  
Binding by the anti-T7 and IgG antibodies was detected using DAB chromagen 
(areas to which the primary antibody bound appear brown) and followed by 
incubation with Harris haematoxylin (nuclei appear blue/purple).  The IgG antibody 
provides a negative control to test for non-specific binding of the primary antibody, 
as the sections incubated with IgG show no brown staining the binding of the 
primary antibody is specific.  L indicates luminal side of aorta.  Scale bar = 100 µm, 
magnification × 40. 
Chapter 3 – Vascular Targeting Anti-Oxidant Therapy 
92 
Phage containing the peptide sequence CRPPR localised to both ECs and SMCs in 
the aorta (Figure 3.9).  There was a high degree of staining in the aorta from animals 
infused with phage inserted with the peptide sequence CSGMARTKC but this was 
diffuse and non-specific (Figure 3.9).  Phage inserted with CSGMARTKC 
selectively bound to the coronary vessels of the heart (Figure 3.9).  In the brain, 
kidney and muscle, the staining was non-specific, indicating little binding by the 
phage in these non-target organs (Figure 3.9). 
Taken together, phage inserted with the CRPPR peptide selectively target both the 
endothelial and smooth muscle layers of the aorta and CSGMARTKC-containing 
phage target the coronary vasculature in the SHRSP.  Therefore, these peptide 
sequences may enhance the efficacy of an anti-oxidant therapy by selectively 
targeting specifically to the vasculature. 
3.2.4 Administration of peptides into SHRSP 
To investigate the effect of targeting the anti-oxidant peptide gp91ds (Rey et al., 
2001) with either the CRPPR or CSGMARTKC peptides in vivo, an in vivo protocol 
was designed in the SHRSP (Figure 3.10A).  Animals underwent baseline, 7 day and 
terminal ECHOs to monitor heart function and were placed on radio-telemetry 10 
days before the start of the experiment.  Telemetry was used to monitor BP, heart 
rate (HR) and activity of the animals from one week prior to administration of the 
peptides and for the three weeks of study duration.  Peptides were continuously 
administered at 10 mg/kg/day for 21 days by subcutaneous osmotic mini-pumps.  BP 
and HR takes up to 7 days to stabilise post-operatively (Davidson et al., 1995), 
therefore, mini-pumps were implanted two weeks after telemetry implantation and 
telemetry data were collected for one week prior to implantation of the mini-pumps 
and for the 21 days on treatment. 
There were four treatment groups in the in vivo study, in addition to a control group 
which only received vehicle by mini-pump.  Four groups of animals were 
continuously administered with a peptide: the two heart-targeting peptides (CRPPR 
and CSGMARTKC) linked to the anti-oxidant peptide, the HIV-tat peptide linked to 
the anti-oxidant peptide as a positive control to allow entry to all cells and the anti-
Chapter 3 – Vascular Targeting Anti-Oxidant Therapy 
93 
oxidant peptide alone as a negative control, to allow determination of the effect 
produced by targeting the anti-oxidant peptide (Figure 3.10B). 
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CSTRIRRQL -NH2GGG[H]-RKKRRQRR
SpacerTargeting Peptide Anti-Oxidant Peptide
CSTRIRRQL -NH2GGG[H]-CRPPR
[
[H]-RKKRRQRRR
 
 
Figure 3.10 – Animal protocol and design of vascular targeting anti-
oxidant peptides. 
(A) In vivo animal protocol used for administration of vascular targeting anti-oxidant 
peptides in the SHRSP.  Day 0 indicates the start of the continuous infusion of 
peptides by subcutaneous osmotic mini-pump.  Peptides were administered at 10 
mg/kg/day for 21 days.  (B) Sequence of anti-oxidant peptide gp91ds (Rey et al., 
2001), the anti-oxidant peptide targeted with either CRPPR or CSGMARTKC 
peptides and non-targeted anti-oxidant peptide linked to the HIV-tat peptide. 
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3.2.5 Effect of vascular targeting anti-oxidant peptide on 
BP 
BP in the SHRSP was determined by radio-telemetry for one week at baseline prior 
to mini-pump implantation, followed by three weeks of study duration before 
sacrifice (Figures 3.11, 3.12, 3.13).  Systolic BP showed a progressive and time-
dependent rise in animals receiving the anti-oxidant peptide gp91ds alone, HIV-tat-
gp91ds, CSGMARTKC-gp91ds and control animals from 177.6 ± 1.1 mmHg to 
200.6 ± 0.7 mmHg (Figure 3.11), characteristic of the SHRSP (Davidson et al., 
1995, Clark et al., 1996).  However, this increase in systolic BP was significantly 
attenuated in animals receiving CRPPR-linked to the anti-oxidant peptide with the 
maximum systolic BP only reaching 187.5 ± 5.2 mmHg (Figure 3.11).  Diastolic BP 
in animals treated with CSGMARTKC-gp91ds, HIV-tat-gp91ds and gp91ds alone 
also showed a progressive rise over the three weeks of the study (Figure 3.12).  
There was also a significant attenuation in the rise in diastolic BP in animals treated 
with CRPPR-gp91ds (Figure 3.12).  However, the average diastolic BP of animals in 
the control group was highly variable and not significantly different for the animals 
which received CRPPR-gp91ds (Figure 3.12). 
Mean arterial pressure (MAP) was also calculated by the telemetry equipment using 
the following formula: 
MAP = DBP + 1/3 PP (where DBP is diastolic BP and PP is pulse pressure, 
defined by the difference between systolic and 
diastolic BP (SBP-DBP)) 
MAP showed a progressive rise in animals receiving CSGMARTKC-gp91ds, HIV-
tat-gp91ds, gp91ds alone and control animals from 163.6 ± 1.1 mmHg to 170.5 ± 0.8 
(Figure 3.13).  This increase in MAP was significantly attenuated in animals 
receiving CRPPR-gp91ds as the maximum MAP only reached 160.0 ± 5.0 mmHg 
(Figure 3.13).  Taken together these data suggest that only when the anti-oxidant 
peptide was targeted by the CRPPR peptide could it produce a significant reduction 
in systolic BP and MAP in the SHRSP. 
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Figure 3.12 – Effect of vascular targeting anti-oxidant peptide on 
diastolic BP. 
Diastolic BP in SHRSP was determined for one week at baseline prior to mini-pump 
implantation, followed by three weeks of study duration before sacrifice.  Error bars 
represent SEM (* p < 0.001 vs. CSGMARTKC-gp91ds, HIV-tat-gp91ds and gp91ds, 
n = 6/group). 
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3.2.6 Effect of vascular targeting anti-oxidant peptide on 
cardiac function 
Animals underwent baseline (at 10 weeks of age), 7 day (at 13 weeks of age) and 
terminal (at 15 weeks of age) trans-thoracic left ventricular M-mode ECHO to 
monitor heart function performed by Dr. K. Gilday (University of Glasgow, UK).  
ECHOs allow measurement of cardiac function parameters including stroke volume 
(SV), left ventricular ejection fraction (LVEF) and left ventricular mass index 
(LVMI).  Also, in combination with the heart rate (HR) data obtained by telemetry, 
the cardiac output (CO) can also be calculated.  ECHO parameters were compared to 
control animals at the corresponding time point. 
Heart rate significantly decreased over the time period of the study, consistent with 
growth of the animal, and there was no significant difference between the groups 
(Figure 3.14).  The stroke volume (the volume of blood pumped from the left 
ventricle per beat) in the control group increased progressively over time (Figure 
3.15).  At 13 weeks, there was a significant difference between the stroke volume of 
the control animals and animals treated with CSGMARTKC-gp91ds, HIV-tat-
gp91ds and the anti-oxidant gp91ds peptide alone (Figure 3.15).  At 15 weeks, the 
stroke volume of the control group had increased to 0.76 ± 0.03 ml and was 
significantly higher than animals treated with HIV-tat-gp91ds and gp91ds alone at 
the same time point (Figure 3.15, Table 4).  As cardiac output is a function of heart 
rate and stroke volume, cardiac output also progressively increased in the control 
animals from 203.5 ± 16.0 ml/min to 315.7 ± 30.6 ml/min between 10 and 15 weeks 
of age (Figure 3.16, Table 4).  The cardiac output of the control animals was 
significantly increased compared to CSGMARTKC-gp91ds, HIV-tat-gp91ds and the 
gp91ds peptide alone at 13 weeks and compared to all treatment groups at 15 weeks 
(Figure 3.16). 
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Figure 3.14 – Effect of vascular targeting anti-oxidant peptide on HR. 
HR in SHRSP was determined for one week at baseline prior to mini-pump 
implantation, followed by three weeks of study duration before sacrifice.  Error bars 
represent SEM (no statistically significant difference between the groups by repeated 
measures ANOVA, n = 6/group).  b/min, beats per minute. 
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Figure 3.15 – Effect of vascular targeting anti-oxidant peptide on stroke 
volume. 
Animals underwent baseline, 7 day and terminal trans-thoracic ECHOs to determine 
stroke volume (SV).  Error bars represent SEM (# p < 0.05 vs. control at 13 weeks, * 
p < 0.05 vs. control at 15 weeks, n = 6/group). 
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Figure 3.16 – Effect of vascular targeting anti-oxidant peptide on 
cardiac output. 
Animals underwent baseline, 7 day and terminal trans-thoracic ECHOs.  By 
determination of stroke volume by ECHO and heart rate by telemetry, cardiac output 
(CO) was calculated.  Error bars represent SEM (# p < 0.05 vs. control at 13 weeks, 
* p < 0.05 vs. control at 15 weeks, n = 6/group). 
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The left ventricular ejection fraction (LVEF), the percentage of blood pumped out of 
the left ventricle with each beat, decreased over time in the control animals and 
animals treated with gp91ds alone (Figure 3.17).  However, in animals treated with 
CRPPR-gp91ds, the LVEF increased from 87.2 ± 4.8% to 89.5 ± 1.0% (Figure 3.17, 
Table 4).  The LVMI of control animals and animals treated with CSGMARTKC-
gp91ds and the anti-oxidant peptide alone increased progressively over time from 10 
to 15 weeks of age, consistent with growth of the animal (Figure 3.18).  Animals 
treated with CRPPR-gp91ds and HIV-tat-gp91ds did not show an increase in LVMI 
over time (Figure 3.18). 
 
 
Treatment Group HR (b/min) SV (ml) CO (ml/min) LVEF (%) LVMI (g/mm)
CRPPR-gp91ds 329.6 ± 5.3 0.64 ± 0.02 211.5 ± 2.3 * 89.5 ± 1.0 1.70 ± 0.09
CSGMARTKC-gp91ds 324.4 ± 5.4 0.73 ± 0.07 217.2 ± 38.4 * 86.0 ± 1.1 1.92 ± 0.10
HIV-tat-gp91ds 331.2 ± 10.5 0.61 ± 0.04 * 203.0 ± 15.8 * 85.1 ± 2.3 1.67 ± 0.06
gp91ds 318.4 ± 8.7 0.58 ± 0.02 * 184.8 ± 9.8 * 85.7 ± 3.2 1.88 ± 0.08
Control 323.2 ± 5.1 0.76 ± 0.03 315.7 ± 30.6 85.5 ± 0.8 1.85 ± 0.05
 
Table 4 – Effect of vascular targeting anti-oxidant peptide on ECHO 
parameters at 15 weeks. 
Animals underwent terminal trans-thoracic ECHOs at 15 weeks of age to determine 
stroke volume (SV), left ventricular ejection fraction (LVEF) and left ventricular 
mass index (LVMI).  Heart rate (HR) was measured by telemetry and cardiac output 
(CO) was calculated.  Value ± SEM (* p < 0.05 vs. control). 
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Figure 3.17 – Effect of vascular targeting anti-oxidant peptide on LVEF. 
Animals underwent baseline, 7 day and terminal trans-thoracic ECHOs to determine 
left ventricular ejection fraction (LVEF).  Error bars represent SEM (no statistically 
significant differences between the treatment groups and control animals at 13 and 
15 weeks by one-way ANOVA, n = 6/group). 
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Figure 3.18 – Effect of vascular targeting anti-oxidant peptide on LVMI. 
Animals underwent baseline, 7 day and terminal trans-thoracic ECHOs to determine 
LVMI.  Error bars represent SEM (no statistically significant differences between 
the treatment groups and control animals at 13 and 15 weeks by one-way ANOVA, n 
= 6/group). 
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3.2.7 Effect of vascular targeting anti-oxidant peptide on 
NO bioavailability 
At sacrifice, the thoracic aorta of all animals (n = 6/group) and the third order 
mesenteric arteries of three animals from each group were removed for functional 
studies by large vessel and small vessel myography, respectively. 
3.2.7.1 Large vessel myography 
At sacrifice, the thoracic aorta of all animals (n = 6/group) was removed for 
functional studies by large vessel myography to determine NO bioavailability.  
Cumulative concentration-response curves to phenylephrine (PE) were performed (1 
nmol/l to 10 µmol/l) and subsequently repeated in the presence of 100 µmol/l N-
nitro-L-arginine methyl ester (L-NAME) to competitively inhibit eNOS.  The 
response to PE was expressed as the percentage of the maximum contraction 
produced during the first PE curve and the difference between the two curves 
indicates the degree of NO bioavailability (Figure 3.19).  PE produces 
vasoconstriction by activation of α1-adrenoceptors and an increased contraction to an 
equivalent concentration of PE in the presence of L-NAME would indicate a degree 
of basal release of NO in the aorta.  However, if the PE concentration-response curve 
was comparable in the presence and absence of L-NAME, this would indicate no 
basal NO release was present, indicative of endothelial dysfunction. 
There was no difference between the two curves for animals treated with the HIV-tat 
peptide linked to anti-oxidant peptide, which indicates impaired endothelial function 
characteristic of the SHRSP and consistent with previous studies (Kerr et al., 1999, 
Hamilton et al., 2002) (Figure 3.19C).  CRPPR-gp91ds (Figure 3.19A), 
CSGMARTKC-gp91ds (Figure 3.19B) and the anti-oxidant peptide gp91ds alone 
(Figure 3.19D) showed significantly improved NO bioavailability.  The greatest 
difference between the two curves in the presence and absence of L-NAME occurred 
in those animals treated with CRPPR linked to the anti-oxidant peptide (Figure 
3.20).  This indicates that targeting the anti-oxidant peptide to the vasculature by the 
CRPPR peptide enhances the ability of the anti-oxidant peptide to increase NO 
bioavailability.
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Figure 3.20 – Differential effect of vascular targeting anti-oxidant 
peptide on NO bioavailability in the aorta. 
Calculated difference between concentration-response curve to PE and PE curve 
repeated in the presence L-NAME for each treatment group. 
 
 
 
LogEC50
(M) Mean (µmol/l) SEM (µmol/l)
CRPPR-gp91ds -3.56 272.6 54.4
CSGMARTKC-gp91ds -3.56 277.4 46.8
HIV-tat-gp91ds -3.47 339.7 57.4
gp91ds -3.53 293.9 37.0
Peptide
EC50
 
Table 5 – LogEC50 and EC50 values for apocynin concentration-
response curves. 
LogEC50 and EC50 values calculated from concentration-response curves to apocynin 
produced by large vessel myography on the thoracic aorta.  SEM, standard error of 
the mean. 
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In addition, other sections of the thoracic aorta were used to perform cumulative 
concentration-response curves to apocynin (10 µmol/l to 1 mmol/l) directly after a 
cumulative concentration-response curve to PE was constructed (n = 6/group).  
Response to apocynin was expressed as the percentage of the maximum contraction 
produced during the first PE curve (Figure 3.21).  Apocynin was first characterised 
as a reversible inhibitor of NAD(P)H oxidase (Simons et al., 1990) and as such has 
been used for numerous studies investigating the action of vascular oxidases.  
However, recently apocynin has been shown to also act an anti-oxidant (Heumuller 
et al., 2008). 
Increasing concentrations of apocynin increased relaxation by the vessel for all 
treatment groups (Figure 3.21).  Only aorta taken from animals treated with CRPPR-
gp91ds achieved a complete relaxation in the presence of apocynin (Figure 3.21A).  
In addition, the EC50 value was calculated for the apocynin concentration-response 
curves to determine half maximal effective concentration of apocynin in each 
treatment group (Table 5).  The targeting peptides CRPPR and CSGMARTKC 
linked to the anti-oxidant peptide had substantially lower EC50 values (272.6 µmol/l 
and 277.4 µmol/l, respectively) compared to HIV-tat-gp91ds and gp91ds alone, EC50 
values of 339.7 µmol/l and 293.9 µmol/l, respectively (Table 5).  Therefore, 
apocynin had a greater efficacy in animals treated with the targeting peptides linked 
to the anti-oxidant peptide, in particular CRPPR-gp91ds. 
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3.2.7.2 Small vessel myography 
In addition to large vessel myography on the thoracic aorta, small vessel myography 
was also performed on third order mesenteric arteries to determine the NO 
bioavailability of resistance vessels.  Vessels were removed at sacrifice from three 
animals from each group, dissected from connective tissue and segments 
(approximately 2 mm in length) were mounted as ring preparations on two stainless 
steel wires on a small vessel myograph.  Following an internal diameter 
normalisation period, a cumulative concentration-response curve to PE (1 nmol/l to 
30 µmol/l) was performed in the absence and presence of 100 µmol/l L-NAME.  The 
difference between the two curves indicates the degree of NO bioavailability (Figure 
3.22). 
There was no significant difference between the two curves for animals treated with 
CRPPR-gp91ds (Figure 3.22A).  However, there was a clear difference between the 
straight sections of the sigmoid curve indicating an enhanced efficacy of PE in the 
presence of L-NAME (Figure 3.22).  CSGMARTKC-gp91ds (Figure 3.22B), HIV-
tat-gp91ds (Figure 3.22C) and the anti-oxidant peptide gp91ds alone (Figure 3.22D) 
showed significantly improved NO bioavailability.  Therefore, this suggests that all 
the peptides are producing an effect on NO bioavailability in resistance arteries. 
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Figure 3.22 – Effect of vascular targeting anti-oxidant peptide on NO 
bioavailability in resistance arteries. 
Concentration-response curve to phenylephrine (PE) produced by small vessel 
myography on third order mesenteric arteries, repeated in the presence of 100 µmol/l 
L-NAME.  Response to PE was expressed as percentage of maximum contraction 
produced during the first PE curve.  Error bars represent SEM (* p < 0.01 vs. PE 
curve, n = 3/group). 
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3.2.8 Effect of vascular targeting anti-oxidant peptide on 
cardiac histology 
Due to the differences in some relevant cardiac parameters between the groups, the 
structure of the heart was investigated by histology.  After the removal of paraffin 
and rehydration, sections were stained with haemotoxylin and eosin (H&E), which 
stains nuclei blue/purple and the cytoplasm of cells pink (Figure 3.23).  For 
investigation into differences in collagen deposition, picro-sirius red and Masson’s 
trichrome staining were used.  Picro-sirius red stains collagen red on a pale yellow 
background (Figure 3.24)  Masson’s trichrome staining produces black cell nuclei, 
red cytoplasm and muscle fibres and collagen was stained blue (Figure 3.25).  There 
were no differences observed between the sections of heart taken from animals from 
each treatment group. 
3.2.9 Effect of vascular targeting anti-oxidant peptide on 
oxidative stress status 
Overall oxidative stress status was assessed by SO release from heparinised whole 
blood by electron paramagnetic resonance (EPR).  Blood samples were taken by 
cardiac puncture at sacrifice and incubated for 30 minutes at 37°C with 500 µmol/l 
of CPH spin probe before being snap frozen in liquid nitrogen.  The rate of SO 
production by the frozen samples was calculated as counts per minute by EPR.  
There was a significant difference in SO production levels between control animals 
and animals treated with CRPPR-gp91ds and HIV-tat-gp91ds (Figure 3.26).  In 
addition, there was a significant reduction in SO production in HIV-tat-gp91ds 
treated animals compared to animals treated with CRPPR-gp91ds (Figure 3.26). 
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Figure 3.23 – Effect of vascular targeting anti-oxidant peptide on the 
heart by H&E staining. 
Histological analysis of sections of the heart from control and treated animals by 
H&E staining.  H&E stains nuclei blue/purple and the cytoplasm of the cells pink.  
Images are from three animals per group.  Scale bar = 100 µm, magnification × 40. 
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Figure 3.24 – Effect of vascular targeting anti-oxidant peptide on 
collagen deposition in the heart by picro-sirius red staining. 
Histological analysis of collagen deposition in sections of the heart from control and 
treated animals by picro-sirius red staining.  Picro-sirius red stains collagen red on a 
pale yellow background.  Images are from three animals per group.  Scale bar = 100 
µm, magnification × 40. 
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Figure 3.25 – Effect of vascular targeting anti-oxidant peptide on 
collagen deposition in the heart by Masson’s trichrome staining. 
Histological analysis of collagen deposition in sections of the heart from control and 
treated animals by Masson’s trichrome staining.  Masson’s trichrome staining 
produces black cell nuclei, red cytoplasm and muscle fibres and collagen was stained 
blue.  Scale bar = 100 µm, magnification × 40. 
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Figure 3.26 – Effect of vascular targeting anti-oxidant on SO production 
in whole blood. 
SO production from heparinised whole blood samples by EPR.  Blood samples were 
taken by cardiac puncture at sacrifice and incubated for 30 minutes at 37°C with 500 
µmol/l of CPH spin probe before being snap frozen in liquid nitrogen.  The rate of 
SO production by the frozen samples was calculated as counts per minute by EPR.  
Error bars represent SEM (* p < 0.05 vs. control, # p < 0.05 vs. CRPPR-gp91ds 
treated animals, n = 6/group). 
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3.3 Discussion 
This study has determined the efficacy produced by targeting an anti-oxidant peptide 
selectively to the vasculature.  Six selectively heart-homing peptides were originally 
determined by ex vivo and in vivo phage display in BALB/c mice (CGRKSKTVC, 
CPKRPR, CPKTRRVPC, CRPPR, CRSTRANPC and CSGMARTKC) (Zhang et 
al., 2005).  The heart-targeting capability of CRPPR was further tested in an 
additional two mouse strains (FVB and C57BL/6) with a similar degree of specific 
cardiac homing seen in the different strains (Zhang et al., 2005).  Three out of the six 
cardiac targeting peptides (CRPPR, CRSTRANPC and CSGMARTKC), retained 
their selectivity for the heart when they where taken across species into the WKY rat 
(Shirley, 2008).  This indicates that there are similarities and significant differences 
between the proteins expressed on the EC surface of these two different species.  
Furthermore, only two of the peptide sequences (CRPPR and CSGMARTKC) could 
produce a degree of selectivity to one organ or vessel in the SHRSP, a model of 
human essential hypertension.  Therefore, careful selection and testing of targeting 
peptide sequences is required before they can be used effectively in the model of 
choice. 
The anti-oxidant peptide gp91ds selectively inhibits production of SO by NAD(P)H 
oxidase (Rey et al., 2001).  In the SHRSP, which has endothelial dysfunction due to 
increased generation of SO and relative NO deficiency (Kerr et al., 1999, Hamilton 
et al., 2002), gp91ds either alone or targeted by CRPPR and CSGMARTKC 
significantly enhanced NO bioavailability, as determined by large vessel myography 
on the thoracic aorta.  Animals treated with CRPPR-gp91ds showed the greatest 
improvement in NO bioavailability, suggesting that targeting the anti-oxidant 
peptide to the vasculature increases the efficacy of the anti-oxidant peptide to 
improve endothelial function.  Small vessel myography performed on third order 
mesenteric resistance arteries suggested that all the peptides were increasing NO 
bioavailability.  This further indicates the differences produced by targeting the anti-
oxidant peptide, when gp91ds was targeted to the aorta by CRPPR it produced the 
greatest increase in NO bioavailability. 
Chapter 3 – Vascular Targeting Anti-Oxidant Therapy 
116 
During myography experiments, the aorta was also exposed to apocynin.  Increasing 
concentrations of apocynin increased relaxation by the vessel for all treatment 
groups but only in the CRPPR-gp91ds treated group did complete relaxation occur in 
the presence of apocynin.  The targeting peptides CRPPR and CSGMARTKC linked 
to the anti-oxidant peptide had substantially lower EC50 values compared to HIV-tat-
gp91ds and gp91ds alone.  This suggests that apocynin had a greater efficacy in 
animals treated with the targeting peptides linked to the anti-oxidant peptide, in 
particular CRPPR-gp91ds, than the non-targeted anti-oxidant peptide.  However, the 
mechanism of action of apocynin in these experiments is unclear.  If apocynin was 
acting as an anti-oxidant (Heumuller et al., 2008), then it would prevent any SO 
released from the vessels interacting with NO, increasing NO bioavailability.  This 
would be consistent with the findings in the presence of L-NAME, whereby CRPPR-
gp91ds has the greatest effect on NO bioavailability.  Conversely, if apocynin was 
inhibiting NAD(P)H oxidase (Simons et al., 1990), the greater relaxation response to 
apocynin by aorta from CRPPR-gp91ds-treated animals could suggest increased SO 
was present in these vessels due to either increased NAD(P)H oxidase activity or 
increased expression of the enzyme.  The highly effective inhibition of NAD(P)H 
oxidase by the CRPPR-gp91ds could lead to an up-regulation in expression of 
NAD(P)H oxidase.  When the anti-oxidant peptide targeted by CRPPR was washed 
off in the myograph bath, the increased SO production by increased levels of 
NAD(P)H oxidase could possibly enable a greater relaxation of the vessel to be 
produced in the presence of increasing concentrations of apocynin. 
The increase in NO bioavailability produced by CRPPR-gp91ds, CSGMARTKC-
gp91ds and gp91ds alone treated animals was only considerable enough in animals 
treated with CRPPR-gp91ds to produce a significant reduction in systolic BP.  The 
anti-oxidant peptide by inhibition of NAD(P)H oxidase has been previously shown 
to reduce SO production in angiotensin II- and salt-induced hypertension (Rey et al., 
2001, Zhou et al., 2006).  Here it has been shown that only when gp91ds was 
targeted to the vasculature could it reduce systolic BP in a disease model, the 
SHRSP.  The rise in systolic BP was progressive and time-dependent in the control 
animals and in animals treated with CSGMARTKC-gp91ds, HIV-gp91ds and 
gp91ds alone, characteristic of the SHRSP (Davidson et al., 1995, Clark et al., 
1996). 
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Animals were treated with the HIV-tat peptide linked to the anti-oxidant peptide as a 
positive control but this treatment provided no benefit in NO bioavailability or 
reduction in systolic BP.  After investigation of the SO production in whole blood 
samples taken from this group by EPR, it was shown that animals treated with HIV-
tat-gp91ds had significantly reduced SO production in the blood compared to 
CRPPR-gp91ds treated animals.  This suggests that the HIV-tat peptide was enabling 
delivery of the anti-oxidant peptide to blood components, most likely mononuclear 
white blood cells, and this resulted in reduced SO production in the whole blood 
sample from these animals.  Previously, gp91ds-tat has been shown to inhibit 
phorbol myristate acetate (PMA)-induced SO production in neutrophils by 35% (Rey 
et al., 2001).  This interaction with the blood would, thereby, reduce the overall 
bioavailability of the HIV-tat-gp91ds peptide, possibly preventing it producing the 
effects on BP seen in other studies (Rey et al., 2001).  Therefore, HIV-tat was 
effective at delivering the anti-oxidant peptide but the lack of selective targeting by 
this peptide means that it was not successful in conveying the anti-oxidant peptide to 
sites of oxidative stress where it would produce significant effects on BP. 
The receptor for CRPPR was previously identified as CRIP-2 (Zhang et al., 2005).  
CRIP-2 was expressed at the highest level in the heart of mice, with much lower 
levels of this receptor present in other tissues (Zhang et al., 2005).  Fluorescein-
conjugated CRPPR peptide extensively co-localised with an anti-CRIP-2 antibody 
and the endothelial marker CD31 in coronary arteries, capillaries and the 
endocardium (Zhang et al., 2005).  However, CRIP-2 has no discernible membrane-
spanning domain and has been previously shown to be a binding partner of sub-
membranous protein tyrosine phosphatase (PTP-BL) (van Ham et al., 2003).  
Therefore, it is possible that the CRIP-2 protein was expressed on the surface of 
ECs, allowing binding by CRPPR.  Recently, a study has shown that the vascular 
targeting capacity of, in particular the CRPPR peptide, was possibly due to the 
presence of a C-terminal arginine residue (R by amino acid single letter code) 
(Teesalu et al., 2009).  It was further shown that a tandem RXXR motif was highly 
efficient at promoting initial phage binding (Teesalu et al., 2009).  Phage inserted 
with peptide sequences containing RXXR demonstrated greater than 1000-fold 
increase in binding over control phage (Teesalu et al., 2009).  Indeed, addition of 
further basic amino acids to the peptide sequence increased binding in a dose-
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dependent manner, contributing to subsequent internalisation (Teesalu et al., 2009), 
possibly due to the increased similarity to the HIV-tat peptide (sequence 
RKKRRQRRR).  The mechanism of internalisation by peptide containing the RXXR 
motif was investigated using the inhibitors of various endocytosis pathways but this 
mechanism of cell entry was not used (Teesalu et al., 2009).  This was expected at 
least for the CRPPR peptide as a putative receptor had been previously identified for 
this peptide (Zhang et al., 2005).  The putative receptor for internalisation of 
peptides with a C-terminal R, neuropilin-1 (NRP-1), was not identified in the 
previous peptide receptor screen for the receptor for CRPPR (Zhang et al., 2005).  
Also, CRPPR bound to HCAECs more strongly than to HUVECs (Zhang et al., 
2005), suggesting specific targeting to the arterial vasculature and not generic 
endothelial targeting. 
When the C-terminal R was capped in peptides containing the RXXR motif with an 
additional non-basic amino acid, it abolished cellular binding by the phage inserted 
with this peptide sequence (Teesalu et al., 2009).  This has important implications as 
the CRPPR peptide was linked to the anti-oxidant peptide through the terminal R 
residue (CRPPR-gp91ds sequence was CRPPR-GGG-CSTRIRRQL).  Although it 
was shown that trypsin, through cleavage of the targeting peptide at basic residues, 
could activate a peptide with a “cryptic binding site” by proteolytic cleavage 
(Teesalu et al., 2009).  It is possible that the binding site for C-terminal R peptides in 
the NRP-1 receptor is small and the presence of the GGG linker sequence in the 
CRPPR-gp91ds peptide allows the anti-oxidant peptide to bend away from the 
receptor, producing interaction between CRPPR and NRP-1.  Indeed the binding site 
of NRP-1 probably requires five amino acids as the conversion from tuftsin (TKPR) 
to enhanced-tuftsin (TKPPR) increased binding to endothelial cells by 20-fold (von 
Wronski et al., 2006).  Vascular endothelial derived growth factor (VEGF) binds to 
NRP-1 to increase vascular permeability (Becker et al., 2005, Mamluk et al., 2005, 
Acevedo et al., 2008).  VEGF binds to the same site of NRP-1 as the HIV-tat peptide 
(Jia et al., 2001).  A peptide with the RXXR motif was shown to significantly 
increase vascular leakage (Teesalu et al., 2009).  This increased vascular 
permeability produced by the presence of the CRPPR peptide could have produced 
the increased effectiveness of the anti-oxidant peptide by increasing delivery to 
VSMCs. 
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The SHRSP has been used in this study as a model of human essential hypertension 
as BP in these animals increases with age (Davidson et al., 1995, Clark et al., 1996).  
Additionally, as the SHRSP has endothelial dysfunction due to oxidative stress, 
which has been previously reversed (Alexander et al., 1999, Dowell et al., 1999, 
Alexander et al., 2000, Fennell et al., 2002, Miller et al., 2005, Graham et al., 2009), 
it was an excellent model for the study of a novel anti-oxidant therapy.  The anti-
oxidant peptide gp91ds was targeted to the vasculature and the effect on BP and 
endothelial function in the SHRSP was then assessed.  The anti-oxidant therapy 
alone shows improvement in NO bioavailability but only when it was targeted with 
CRPPR was a significant improvement in NO bioavailability and an attenuation of 
the time-dependent and progressive increase in systolic BP observed in the SHRSP. 
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4.1 Introduction 
There are significant hindrances in the deployment of Ad5-based gene therapy 
vectors, including extensive liver and spleen accumulation (Huard et al., 1995, 
Connelly, 1999, Parker et al., 2006, Waddington et al., 2007, Kalyuzhniy et al., 
2008, Waddington et al., 2008), broad seroprevalence of neutralising antibodies 
(Christ et al., 1997, Sprangers et al., 2003, Vogels et al., 2003, Sumida et al., 2005, 
Abbink et al., 2007, Parker et al., 2009) as well as interactions with erythrocytes 
(Nicol et al., 2004, Carlisle et al., 2009, Subr et al., 2009) and platelets (Hofherr et 
al., 2007, Othman et al., 2007, Stone et al., 2007b) which all serve to limit efficacy.  
Consequently, research has been undertaken to find an alternative gene therapy 
vector with one possible solution being to develop alternative serotype Ad vectors 
which circumvent some of the negative aspects of Ad5.  Sub-species B Ads are a 
relatively well characterised sub-species of Ad with many potentially favourable 
differences to Ad5 due to alternative receptors and lower seroprevalence. 
4.1.1 Sub-species B Ads 
The sub-species B Ads include Ad3, 7, 11, 16, 35 and 50.  Relative to sub-species C 
Ads, sub-species B Ad fibers are short-shafted, consisting of 5.5 repeats in 
comparison to the 22 repeats in the sub-species C Ads (Ad2 and Ad5).  The sub-
species B Ads form two genetic clusters, B1 (Ad3, Ad7, Ad16, Ad21, and Ad50) and 
B2 (Ad11, Ad14, Ad34, and Ad35) (Wadell et al., 1980) (Figure 1.3).  The sub-
species B Ads were originally shown to use CD46 as their high affinity cellular 
receptor (Gaggar et al., 2003, Segerman et al., 2003b, Sirena et al., 2004).  The high 
affinity interaction between the Ad35 fiber knob and CD46 has a dissociation 
constant of 14.64 nM (Wang et al., 2008b), which is similar to the affinity of the 
Ad5 fiber knob:CAR interaction (Kirby et al., 2000, Kirby et al., 2001).  Short 
consensus repeats 1 and 2, two distal extracellular domains of CD46, are involved in 
Ad35 binding (Gaggar et al., 2003, Fleischli et al., 2005, Sakurai et al., 2006b) 
(Figure 4.1). 
CD46 is a 56-66 kDa membrane glycoprotein which protects cells from 
complement-mediated damage and is usually present on all human nucleated cells at 
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a relatively low level.  There are four major isoforms of CD46 (BC1, BC2, C1 and 
C2, Figure 4.1) produced by alternative splicing of a region encoding an 
extracellular domain and the choice between one of two cytoplasmic tails, Cyt-1 and 
Cyt-2.  The use of CD46 as a virus receptor allows the sub-species B Ads to produce 
more efficient transduction of both VSMCs and ECs, in comparison to other sub-
species due to the low CAR expression of these cells (Havenga et al., 2001, Havenga 
et al., 2002). 
Several of the sub-species B Ads also use an unidentified receptor for the infection 
of human cells, named receptor X (Tuve et al., 2006).  By using soluble CD46 and 
an anti-CD46 antibody, three sub-groups of the sub-species B Ads were determined 
(Tuve et al., 2006).  Ad16, Ad21, Ad35 and Ad50 nearly exclusively use CD46 as 
their receptor, Ad3, Ad7p and Ad14 use receptor X and not CD46 and Ad11p 
utilises both CD46 and receptor X (Tuve et al., 2006).  Competition studies with 
recombinant fiber knob protein showed that the interaction of Ad3, Ad7p, Ad11p 
and Ad14 with receptor X was mediated through the fiber knob (Tuve et al., 2006).  
Further analysis demonstrated that receptor X is likely to be an abundantly expressed 
glycoprotein, present on a variety of cancer and primary cells (Tuve et al., 2006).  
Ad3, Ad7p, Ad11p and Ad14 bind to receptor X with low affinity in a calcium-
dependent manner (Tuve et al., 2006). 
Many previous studies have focused on chimeric vectors, where the fiber of sub-
species B Ads is “pseudotyped” onto the Ad5 capsid through swapping of either the 
knob domain (Shayakhmetov and Lieber, 2000, Gaggar et al., 2003, Shayakhmetov 
et al., 2004, Shayakhmetov et al., 2005a, Wang et al., 2008a) or the full length fiber 
(Shayakhmetov et al., 2000, Havenga et al., 2001, Shayakhmetov et al., 2002, 
Sakurai et al., 2003a, Sakurai et al., 2003b, Shayakhmetov et al., 2004, Di Paolo et 
al., 2006, Ni et al., 2006, Shinozaki et al., 2006, Tuve et al., 2006, Brouwer et al., 
2007, Stone et al., 2007a).  In vitro this strategy was effective at improving delivery 
through CD46 (Di Paolo et al., 2006, Ni et al., 2006, Brouwer et al., 2007). 
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Figure 4.1 – Structure of CD46 isoforms. 
There are four major isoforms of CD46 (BC1, BC2, C1 and C2) produced by 
alternative splicing of a region encoding an extracellular domain and the choice 
between one of two cytoplasmic tails, Cyt-1 and Cyt-2.  Short consensus repeats 
(SCR) I and II are crucial for Ad35 binding.  Adapted from Manchester et al. 
(Manchester et al., 1994). 
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4.1.2 Sub-species B pseudotype vectors 
The first studies using a sub-species B pseudotype vector, Ad5/f35 (a vector 
consisting of the hexon and penton of Ad5 and the Ad35 fiber) showed that Ad5/f35 
could efficiently transduce haematopoietic CD34+ cells (Shayakhmetov et al., 2000, 
Di Paolo et al., 2006).  Ad5/f35 transduced 54% of CD34+ cells, whereas 
transduction by Ad5 was restricted to the 25% of CD34+ cells which expressed αv-
integrins (Shayakhmetov et al., 2000).  The remaining CD34+ cells were refractory 
to Ad5 transduction as they did not express CAR or αv-integrins (Shayakhmetov et 
al., 2000).  In addition, studies investigating alternative human serotypes for 
cardiovascular gene therapy utilised a “pseudotype library” for screening on cell 
lines to determine the most efficient fiber for transduction (Havenga et al., 2001, 
Havenga et al., 2002).  The sub-species B pseudotype Ad5/f16 was found to increase 
transduction of human ECs and SMCs by 8- and 64-fold, respectively, compared to 
the Ad5 control (Havenga et al., 2001).  When other sub-species B pseudotype 
vectors were tested, namely Ad5/f11 and Ad5/f35, they both increased transduction 
efficiency compared to Ad5 but not to the same efficiency as Ad5/f16 (Havenga et 
al., 2001).  These data in ECs were corroborated in another study where Ad5/f35 
transduced 95-100% of both HUVECs and HAECs, whereas Ad5 transduced less 
than 10% of both cell types (Shinozaki et al., 2006).  This was due to the relatively 
low level of CAR expression by SMCs and ECs (Havenga et al., 2001).  Therefore, 
as the sub-species B vectors use CD46 and not CAR as their cellular receptor, which 
is expressed at high levels on SMCs and ECs (Shinozaki et al., 2006), they are able 
to efficiently transduce SMCs and ECs.  Whilst SMCs can be transduced by Ad5, it 
requires a very high multiplicity of infection of Ad5 per cell and this has 
implications for toxicity (Havenga et al., 2001, Work et al., 2004). 
The sub-species B pseudotype vectors also demonstrate increased infectivity of 
many cancer cell lines compared to Ad5 (Havenga et al., 2002, Shayakhmetov et al., 
2002, Brouwer et al., 2007), likely due to CD46 being up-regulated in many human 
cancers (Kinugasa et al., 1999, Murray et al., 2000, Ni et al., 2006).  In addition, 
expression of CAR correlates negatively with tumour malignancy in vivo (Miller et 
al., 1998, Li et al., 1999, Okegawa et al., 2000, Ni et al., 2006), indicating that 
vectors using a CAR-dependent pathway for infection would be largely ineffective at 
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transducing the most aggressive forms of cancer.  In vitro, the cancer cell line MDA-
MB-435 was efficiently transduced by Ad5/f35, whereas this cell line was refractory 
to Ad5 transduction due to very low CAR expression by these cells (Shayakhmetov 
et al., 2002).  There was a strong correlation between transduction efficiency of 
primary cancer cells in vitro by Ad5 and Ad5/f35 and the CAR and CD46 expression 
levels (Ni et al., 2006, Suominen et al., 2006, Brouwer et al., 2007). 
Pseudotype vectors from the sub-species B Ads have been shown to significantly 
enhance transduction of primary glioma cells taken from patients with brain 
tumours, compared to Ad5 (Brouwer et al., 2007).  Transduction was enhanced by 
the presence of the sub-species B fiber due to the low level of CAR expression by 
the cells and the primary glioma cell suspensions readily expressed the BC1 isoform 
of CD46 (Brouwer et al., 2007).  Transgene expression by the Ad35 vector was 
significantly enhanced in the primary glioma cells compared to Ad5 (Brouwer et al., 
2007).  However, there was no direct comparison made between the Ad35 vector and 
the pseudotype Ad5/f35 vector. 
The properties displayed by the Ad5/f35 pseudotype vector are maintained in the 
Ad35 vector.  Ad35 displays a higher transduction efficiency into human CD34+ 
cells compared to both Ad5 and Ad5/f35 (Sakurai et al., 2003a).  In CAR expressing 
cell lines, Ad35 produced similar or lower levels of transduction compared to Ad5 
and Ad5/f35 (Sakurai et al., 2003b).  Furthermore, in cell lines which did not express 
CAR, transduction by Ad35 was significantly enhanced compared to Ad5, as 
expected (Sakurai et al., 2003b). 
Therefore, in vitro studies suggest that it would be possible to selectively target and 
effectively transduce cancer cells, possibly either as part of a solid tumour or ideally 
disseminated metastases, by systemic administration of vectors based on the sub-
species B Ads as this sub-species also shows reduced hepatocyte transduction 
(compared to Ad5) but efficient cancer cell transduction.  Indeed, Ad5/f35 has been 
approved in the UK for a cancer gene therapy phase I clinical trial 
(http://www.dh.gov.uk/ab/GTAC/index.htm). 
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4.1.3 Animal models for in vivo study of the tropism of 
sub-species B Ads 
Many of the in vivo studies into the efficacy and safety of vectors based on the sub-
species B Ads have produced variable results.  In many cases, this could be due to 
the use of wild-type mice, rather than CD46 transgenic mice.  Although humans 
ubiquitously express CD46, expression in rodents is restricted to the testes (Inoue et 
al., 2003).  In addition, there is no homology between the mouse and human 
cytoplasmic domains of CD46.  When non-transgenic mice are used for the in vivo 
studies, the sub-species B Ad vectors showed no retargeting away from the liver 
(Shayakhmetov et al., 2002).  This was entirely expected based on the lack of 
expression of CD46.  However, the sub-species B Ads did demonstrate reduced liver 
transduction in comparison to Ad5 (Shayakhmetov et al., 2002). 
The difficulties in using animal models to translate the tropism of sub-species B Ad 
vectors to humans were first highlighted by the differences in Ad5/f16 transduction 
of human SMCs to those taken from rats, pigs and rhesus monkeys (Havenga et al., 
2001).  In human SMCs, Ad5/f16 produced a 64-fold increase in transduction in 
comparison to Ad5 (Havenga et al., 2001).  This increase in transduction efficiency 
was also seen in rhesus monkey SMCs, where Ad5/f16 increased transduction by 5-
fold compared to Ad5 (Havenga et al., 2001).  However, in pig and rat SMCs, 
transduction by Ad5/f16 was reduced 10- and 100-fold, respectively, compared to 
Ad5 (Havenga et al., 2001).  This was later explained when it was found that rodents 
only express CD46 in the testes (Inoue et al., 2003).  Therefore, rat SMCs would not 
express CD46 preventing efficient transduction by a sub-species B pseudotype 
vector.  This also suggests that porcine SMCs express CD46 at a moderate level 
(lower than human SMC CD46 expression) as, although transduction by Ad5/f16 
was reduced in cells taken from the pig, transduction was not attenuated.  Therefore, 
the pig is also a poor animal model for studies into the in vivo tropism of sub-species 
B Ad vectors. 
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4.1.3.1 Studies in non-CD46 transgenic mice 
Although non-CD46 transgenic mice do not provide a good animal model for the use 
of sub-species B Ads in humans, studies in these animals have provided useful data 
on the selective targeting capacity of these vectors.  In vivo studies in immuno-
deficient CB17/SCID mice demonstrated attenuated liver transduction by Ad5/f35 
compared to Ad5 (Shayakhmetov et al., 2002), indicating that Ad5/f35 had a 
reduced liver tropism.  Therefore, it was hoped that due to the reduced liver tropism 
of Ad5/f35 and the enhanced transduction of cancer cell lines by this vector, Ad5/f35 
would be an effective vector for potentially targeting metastases after intravenous 
administration.  In a xenograft model of liver metastases produced by transplantation 
of a human breast carcinoma cell line (MDA-MB-435) into the portal vein of 
immuno-deficient CB17/SCID mice, Ad5/f35 transduced 8% of liver metastases 
(Shayakhmetov et al., 2002).  Due to the up-regulation of CD46 in many human 
cancer cell lines and the lack of native CD46 expression in the mouse, Ad5/f35 
should selectively and efficiently transduce the cancer cells.  Another similar study 
did find that Ad5/f35 could selectively target a transplanted human cancer cell line 
(Bernt et al., 2003).  Immuno-deficient CB17/SCID mice were transplanted with a 
human carcinoma cells (HeLa) via portal vein injection and Ad5 selectively 
transduced mouse hepatocytes (Bernt et al., 2003).  Transduction by Ad5/f35 was 
selectively restricted to liver metastases with no obvious transduction of hepatocytes 
(Bernt et al., 2003).  The reason behind the difference between these two studies is 
unclear, possibly due to CD46 expression levels on the different human cancer cell 
lines used to produce the liver metastases. 
There are also differences between Ad5 and Ad5/f35 transduction after local 
delivery in vivo.  In an in vivo model of head and neck cancer, created by 
subcutaneous injection of a human squamous cell carcinoma cell line into 
immunodeficient SCID knockout mice, Ad5/f35 transgene expression was detected 
uniformly across 60% of the tumour (Suominen et al., 2006).  However, 
administration of Ad5 by the same route resulted in transduction of only those cells 
directly surrounding the injection site (Suominen et al., 2006).  The dispersion by the 
Ad5/f35 vector, allowing transduction of cells not immediately adjacent to the site of 
injection, suggests that administration of Ad5/f35 by a single intra-tumoural 
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injection is a therapeutically relevant route of administration and may be clinically 
relevant. 
The pseudotype vector Ad5/f35 has also been used in a rat hepatic tumour model 
(Shinozaki et al., 2006).  Cancer cells (McA-RH7777) were implanted into non-
transgenic rats 14 days before administration of either Ad5 or Ad5/f35 into the 
hepatic artery (Shinozaki et al., 2006).  Ad5 transgene expression was detected 
primarily in the liver parenchyma with transduction occurring in only a few tumour 
cells (Shinozaki et al., 2006).  However, Ad5/f35 selectively targeted the rim of the 
hepatic tumour, co-localising with the endothelial cell markers CD31 and Flk-1, 
indicating transduction of endothelial cells in vivo (Shinozaki et al., 2006).  
Additionally, Ad5/f35 produced very little transduction of normal liver tissue 
(Shinozaki et al., 2006), suggesting that Ad5/f35 could be used to deliver genes via 
the hepatic artery to sites of neoangiogensis associated with liver tumours.  
However, this study was performed in the rat which does not share the CD46 
expression pattern of humans and it is difficult to correlate the observed vector 
distribution with this receptor expression. 
The Ad35 vector behaves similarly to the pseudotype Ad5/f35 vector in vivo in non-
transgenic mice.  Ad5/f35 and Ad35 produced their highest levels of organ 
transduction in the liver but transduction by these vectors was 3 and 4 log orders, 
respectively, lower than transgene expression mediated by Ad5 (Sakurai et al., 
2003b).  In other organs, including spleen, kidney, heart and lung, transduction by 
Ad35 was lower than transduction by Ad5/f35 (Sakurai et al., 2003b).  To 
investigate why there was a difference in the transduction efficiency by Ad35 and 
the pseudotype Ad35 vectors, the blood clearance kinetics of Ad5 and Ad35 were 
determined (Sakurai et al., 2003b).  The clearance of Ad5 and Ad35 from the blood 
was rapid for both vectors and not significantly different to each other; both had a 
half-life in the blood of approximately three minutes (Sakurai et al., 2003b).  The 
blood clearance kinetics of Ad5/f35 was not reported.  Therefore, the rate of 
clearance from the animal was not involved in producing the overall reduced 
transduction efficiency by Ad35.  One hour post intravenous infusion of the vector 
into non-transgenic mice, the majority of the viral dose accumulated in the liver due 
to the action of Kupffer cells (Sakurai et al., 2003b).  However, 48 hours after 
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administration of the vectors, 43% of the Ad5 dose remained in the liver due to 
transduced hepatocytes, whereas no Ad35 DNA was detected (Sakurai et al., 2003b).  
This was likely due to the absence of CD46 in the non-transgenic mice. 
In the same study, non-transgenic mice were given Ad5, Ad5/f35 and Ad35 vectors 
by intramuscular injection (Sakurai et al., 2003b).  Although, skeletal muscle cells 
express low levels of CAR (Tomko et al., 1997, Bergelson et al., 1998, Nalbantoglu 
et al., 1999), Ad5 produced the highest level of transgene expression but this was not 
significantly different to Ad5/f35 and Ad35 (Sakurai et al., 2003b).  This suggests 
that the efficacy of the Ad5/f35 and Ad35 vectors to infect skeletal muscle cells was 
poor.  Additionally, the hepatotoxicity produced by Ad5 and Ad35 vectors was 
significantly different.  The level of the liver enzyme aspartate aminotransferase 
(AST) was used as a measure of hepatotoxicity, as release of this enzyme into the 
bloodstream occurs after acute damage to the liver.  One day after administration, 
Ad35 and Ad5 produced a 2- and 5-fold increase in AST levels, respectively 
(Seshidhar Reddy et al., 2003).  In mice injected with Ad35, the AST level returned 
to baseline four days after delivery of the vector.  However, four days after 
administration of Ad5, the level of AST had increased by 40-fold (Seshidhar Reddy 
et al., 2003).  These data suggest that Ad35 may be less toxic to the liver than Ad5 
but, as these experiments were performed in non-transgenic mice, it does not predict 
the immune reactions to administration of an Ad35 vector in humans. 
4.1.3.2 Studies in CD46 transgenic mice 
Transgenic mice with different expression profiles of human CD46 were used to 
evaluate Ad35 transduction in vivo.  However, there were some distinct differences 
between transgenic strains, for example, CD46 was not detected on the erythrocytes 
of some CD46 transgenic mice (Sakurai et al., 2006a) but other studies have shown 
this (Oldstone et al., 1999, Kemper et al., 2001).  The reason for the differential 
expression of CD46 on erythrocytes is likely due to the method of production of the 
CD46 transgenic mice strains.  Transgenic mice produced using a yeast artificial 
chromosome under the control of a β-actin promoter to transfer DNA encoding 
CD46, expressed CD46 on their red blood cells (Oldstone et al., 1999).  Whereas 
erythrocytes did not express CD46 when a bacterial artificial chromosome was used, 
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driven by the human CD46 promoter (Sakurai et al., 2006a).  This produced an 
expression profile similar to that in humans (Mrkic et al., 1998, Oldstone et al., 
1999, Kemper et al., 2001). 
There are distinct differences in the transduction properties of sub-species B Ad 
vectors after local delivery in CD46 transgenic and non-transgenic mice.  After 
intramuscular injection, Ad5/f35 selectively transduced myocytes surrounding the 
injection site in CD46 transgenic mice but this did not occur in non-transgenic mice 
(Di Paolo et al., 2006).  Intramuscular injections led to leakage of a proportion of the 
delivered vector into the bloodstream and resulted in liver transduction (Di Paolo et 
al., 2006).  Liver transduction after intramuscular injection in non-transgenic mice 
was increased, compared to transduction in CD46 transgenic mice (Di Paolo et al., 
2006).  There was also some lung accumulation in CD46 transgenic animals 
administered with Ad5/f35 by intramuscular injection (Di Paolo et al., 2006). 
In CD46-transgenic mice, intravenous administration of Ad5/f35 selectively targeted 
metastatic tumours, which had grown from cells engineered to express CD46 at a 
level comparable to human tumours (Ni et al., 2006).  This indicates that the 
transduction efficiency of Ad5/f35 depends on the CD46 expression density; since 
the cancer cells expressed more CD46, they were efficiently targeted. 
Hemizygous and homozygous CD46 transgenic mice have been developed to 
investigate the differences in tropism by Ad35 (Sakurai et al., 2006a).  Intravenous 
administration of Ad35 produced increased transduction of liver, lung and kidney in 
CD46 transgenic mice, in comparison to non-transgenic mice, with no differences in 
transduction by Ad35 between the hemizygous and homozygous CD46 transgenic 
mice (Sakurai et al., 2006a).  Unfortunately, this study did not compare Ad5 and 
Ad35 transduction in CD46 transgenic mice.  In a similar study, intravenous delivery 
of Ad35 into CD46 transgenic mice did not result in effective transduction of any 
organ when measured 24 hours after administration (Verhaagh et al., 2006).  
However, 48 hours after administration, there were detectable levels of Ad35 in the 
lung (Verhaagh et al., 2006).  There was no Ad35 detected in the liver of the CD46 
transgenic mice at either time point (Verhaagh et al., 2006).  When Ad35 was 
administered by intramuscular injection, the level of transduction produced was 
Chapter 4 – Influence of FX on Ad35 
131 
comparable between non-transgenic and CD46 transgenic mice (Verhaagh et al., 
2006).  In both of these studies in CD46 transgenic mice, there was no comparison 
made to gene transfer mediated by Ad5.  Therefore, it is difficult to obtain an 
indication of the likely tropism in humans relative to the other previously tested 
vectors, for example, Ad5. 
4.1.3.3 Studies in non-human primates 
Non-human primates have a similar CD46 expression pattern to humans (Hsu et al., 
1997) with high homology in the short consensus repeats 1 and 2 regions, which are 
crucial for Ad35 binding (Fleischli et al., 2005, Gaggar et al., 2005, Sakurai et al., 
2006b).  Non-human primates have been extensively used for studies with measles 
virus as it also uses CD46 as a receptor (Sakaguchi et al., 1986, McChesney et al., 
1997, Premenko-Lanier et al., 2003).  In baboons, intravenous administration of Ad5 
resulted in significantly increased levels of transduction in the liver, brain and 
stomach in comparison to the sub-species B pseudotype vectors Ad5/f11 and 
Ad5/f35 (Ni et al., 2005).  Interestingly, 5% of hepatocytes were transduced and 
areas of the arterial endothelium in the lung showed 100% transgene expression 
produced by Ad5 (Ni et al., 2005), which was very different to previous findings 
where Ad5 usually demonstrates very high liver transduction.  The toxicity of the 
vectors was also investigated with all vectors producing an increase in alanine 
aminotransferase (ALT), a marker of hepatocellular damage, one hour after 
administration (Ni et al., 2005).  The ALT level 72 hours post-administration was 
increased further in Ad5 treated animals, whereas 72 hours after delivery of Ad5/f11 
and Ad5/f35, the ALT level had returned to normal (Ni et al., 2005).  Therefore, the 
sub-species B pseudotype vectors appear to possess a better safety profile than Ad5 
in baboons but the levels of transduction by these pseudotype vectors are relatively 
low. 
Experiments investigating the in vivo tropism of Ad35 after intravenous 
administration were reproduced in another non-human primate, the cynomolgus 
monkey (Sakurai et al., 2008).  Ad35 transduction mostly occurred in the liver, lung 
and kidney but all at substantially lower levels than transduction produced by Ad5 in 
these organs (Sakurai et al., 2008).  There was no difference in the blood-clearance 
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kinetics between Ad5 and Ad35 (Sakurai, 2008).  However, Ad35 vectors remained 
associated with blood cells throughout the four days of study duration (Sakurai et al., 
2008).  As the erythrocytes of the cynomolgus monkey express CD46 (Hsu et al., 
1999), this suggests that Ad35 may bind to blood cells or was taken up by blood 
cells after delivery of the vector, resulting in the increased association of this vector 
with blood cells over the course of the study and limiting bioavailability. 
As Ad35 has relatively poor tissue transduction efficiency after systemic 
administration, this makes it a potential candidate for development into a targeted 
gene therapy vector.  Targeting Ad35 by local delivery could potentially produce 
fewer side effects on non-target organs when Ad35 drains from the injection site into 
the bloodstream.  Sakurai et al. administered Ad35 by direct injection into the liver 
of cynomolgus monkeys, which resulted in transgene expression only in those cells 
bordering the injection site (Sakurai et al., 2009).  Injection of Ad35 into skeletal 
muscle of cynomolgus monkey resulted in no transduction of muscle fibers (Sakurai 
et al., 2009), in comparison to the transduction produced by this vector in both non-
transgenic and CD46 transgenic mice (Sakurai et al., 2003b, Verhaagh et al., 2006).  
Renal tubular epithelial cells were transduced by Ad35 after local delivery to the 
kidney with some dispersion from the injection site (Sakurai et al., 2009).  
Additionally, inflammatory cell infiltration was seen at many of the injection sites 
but there was no transduction observed in organs which were not injected (Sakurai et 
al., 2009).  However, this study did not compare the effects of local delivery of Ad35 
to that of Ad5.  Therefore, it is difficult to draw any firm conclusions on the 
efficiency of this vector. 
As some non-human primates express CD46 on erythrocytes, whereas humans do 
not (Hsu et al., 1999, Baker, 2007, Sakurai, 2008), this prevents their use as a truly 
relevant in vivo model.  The sub-species B Ad vectors would have a reduced 
circulation time in these primates since the majority of the vector would bind to the 
available CD46 receptors on red blood cells rapidly after injection.  Therefore, it is 
appropriate to use mice transgenic for human CD46 which display a similar 
expression profile to humans (Sakurai et al., 2006a). 
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4.1.4 Interaction of sub-species B Ads with blood 
Recent studies were designed to investigate the interaction(s) between blood and the 
sub-species B vectors in CD46 transgenic mice after it was shown that the Ad35 
knob domain was sensitive to FIX binding (Shayakhmetov et al., 2005b).  After 
intravenous administration of Ad5 and Ad5/f35 into non-transgenic mice, both 
vectors produced similar levels of liver transduction (Shayakhmetov et al., 2005b).  
Strikingly, in vitro Ad5/f35 produced significantly reduced transduction of 
hepatocytes compared to Ad5 (Shayakhmetov et al., 2005b), suggesting an 
alternative CAR-independent, blood factor-dependent pathway exists for hepatocyte 
transduction in vivo.  Liver transduction by Ad5/f35 was significantly reduced in an 
in situ perfusion model but the level of Ad5 transduction remained the same 
(Shayakhmetov et al., 2005b).  These experiments were performed in non-transgenic 
mice.  Therefore, Ad5/f35 required the presence of the blood for efficient liver 
transduction due to the lack of its primary receptor in non-CD46 transgenic mice.  
However, when the blood was removed, Ad5 could still efficiently transduce the 
hepatocytes using a CAR-dependent pathway. 
Intravenous infusion of heparinase I into mice before administration of the vectors 
significantly reduced liver transduction by both Ad5 and Ad5/f35 (Shayakhmetov et 
al., 2005b).  This indicates that in the presence of blood, both vectors use HSPGs as 
their cellular receptors.  The presence of human FIX significantly enhanced in vitro 
transduction by Ad5/f35 (Shayakhmetov et al., 2005b).  Ex vivo liver perfusion in 
the presence of FIX also increased transduction by Ad5/f35 to levels comparable 
with Ad5, with a significant increase in accumulation of both vectors by Kupffer 
cells (Shayakhmetov et al., 2005b).  There was no significant difference in liver 
transduction by Ad5/f35 in control and FIX knockout mice (Shayakhmetov et al., 
2005b), suggesting an influence by other blood factors in vivo. 
Ad5/f35 and Ad35 also interact with platelets in vivo.  Early blood clearance kinetics 
were determined for Ad5, Ad5/f35 and Ad35 using a blood sample taken 10 minutes 
post-intravenous infusion of the vector (Stone et al., 2007a).  There was very little 
Ad35 remaining in the circulation 10 minutes after administration, whereas the level 
of both Ad5 and Ad5/f35 in the blood was higher (Stone et al., 2007a).  This 
Chapter 4 – Influence of FX on Ad35 
134 
suggests that the interaction with the blood was not dependent on CD46 as Ad35 and 
Ad5/f35 both have the Ad35 fiber, which binds to CD46.  Ad5/f35 and Ad35 have 
different levels of association with the blood indicating the involvement of other 
capsid proteins for the interaction with the blood.  Six hours after systemic 
administration of the vectors, Ad5 and Ad35 expressed similar levels of liver 
transduction (contrary to reports 48-72 hours after administration (Verhaagh et al., 
2006)) with Ad35 producing significantly higher levels of transduction of the lung 
and spleen (Stone et al., 2007a).  Ad5, Ad5/f35 and Ad35 were shown to co-localise 
with platelets in hepatic sinusoids by co-staining for Ad hexon and the platelet 
marker CD41 (Stone et al., 2007a).  Ad5, Ad5/f35 and Ad35 also co-localised with 
platelets after sequestration in the marginal zone of the spleen (Stone et al., 2007a).  
However, in the lung, there was no evidence of interaction between Ad35 and 
platelets, indicating that the Ad vector-platelet interaction was not required for lung 
tropism. 
4.1.5 Interaction of sub-species B Ads with FX 
Whilst the Ad5 hexon has been shown to reproducibly interact with FX (Kalyuzhniy 
et al., 2008, Vigant et al., 2008, Waddington et al., 2008), the interaction of FX with 
Ad35 was controversial.  Previously, it has been reported that FX bound to Ad35 as 
demonstrated by SPR with an equilibrium dissociation constant of 5.2x10-8 M 
(Waddington et al., 2008).  Conversely, Kalyuzhniy and colleagues (Kalyuzhniy et 
al., 2008) reported no interaction between Ad35 and FX by SPR.  There was also a 
difference between the reports for the sub-species B vector Ad50, which was either 
reported as a very strong FX binder (Waddington et al., 2008) or no binding to FX 
was detected (Kalyuzhniy et al., 2008).  However, binding to FX by Ad16 was 
reported as strong by both groups (Kalyuzhniy et al., 2008, Waddington et al., 
2008). 
Based on the importance of virus capsid design in gene therapeutics, the aim of this 
study was to fully define the interaction and effect of FX on Ad35 and chimeric 
Ad5/Ad35 vectors in vitro and in vivo. 
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4.2 Results 
4.2.1 Chimeric Ad5/Ad35 vectors 
To fully define the interaction of FX with Ad35 vectors in vitro and in vivo, several 
chimeric vectors were used (Figure 4.2).  In addition to Ad5 and Ad35 vectors, the 
following chimeric vectors used were: the pseudotype Ad5/f35, which contains the 
hexon and penton of Ad5 with the Ad35 fiber (f), Ad5/p35/f35, which has the hexon 
of Ad5 and the penton (p) and fiber of Ad35, and Ad35/f5, the reverse pseudotype 
(Figure 4.2). 
Ad5 Ad5/f35 Ad5/p35/f35
Ad35 Ad35/f5
 
Figure 4.2 – Capsid configuration of Ad5, Ad35 and chimeric Ad5/Ad35 
vectors. 
Schematic to highlight the different vectors used in this study.  Ad5 components are 
shown in blue and Ad35 components are shown in yellow/red.  Ad5 and Ad35/f5 
contain the long-shafted Ad5 fiber.  Ad5/f35, Ad5/p35/f35 and Ad35 vectors all 
contain the short-shafted Ad35 fiber. 
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4.2.2 Affinity analysis of Ad5, Ad35 and chimeric 
Ad5/Ad35 vectors 
The ability of Ad5, Ad35 and the chimeric Ad5/Ad35 vectors to bind the blood 
coagulation factor FX was analysed by SPR by Dr. J.H. McVey (Thrombosis 
Research Institute, London, UK).  Following biotinylation of each vector, covalent 
linkage to a biosensor chip was performed and FX was injected over the chip at a 
flow rate of 30 µl/min.  The presence of FX binding to the vectors was detected as a 
change in response units (RU) and kinetic analysis was performed post-hoc.  SPR 
data was then compared to previous data characterising the Ad5:FX interaction 
(Waddington et al., 2008). 
SPR analysis revealed that Ad5, Ad35 and the chimeric Ad5/Ad35 vectors bound to 
FX and sensograms of the kinetic analysis for each vector are shown in Figure 4.3.  
The shape of the sensogram produced by each vector binding to FX was distinctly 
different depending on the capsid configuration.  Ad5, Ad5/f35 and Ad5/p35/f35, 
which share the Ad5 hexon, had similar binding characteristics (Figure 4.3A, C, E).  
Conversely, Ad35 and Ad35/f5, which share the Ad35 hexon, have different binding 
characteristics (Figure 4.3B, D).  The difference in binding characteristics was 
reflected in the kinetic analysis.  Vectors containing the Ad5 hexon (Ad5, Ad5/f35 
and Ad5/p35/f35) fitted to a 1:1 binding model with equilibrium dissociation 
constants of 2.7x10-9 M, 1.9x10-9 M and 1.0x10-9 M, respectively (Table 6), which is 
similar to previously reported findings for Ad5 (Waddington et al., 2008).  It should 
be noted that the biotinylated Ad5/p35/f35 bound much less FX than the other 
viruses, indicated by a lower change in RU (Figure 4.3E).  In contrast, vectors 
containing the Ad35 hexon (Ad35 and Ad35/f5) fitted poorly to a 1:1 binding model 
but fitted to a heterogenous ligand model with equilibrium dissociation constants of 
5.4x10-8 M and 3.5x10-9 M for Ad35 and 2.4x10-8 M and 6.6x10-9 M for Ad35/f5 
(Table 6).  Therefore, both the Ad5 and Ad35 pseudotypes have FX binding 
affinities akin to other vectors possessing the same hexon, with vectors containing 
the Ad5 hexon having an approximately ten-fold higher affinity for FX than those 
vectors containing the Ad35 hexon (Table 6). 
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A
E
DC
B
 
Figure 4.3 – Ad5, Ad35 and chimeric Ad5/Ad35 vectors bind FX. 
Representative SPR sensograms for (A) Ad5, (B) Ad35, pseudotype vectors (C) 
Ad5/f35 and (D) Ad35/f5, and (E) chimeric vector Ad5/p35/f35.  All vectors bind 
FX as shown by an increase in response units (RU). 
Chapter 4 – Influence of FX on Ad35 
138 
Ad5 Ad5/f35 Ad5/p35/f35 Ad35 Ad35/f5 
ka1 (1/Ms) 9.53x105 1.27x106 1.90x106 1.98x105 1.11x1010
kd1 (1/s) 2.5x10-3 2.4x10-3 2.0x10-4 1.1x10-2 269.7
KD1 (M) 2.7x10-9 1.9x10-9 1.0x10-9 5.4x10-8 2.4x10-8
Rmax1 (RU) 18.37 21.11 1.9 10.61 30.72
ka2 (1/Ms) 2.09x105 2.29x105
kd2 (1/s) 7.42x10-4 1.52x10-3
KD2 (M) 3.5x10-9 6.6x10-9
Rmax2 (RU) 4.076 22.39
 
Table 6 – Ad5, Ad35 and chimeric Ad5/Ad35 vectors bind FX. 
SPR kinetic analysis determined the calculated association rate (ka), dissociation rate 
(kd) and equilibrium dissociation constant (KD) values for each vector. 
 
 
4.2.3 Ad35 hexon binds to FX 
CyroEM was performed by Dr. D. Bhella and Ms. R. Pink (MRC Virology Unit, 
University of Glasgow, UK) to further investigate the interaction between FX and 
Ad35.  Ad35 virions were incubated overnight at 4°C in the presence of FX to allow 
FX to complex with the vector.  Images of both the complexed and non-complexed 
vector and a composite image were resolved to 35Å resolution (Figure 4.4).  The 
areas of green on the composite image indicate that FX bound to the Ad35 hexon 
with a clear density in the centre of the trimeric hexon proteins (Figure 4.4).  
Interestingly, in the presence of FX, the fibers of Ad35 are resolved (Figure 4.4).  
The Ad35 fibers are not usually present in cyroEM reconstructions due to the 
flexibility of the fiber (Saban et al., 2005). 
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Figure 4.4 – FX binds to the Ad35 hexon. 
Cryo-electron microscopic reconstruction of Ad35 in the presence and absence of 
FX.  Composite image shows FX bound within a cavity formed by Ad35 trimeric 
hexon proteins. 
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4.2.4 CD46 expressing cell line 
To investigate the effect of these interactions between Ad5, Ad35 and the chimeric 
Ad5/Ad35 vectors with FX in vitro, two cell lines were used.  These were Chinese 
hamster ovary (CHO)-BC1 and CHO-WTR cells, obtained as a gift from Professor J. 
Atkinson (Washington University School of Medicine, St. Louis, MO, USA).  The 
CHO-BC1 cell line stably expresses the BC1 isoform of the human membrane 
glycoprotein CD46, whereas the control CHO-WTR cells do not express CD46 as 
they were transfected with a control plasmid (Figure 4.5). 
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Figure 4.5 – Western blot for CD46 expression in CHO cell lines. 
Anti-CD46 antibody probed membrane to detect relative levels of CD46 expression.  
Cells were cultured and lysed before determination of protein concentration by BCA 
assay.  The same concentration of protein from each cell line was run on a 12% 
polyacrylamide gel with a rainbow ladder as a marker of protein size at 200 V for 
approximately 6 hours to achieve separation of the CD46 isoforms (56-66 kDa).  
CHO-WT, control CHO cells.  CHO-WTR, transfected with a control plasmid.  
CHO-BC1, BC2, C1 and C2, cells stably expressing the BC1, BC2, C1 and C2 
isoforms of CD46, respectively. 
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To confirm that gene transfer was mediated by CD46 in the CHO-BC1 cell line, the 
anti-CD46 antibody MEM258 was used (Figure 4.6).  Transduction by the vectors in 
the presence of MEM258 was compared to transduction in the presence of control 
IgG (Figure 4.6).  In CHO-WTR cells, which do not express CD46, transduction by 
Ad5, Ad5/f35, Ad5/p35/f35 and Ad35 was low and not effected by the presence of 
MEM258 (Figure 4.6A).  The addition of MEM258 did not effect Ad5 transduction 
in CHO-BC1 cells (Figure 4.6B), where Ad5 produced a similar level of 
transduction in CHO-WTR cells (Figure 4.6A).  In CHO-BC1 cells, the presence of 
MEM258 significantly reduced transduction by Ad5/f35, Ad5/p35/f35 and Ad35 by 
6.7-, 14.2- and 22.6-fold, respectively (Figure 4.6B).  Therefore, as MEM258 
significantly reduced transduction by vectors possessing the Ad35 fiber (which is 
responsible for binding to CD46), CHO-BC1 cells stably express CD46 and gene 
transfer is mediated through this receptor for vectors with the Ad35 fiber. 
4.2.5 Effect of FX on cell binding by Ad5, Ad35 and 
chimeric Ad5/Ad35 vectors in CHO-CD46 cells 
The ability of the vectors to bind to CHO-BC1 and CHO-WTR cells in the presence 
and absence of FX was assessed by infecting the cell lines with the vectors at 4°C for 
one hour.  Incubation with the vectors at 4°C allows binding by the vectors to the 
cell surface but not internalisation, which is energy-dependent and hence occurs at 
37°C.  After washing to remove unbound vectors, cells were collected, viral and total 
genomic DNA was isolated and qPCR was preformed to calculate the number of 
vector genomes per ng total DNA isolated. 
The addition of physiological levels of FX significantly increased binding of Ad5 to 
both CHO-BC1 and CHO-WTR cells by 5.0- and 15.9-fold, respectively (Figure 
4.7).  This increase in binding in the presence of FX was significantly inhibited by 
the FX binding protein X-bp (Figure 4.7).  X-bp is a 29 kDa protein isolated from 
Deinagkistrodon acutus (the hundred pace snake) which binds with high affinity to 
the Gla domain of human and murine FX (Atoda et al., 1998), thus preventing the 
interaction between FX and the vector from occurring (Waddington et al., 2008).  
Ad35/f5 showed a similar profile to Ad5 in both CHO-WTR and CHO-BC1 cells 
with a significant increase of 6.5- and 3.7-fold, respectively, in the presence of FX, 
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which was completely inhibited by the addition of X-bp (Figure 4.7A, B).  In the 
absence of FX, binding of Ad5/f35, Ad5/p35/f35 and Ad35 was considerably higher 
in CHO-BC1 cells compared to binding in CHO-WTR cells (Figure 4.7).  The 
addition of FX had no effect on CHO-BC1 cell binding mediated by Ad5/f35, 
Ad5/p35/f35 and Ad35 (Figure 4.7B) but enhanced binding in CHO-WTR cells by 
7.3-, 3.6- and 2.0-fold, respectively (Figure 4.7A). 
In summary, in CHO-WTR cells binding by Ad5, Ad5/f35, Ad5/p35/f35, Ad35 and 
Ad35/f5 was significantly increased in the presence of FX and blocked by X-bp, 
confirming the FX:Ad35 interaction.  The interaction between the Ad35 fiber and 
CD46 in CHO-BC1 cells is very efficient and cannot be further enhanced by FX or 
blocked with X-bp.  The presence of the Ad5 fiber on the Ad35 capsid in Ad35/f5 
converts the binding profile back to one similar to Ad5.  Thus, these data indicate the 
importance of both hexon and fiber in the cell binding process. 
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Figure 4.6 – Inhibition of transduction by Ad35 and chimeric Ad5/Ad35 
vectors in CHO-WTR and CHO-CD46 cells in the presence of anti-CD46 
antibody. 
(A) CHO-WTR cells and (B) CHO-BC1 cells were exposed to each Ad vector at a 
concentration of 1000 VP/cell in the presence and absence of the anti-CD46 
antibody MEM258 or IgG control for 3 hours at 37ºC.  Cells were washed and 
maintained at 37°C for a further 72 hours before quantification of transgene 
expression by luciferase assay, normalised to total protein content determined by 
BCA assay.  Error bars represent SEM (* p < 0.05 versus IgG control). 
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Figure 4.7 – Binding by Ad5, Ad35 and chimeric Ad5/Ad35 vectors in 
CHO-WTR and CHO-CD46 cells. 
(A) CHO-WTR and (B) CHO-BC1 cells were exposed to each Ad vector at a 
concentration of 1000 VP/cell in the presence and absence of physiological FX 
levels and 15 µg/ml FX binding protein, X-bp, for 1 hour at 4ºC.  Viral and total 
genomic DNA was extracted and the cell-bound adenovirus quantified by qPCR.  
Error bars represent SEM (* p < 0.05 versus absence of FX, # p < 0.05 versus 
presence of FX). 
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4.2.6 Effect of FX on cell internalisation by Ad5, Ad35 and 
chimeric Ad5/Ad35 vectors in CHO-CD46 cells 
Previous reports have demonstrated differences in intracellular trafficking by vectors 
based on the sub-species B Ads in comparison to Ad5 (Miyazawa et al., 1999, 
Shayakhmetov and Lieber, 2000, Shayakhmetov et al., 2003, Shayakhmetov et al., 
2005a).  These potentially very important differences in trafficking and the resulting 
differences in Ad genome localisation to the nucleus of infected cells could lead to a 
substantial difference in the level of transduction achieved by each vector.  
Therefore, the level of cellular internalisation mediated by Ad35 and the chimeric 
Ad5/Ad35 vectors was assessed through repetition of the binding experiment 
outlined above with an additional one hour incubation at 37°C (to allow 
internalisation) and concomitant removal of cell surface bound vector by washing 
with 0.2 M glycine, pH 2.2 (Figure 4.8). 
Cell internalisation by all vectors was significantly enhanced by the addition of 
physiological levels of FX in CHO-WTR cells (Figure 4.8A).  In the absence of FX 
all vectors likely use the low affinity HSPG pathway for cell entry (Tuve et al., 
2008).  The addition of FX and resultant FX binding to both the Ad5 and Ad35 
hexon possibly leads to all vectors being able to utilise the high affinity HSPG 
pathway for cell internalisation (Waddington et al., 2008).  The addition of FX 
significantly enhanced cell entry by vectors containing the Ad5 fiber (Ad5 and 
Ad35/f5) by 17.2- and 4.8-fold, respectively, in the CHO-BC1 cell line (Figure 
4.8B).  In the presence of FX, Ad5 and Ad35/f5 can utilise the HSPG pathway for 
enhanced internalisation.  FX significantly increased cell internalisation by Ad35 by 
1.8-fold in CHO-BC1 cells, indicating that FX and the resulting interaction of the 
Ad35:FX complex with the cellular receptor system (as yet undefined) can further 
enhance cell entry by Ad35 (Figure 4.8B). 
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Figure 4.8 – Internalisation by Ad5, Ad35 and chimeric Ad5/Ad35 
vectors in CHO-WTR and CHO-CD46 cells. 
(A) CHO-WTR and (B) CHO-BC1 cells were exposed to each Ad vector at a 
concentration of 1000 VP/cell in the presence and absence of physiological FX 
levels for 1 hour at 4ºC, followed by 1 hour at 37°C.  After washing with 0.2 M 
glycine, pH 2.2 to remove cell surface-bound vectors, viral and total genomic DNA 
was extracted and adenovirus quantified by qPCR.  Error bars represent SEM (* p < 
0.05 versus absence of FX). 
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4.2.7 FX limits cellular transduction by Ad35 and chimeric 
Ad5/Ad35 vectors containing the Ad35 fiber in CHO-
CD46 cells 
The recombinant Ad5, Ad35 and chimeric Ad5/Ad35 vectors express the luciferase 
reporter gene allowing transduction experiments to be performed and quantified by 
expression of the luciferase transgene after normalisation to the total protein content 
of the cells used in the experiment.  In the presence of physiological levels of FX, 
the level of transgene expression mediated by Ad5 was significantly increased 3.6-
fold in the CHO-BC1 cells and 38.6-fold in the CHO-WTR cells (Figure 4.9).  In 
both cells lines, this enhancement in transduction produced by the addition of FX 
was entirely inhibited by X-bp (Figure 4.9). 
In the presence of FX transduction by Ad5/f35, Ad5/p35/f35 and Ad35 in the CHO-
BC1 cells was significantly inhibited by 2.7-, 1.9- and 2.2-fold, respectively (Figure 
4.9B).  Levels of expression were substantially lower for all three viruses in CHO-
WTR cells, where FX significantly enhanced transduction by all vectors (Figure 
4.9A). 
Taken together, these data suggests that FX limits post-binding or post-
internalisation mechanism(s) that leads to cellular transduction by viruses containing 
the Ad35 fiber (Ad5/f35, Ad5/p35/f35 and Ad35) in CHO-BC1 cells, where the high 
affinity interaction with CD46 is important.  Such a limitation was not observed for 
Ad5 since strong potentiation of binding and transduction in the presence of FX was 
observed.  Ad35/f5 also showed a significant increase in transduction in the presence 
of FX, which was inhibited by X-bp similar to Ad5 in both cell lines (Figure 4.9).  
However, in both CHO-BC1 and CHO-WTR cells, the level of transduction 
produced was very low (Figure 4.9). 
The effect of FX on binding (attachment), internalisation and transduction (transgene 
expression) by Ad5, Ad35 and chimeric Ad5/Ad35 vectors in the CHO-BC1 and 
CHO-WTR cell lines is summarised in Table 7. 
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Figure 4.9 – Transduction by Ad5, Ad35 and chimeric Ad5/Ad35 vectors 
in CHO-WTR and CHO-CD46 cells. 
(A) CHO-WTR and (B) CHO-BC1 cells were exposed to each Ad vector at a 
concentration of 1000 VP/cell in the presence and absence of physiological levels of 
FX and 15 µg/ml FX binding protein, X-bp, for 3 hours at 37ºC.  Cells were washed 
and maintained at 37°C for a further 72 hours before quantification of transgene 
expression by luciferase assay, normalised to total protein content determined by 
BCA assay.  Error bars represent SEM (* p < 0.05 versus absence of FX, # p < 0.05 
versus presence of FX). 
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Table 7 – Effect of FX on attachment, internalisation and transgene 
expression by Ad5, Ad35 and chimeric Ad5/Ad35 vectors in vitro. 
Summary of the effect of FX on attachment (binding), internalisation and transgene 
expression (transduction) by Ad5, Ad35 and chimeric Ad5/Ad35 vectors in CHO-
BC1 and CHO-WTR cell lines.  + indicates enhancement in the presence of FX, - 
indicates inhibition in the presence of FX and 0 indicates no effect of FX. 
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4.2.8 Effect of NAPc2 on Ad35 transduction in CHO-CD46 
cells 
To confirm the effect of FX on Ad35 transduction, in vitro transduction experiments 
were performed in the presence of increasing concentrations of NAPc2 (Figure 
4.10).  NAPc2 is nematode anticoagulant peptide which is a potent inhibitor of Ad5 
transduction (Waddington et al., 2008).  NAPc2 binds to a putative heparin binding 
exosite in the FX serine protease domain with high affinity (Murakami et al., 2007).  
Therefore, the presence of NAPc2 prevents the interaction between the Ad5:FX 
complex and (putatively) HSPGs, resulting in ablation of Ad5 transduction through 
blockade of receptor binding (Waddington et al., 2008).  As previously reported 
above, the addition of physiological levels of FX significantly increased transduction 
by Ad5 in both CHO-WTR and CHO-BC1 cell lines (Figure 4.10).  The addition of 
10 µg/ml NAPc2 completely ablated transduction by Ad5 by 574.4- and 341.5-fold 
in CHO-WTR and CHO-BC1 cells, respectively (Figure 4.10).  This inhibition of 
transduction was concentration-dependent (Figure 4.10).  Although 0.1 µg/ml 
NAPc2 produced a significant reduction in Ad5 transduction in CHO-WTR and 
CHO-BC1 cells, dilution of NAPc2 to a concentration of 0.01 µg/ml did not 
significantly reduce transduction by Ad5 in either cell line (Figure 4.10).  This is 
similar to results previously reported in HepG2 cells (Waddington et al., 2008). 
Transduction by Ad35 was significantly inhibited 1.7-fold in the presence of FX in 
CHO-BC1 cells (Figure 4.10B), as previously shown.  The addition of 1 and 10 
µg/ml NAPc2 significantly reduced transduction further (Figure 4.10B).  This 
suggests that the Ad35:FX complex also uses the HSPG pathway for transduction.  
In the presence of NAPc2, transduction by Ad35 was significantly inhibited, likely 
due to an inability to utilise HSPGs as cellular receptors for transduction.  However, 
there was an indication that transduction by Ad35 in the presence of FX was not 
singularly dependent on HSPGs, in comparison to transduction by Ad5.  Although 
NAPc2 produced a significant reduction in transduction by Ad35, this was not to the 
same degree as the inhibition of Ad5 transduction.  This indicates that a modest level 
of transduction by Ad35 was still CD46-dependent.  In CHO-WTR cells, Ad35 
produced very low levels of transduction under all conditions (Figure 4.10A). 
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Figure 4.10 – Transduction by Ad5 and Ad35 vectors in CHO-WTR and 
CHO-CD46 cells in the presence of NAPc2. 
(A) CHO-WTR and (B) CHO-BC1 cells were exposed to each Ad vector at a 
concentration of 1000 VP/cell in the presence and absence of physiological levels of 
FX and 0.01 – 10 µg/ml NAPc2  for 3 hours at 37ºC.  Cells were washed and 
maintained at 37°C for a further 72 hours before quantification of transgene 
expression by luciferase assay, normalised to total protein content determined by 
BCA assay.  Error bars represent SEM (* p < 0.05 versus absence of FX, # p < 0.01 
versus presence of FX). 
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4.2.9 Effect of FX on cell binding and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in human 
cancer cell lines 
Vectors containing the Ad35 fiber are becoming increasing popular as gene therapy 
vectors, especially for use in cancer gene therapy.  Therefore, the effect of FX on 
binding and transduction by Ad35 and the chimeric Ad5/Ad35 vectors was 
investigated in three cancer cell lines, MDA-MB-435, SKOV-3 and T-47D cells.  
These cell lines were selected from the NCI60 database (http://dtp.nci.nih.gov) as 
they expressed a range of CAR and CD46 levels determined by RNA level, RNA 
expression and normalised gene expression (Table 8).  MDA-MB-435 cells have a 
low CAR and CD46 expression levels, SKOV-3 cells have moderate CAR 
expression and low CD46 expression and T-47D cells have high expression of both 
CAR and CD46 (Table 8). 
Additionally, the relative expression of CAR and CD46 in these cancer cell lines was 
confirmed by TaqMan qPCR (Figures 4.11, 4.12) and by western blot for CD46 
(Figure 4.13).  A western blot was performed to detect the relative CAR expression 
level but the anti-CAR antibody (RmcB clone; Upstate, Lake Placid, NY, USA) did 
not perform to the standard required.  MDA-MB-435 cells have also been previously 
reported to express very low levels of CAR by flow cytometry (Shayakhmetov et al., 
2002). 
 
RNA 
Levels
RNA 
Expression
Normalised 
Gene 
Expression
RNA 
Levels
RNA 
Expression
Normalised 
Gene 
Expression
MDA-MB-435 5.0 -0.9 18.3 200.2 45.3 92.7
SKOV-3 79.8 44.3 83.5 401.2 -14.7 64.6
T-47D 226.1 108.7 274.1 1024.9 150.3 569.7
CAR CD46
Cell Line
 
Table 8 – CAR and CD46 levels in human cancer cell lines. 
CAR and CD46 RNA level, RNA expression and normalised gene expression data 
taken from the NCI60 database (http://dtp.nci.nih.gov). 
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Figure 4.11 – Amplification plots from TaqMan qPCR for CAR and CD46 
expression in human cancer cell lines. 
RNA was extracted from each of the three cancer cell lines.  cDNA was synthesised 
and amplified using primers specific for CAR and CD46 and TaqMan qPCR was 
performed using the Power SYBR Green detection system.  The amount of 
fluorescence released during the amplification cycle is proportional to the amount of 
product generated in each cycle and these representative traces from qPCR show the 
relative CAR and CD46 expression levels in the three cancer cell lines. 
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Figure 4.12 – TaqMan quantification of relative CAR and CD46 
expression in cancer cell lines. 
RNA was extracted from each of the three cancer cell lines.  cDNA was synthesised 
and amplified using primers specific for CAR and CD46 and TaqMan qPCR was 
performed using the Power SYBR Green detection system.  Acquisition of data 
occurs when PCR amplification is in the exponential stage.  Data expressed as 
inverted CT value (40-CT) showing the relative CAR and CD46 expression levels in 
the three cancer cell lines. 
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Figure 4.13 – Western blot for CD46 expression in human cancer cell 
lines. 
Anti-CD46 (56-66 kDa) antibody probed membranes to detect relative levels of 
receptor expression in cancer cell lines.  Cells were cultured and lysed before 
determination of protein concentration by BCA assay.  The same concentration of 
protein from each cell line was run on a 12% polyacrylamide gel with a rainbow 
ladder as a marker of protein size at 200 V for approximately 6 hours to achieve 
separation of the CD46 isoforms. 
 
 
4.2.9.1 Effect of FX on binding and transduction by Ad5, Ad35 and 
chimeric Ad5/Ad35 vectors in MDA-MB-435 cells 
The addition of physiological levels of FX significantly enhanced binding by Ad5 
and Ad35/f5 by 49.6- and 16.3-fold, respectively, in MDA-MB-435 cells (Figure 
4.14A).  Transduction by Ad5 and Ad35/f5 was also significantly enhanced in the 
presence of FX by 65.4- and 3.7-fold, respectively (Figure 4.14B).  However, the 
level of transduction produced by Ad35/f5 was very low in this cell line (Figure 
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4.14B).  The low CAR expression on MDA-MB-435 cells (Figure 4.12) results in 
low levels of binding by vectors with the Ad5 fiber in the absence of FX (Figure 
4.14A).  The addition of FX produces a significant enhancement in binding (Figure 
4.14A). 
The addition of FX had no effect on binding by Ad5/f35 and Ad5/p35/f35, possibly 
due the nature of the high affinity interaction between the Ad35 fiber and CD46, 
which could not be further enhanced by possible inclusion of binding to HSPGs in 
the presence of FX (Figure 4.14A).  However, the presence of FX binding by Ad35 
was significantly enhanced by 1.9-fold in the MDA-MB-435 cells (Figure 4.14A), 
indicating differences between vectors with the Ad35 fiber (Ad5/f35 and 
Ad5/p35/f35) and the complete Ad35 vector in binding to this cancer cell line. 
The addition of FX significantly inhibited transduction by Ad5/p35/f35 and Ad35 by 
1.8- and 1.9-fold, respectively, in MDA-MB-435 cells (Figure 4.14B).  Ad5/f35 
produced very low levels of transduction in this cancer cell line (Figure 4.14B).  This 
adds further evidence to the hypothesis that FX limits a post-binding or post-
internalisation mechanism(s) that leads to cellular transduction by vectors containing 
the Ad35 fiber (Ad5/p35/f35 and Ad35).  Although Ad5/p35/f35 and Ad35 both 
demonstrated high levels of binding to the MDA-MB-435 cells, this did not translate 
to similar transduction levels in this cell line. 
4.2.9.2 Effect of FX on binding and transduction by Ad5, Ad35 and 
chimeric Ad5/Ad35 vectors in T-47D cells 
The addition of physiological levels of FX significantly increased binding by Ad5 
and Ad35/f5 in the T-47D cell line by 2.84- and 4.6-fold, respectively (Figure 
4.15A).  However, the difference between binding in the presence and absence of FX 
was less in this cell line compared to MDA-MB-435 cells (Figure 4.15A).  The T-
47D cell line has high CAR expression (Figure 4.12) and, although binding can be 
significantly enhanced in the presence of FX, the difference was not so profound, 
likely due to increased binding by vectors with the Ad5 fiber in the absence of FX. 
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Binding by Ad5/f35 and Ad5/p35/f35 was significantly reduced in the presence of 
FX by 1.8- and 2.6- fold, respectively (Figure 4.15A).  However, the addition of FX 
had no effect on binding by Ad35 (Figure 4.15A).  This suggests that FX binding to 
the Ad5 hexon in the presence of the Ad35 fiber in both Ad5/f35 and Ad5/p35/f35 
inhibits cell binding by these vectors (Figure 4.15A).  Overall, the level of cell 
binding by all vectors in the T-47D cell line was enhanced compared to binding to 
MDA-MB-435 cells, likely due to the increased expression of both CAR and CD46 
receptors on T-47D cells (Figure 4.12). 
In T-47D cells, transduction by Ad5 was significantly enhanced by 1.9-fold in the 
presence of FX (Figure 4.15B).  However, the addition of FX significantly inhibited 
transduction by Ad5/p35/f35 by 2.3-fold (Figure 4.15B), possibly due to the 
significantly reduced binding by this vector in the presence of FX (Figure 4.15A).  
FX had no effect on transduction by Ad35, in comparison to other cell lines where 
the presence of FX significantly inhibits transduction (Figures 4.9, 4.15).  However, 
the level of transduction by Ad35 in T-47D cells was greater than in the other cell 
lines, likely due to the increased CD46 expression in this cell line (levels are similar 
or higher than in CHO-BC1 cells (Figures 4.5, 4.13, taken from the same western 
blot)).  Ad5/f35 and Ad35/f5 both produced very low levels of transduction in T-
47D cells (Figure 4.15B). 
Chapter 4 – Influence of FX on Ad35 
158 
Ad5 Ad5/f35 Ad5/
p35/f35
Ad35 Ad35/f5
0
1.0
2.0
3.0
4.0
5.0
6.0
N
o
rm
al
is
e
d
Lu
ci
fe
ra
se
 
Ex
pr
e
ss
io
n
(R
LU
 
x
10
5 /m
g 
pr
o
te
in
)
N
o
rm
al
is
e
d
Lu
ci
fe
ra
se
 
Ex
pr
e
ss
io
n
(R
LU
 
x
10
5 /m
g 
pr
o
te
in
)
- FX
A
B
+ FX
* *
*
*
* *
*
Ad5 Ad5/f35 Ad5/
p35/f35
Ad35 Ad35/f5
0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
Ve
ct
o
r 
G
e
n
o
m
es
 
x
10
6 /1
00
n
g 
D
N
A
Ve
ct
o
r 
G
e
n
o
m
es
 
x
10
6 /1
00
n
g 
D
N
A
N
o
rm
al
is
e
d
Lu
ci
fe
ra
se
 
Ex
pr
e
ss
io
n
(R
LU
 
x
10
5 /m
g 
pr
o
te
in
)
N
o
rm
al
is
e
d
Lu
ci
fe
ra
se
 
Ex
pr
e
ss
io
n
(R
LU
 
x
10
5 /m
g 
pr
o
te
in
)
Ve
ct
o
r 
G
e
n
o
m
es
 
x
10
6 /1
00
n
g 
D
N
A
Ve
ct
o
r 
G
e
n
o
m
es
 
x
10
6 /1
00
n
g 
D
N
A
 
Figure 4.14 – Binding and transduction by Ad5, Ad35 and chimeric 
Ad5/Ad35 vectors in MDA-MB-435 cells. 
(A) MDA-MB-435 cells were exposed to each Ad vector at a concentration of 1000 
VP/cell in the presence and absence of physiological FX levels for 1 hour at 4ºC.  
Viral and total genomic DNA was extracted and the cell-bound adenovirus 
quantified by qPCR.  Error bars represent SEM (* p < 0.05 versus absence of FX).  
(B) MDA-MB-435 cells were exposed to each Ad vector at a concentration of 1000 
VP/cell in the presence and absence of physiological levels of FX for 3 hours at 
37ºC.  Cells were washed and maintained at 37°C for a further 72 hours before 
quantification of transgene expression by luciferase assay, normalised to total protein 
content determined by BCA assay.  Error bars represent SEM (* p < 0.05 versus 
absence of FX). 
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Figure 4.15 – Binding and transduction by Ad5, Ad35 and chimeric 
Ad5/Ad35 vectors in T-47D cells. 
(A) T-47D cells were exposed to each Ad vector at a concentration of 1000 VP/cell 
in the presence and absence of physiological FX levels for 1 hour at 4ºC.  Viral and 
total genomic DNA was extracted and the cell-bound adenovirus quantified by 
qPCR.  Error bars represent SEM (* p < 0.05 versus absence of FX).  (B) T-47D 
cells were exposed to each Ad vector at a concentration of 1000 VP/cell in the 
presence and absence of physiological levels of FX for 3 hours at 37ºC.  Cells were 
washed and maintained at 37°C for a further 72 hours before quantification of 
transgene expression by luciferase assay, normalised to total protein content 
determined by BCA assay.  Error bars represent SEM (* p < 0.05 versus absence of 
FX). 
Chapter 4 – Influence of FX on Ad35 
160 
4.2.9.3 Effect of FX on binding and transduction by Ad5, Ad35 and 
chimeric Ad5/Ad35 vectors in SKOV-3 cells 
The addition of physiological levels of FX significantly enhanced binding by Ad5, 
Ad5/f35, Ad35 and Ad35/f5 by 19.3-, 3.6-, 6.0- and 19.8-fold, respectively, in 
SKOV-3 cells (Figure 4.16A).  For each of these vectors, the addition of X-bp 
significantly inhibited the enhancement in binding produced in the presence of FX 
(Figure 4.16A).  SKOV-3 cells express a moderate level of CAR in comparison to 
the other two cancer cell lines (Figure 4.12).  Thus, the fold change increase in 
binding by Ad5 and Ad35/f5 in the presence of FX was between that produced in the 
MDA-MB-435 and T-47D cells (Figures 4.14A, 4.15A, 4.16A).  The addition of FX 
significantly enhances binding by Ad5/f35 and Ad35 (Figure 4.16A).  This was 
likely due to SKOV-3 cells also having low CD46 expression (Figure 4.12).  
Therefore, FX binding to the Ad35 hexon and the subsequent use of alternative 
receptors (possibly HSPGs) produced an increase in binding. 
The presence of FX has a very similar effect on transduction as on cell binding by 
each Ad vector in the SKOV-3 cells (Figure 4.16).  Transduction by Ad5, 
Ad5/p35/f35, Ad35 and Ad35/f5 was significantly increased in the presence of FX 
by 51.9-, 2.6-, 1.8- and 10.2-fold, respectively (Figure 4.16B).  The increase in 
transduction by these vectors was also significantly inhibited in the presence of X-bp 
(Figure 4.16B). 
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Figure 4.16 – Binding and transduction by Ad5, Ad35 and chimeric 
Ad5/Ad35 vectors in SKOV-3 cells. 
(A) SKOV-3 cells were exposed to each Ad vector at a concentration of 1000 
VP/cell in the presence and absence of physiological FX levels and 15 µg/ml FX 
binding protein, X-bp, for 1 hour at 4ºC.  Viral and total genomic DNA was 
extracted and the cell-bound adenovirus quantified by qPCR.  Error bars represent 
SEM (* p < 0.05 versus absence of FX, # p < 0.05 versus presence of FX).  (B) 
SKOV-3 cells were exposed to each Ad vector at a concentration of 1000 VP/cell in 
the presence and absence of physiological levels of FX and 15 µg/ml FX binding 
protein, X-bp, for 3 hours at 37ºC.  Cells were washed and maintained at 37°C for a 
further 72 hours before quantification of transgene expression by luciferase assay, 
normalised to total protein content determined by BCA assay.  Error bars represent 
SEM (* p < 0.05 versus absence of FX, # p < 0.05 versus presence of FX). 
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To further investigate the effect of FX on Ad35 transduction in SKOV-3 cells, the 
transduction experiment was repeated in the presence of increasing concentrations of 
NAPc2 (Figure 4.17).  As reported above (Figure 4.16), the addition of physiological 
levels of FX significantly increased transduction by Ad5 (Figure 4.17).  The addition 
of 10, 1 and 0.1 µg/ml NAPc2 significantly reduced transduction by Ad5 by 138.1-, 
105.8- and 1.3-fold, respectively, with the difference decreasing after each ten-fold 
dilution of NAPc2 (Figure 4.17).  0.01 µg/ml NAPc2 did not significantly inhibit 
transduction by Ad5 in the SKOV-3 cells (Figure 4.17).  The addition of FX 
significantly increased transduction by Ad35 by 1.1-fold in SKOV-3 cells (Figure 
4.17).  Addition of 10 µg/ml and 1 µg/ml NAPc2 significantly inhibited transduction 
by Ad35 by 3.2- and 3.7-fold, respectively (Figure 4.17).  However, the level of 
transduction produced by Ad35 was very low in all cases (Figure 4.17).  This 
illustrates that in the SKOV-3 cancer cell line, the Ad35:FX complex also uses the 
putative HSPG pathway for transduction as transduction was significantly inhibited 
in the presence of NAPc2. 
4.2.10 Effect of FX on cell trafficking by Ad5, Ad35 and 
chimeric Ad5/Ad35 vectors in SKOV-3 cells 
To investigate the differences in intracellular trafficking between Ad5, Ad35 and the 
chimeric vectors Ad5/f35 and Ad5/p35/f35, the vectors were labelled with Alexa 
Fluor® 488 (Figures 4.18, 4.19, 4.20, 4.21).  SKOV-3 cells were exposed to vectors 
in the presence and absence of physiological levels of FX for one hour at 4ºC to 
allow binding to occur.  The cells were then either immediately fixed or fixed after 
incubation at 37°C for 15 minutes, one hour or three hours to allow vector 
internalisation.  Images were taken after visualisation on a confocal microscope. 
After one hour at 4°C (time 0), the labelled vectors were visualised bound to the cell 
surface as expected for Ad vectors (Figures 4.18, 4.19, 4.20, 4.21).  Ad5 had reached 
the nucleus after one hour incubation at 37°C in both the presence and absence of 
FX, although the concentration of labelled Ad5 vectors was higher in the presence of 
FX (Figure 4.18).  This correlates well with the enhanced transduction produced in 
vitro by the addition of FX in SKOV-3 cells (Figure 4.16).  After three hours at 
37°C, there was a higher concentration of labelled Ad5 in the perinuclear space (seen 
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by co-localisation with DAPI nuclear stain) and possibly indicating localisation of 
the vector with the microtubule organising centre (Figure 4.18).  However, after the 
same incubation time Ad5/f35, Ad5/p35/f35 and Ad35 remained in the cytosol, 
indicating that vectors with the Ad35 fiber had inefficient intracellular trafficking 
(Figures 4.19, 4.20, 4.21, respectively).  The intracellular trafficking for these 
vectors was similar in the presence and absence of FX (Figures 4.19, 4.20, 4.21).  
The lack of nuclear localisation after three hours (the time period the cells were 
exposed to the vector in the transduction experiments) by Ad35 and Ad35 fiber-
containing vectors is one possible explanation for the lower levels of transduction 
produced by these vectors. 
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Figure 4.17 – Transduction by Ad5 and Ad35 vectors in SKOV-3 cells in 
the presence of NAPc2. 
SKOV-3 cells were exposed to adenoviral vectors at a concentration of 1000 VP/cell 
in the presence and absence of physiological levels of FX and 0.01 – 10 µg/ml 
NAPc2 for 3 hours at 37ºC.  Cells were washed and maintained at 37°C for a further 
72 hours before quantification of transgene expression by luciferase assay, 
normalised to total protein content determined by BCA assay.  Error bars represent 
SEM (* p < 0.05 versus absence of FX, # p < 0.01 versus presence of FX). 
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Figure 4.18 – Cell trafficking in SKOV-3 cells by Ad5. 
Vectors were labelled with Alexa Fluor® 488 and the nuclei of SKOV-3 cells were 
counterstained with DAPI.  SKOV-3 cells were exposed to 10000 VP/cell of labelled 
Ad5.  Binding was allowed to occur for 1 hour at 4°C and cells were fixed either 
immediately or after incubation for 15 minutes, 1 hour or 3 hours at 37°C to allow 
vector internalisation in the absence or presence of FX.  After 1 hour at 37°C, Ad5 
had reached the nucleus of the cell.  After 3 hours at 37°C, there was a higher 
concentration of Ad5 in the perinuclear space (co-localisation with DAPI).  This 
possibly indicates localisation of Ad5 with the microtubule organising centre.  Scale 
bar = 20 µm. 
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Figure 4.19 – Cell trafficking in SKOV-3 cells by Ad5/f35. 
Vectors were labelled with Alexa Fluor® 488 and the nuclei of SKOV-3 cells were 
counterstained with DAPI.  SKOV-3 cells were exposed to 10000 VP/cell of labelled 
Ad5/f35.  Binding was allowed to occur for 1 hour at 4°C and cells were fixed either 
immediately or after incubation for 15 minutes, 1 hour or 3 hours at 37°C to allow 
vector internalisation in the absence or presence of FX.  After 3 hours at 37°C, 
Ad5/f35 remained in the cytosol of the cells, indicating inefficient trafficking by this 
vector.  Scale bar = 20 µm. 
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Figure 4.20 – Cell trafficking in SKOV-3 cells by Ad5/p35/f35. 
Vectors were labelled with Alexa Fluor® 488 and the nuclei of SKOV-3 cells were 
counterstained with DAPI.  SKOV-3 cells were exposed to 10000 VP/cell of labelled 
Ad5/p35/f35.  Binding was allowed to occur for 1 hour at 4°C and cells were fixed 
either immediately or after incubation for 15 minutes, 1 hour or 3 hours at 37°C to 
allow vector internalisation in the absence or presence of FX.  After 3 hours at 37°C, 
Ad5/p35/f35 remained in the cytosol of the cells, indicating inefficient trafficking by 
this vector.  Scale bar = 20 µm. 
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Figure 4.21 – Cell trafficking in SKOV-3 cells by Ad35. 
Vectors were labelled with Alexa Fluor® 488 and the nuclei of SKOV-3 cells were 
counterstained with DAPI.  SKOV-3 cells were exposed to 10000 VP/cell of labelled 
Ad35.  Binding was allowed to occur for 1 hour at 4°C and cells were fixed either 
immediately or after incubation for 15 minutes, 1 hour or 3 hours at 37°C to allow 
vector internalisation in the absence or presence of FX.  After 3 hours at 37°C, Ad35 
remained in the cytosol of the cells, indicating inefficient trafficking by this vector.  
Scale bar = 20 µm. 
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4.2.11 In vivo study with Ad5, Ad35 and chimeric Ad5/Ad35 
vectors 
To assess the influence of FX interactions in vivo, CD46 transgenic mice were used.  
In rodents, CD46 expression is restricted to the testes, whereas CD46 is present on 
every nucleated cell in humans (Inoue et al., 2003).  Therefore, it was more 
appropriate for this study to produce an animal model with a similar CD46 
expression profile as that in humans.  The CD46 transgenic mice were generated by 
back-crossing an established CD46 transgenic line (Oldstone et al., 1999) onto white 
MF1 mice to allow better bioluminescence images to be produced and these were 
used for all in vivo experiments.  White MF1 non-transgenic mice were also used as 
a control. 
Mice were injected intravenously with 5x1010 VP/mouse in the absence or presence 
of a pre-injection of X-bp 30 minutes beforehand.  Luciferase transgene expression 
was visualised by whole-body bioluminescence imaging 48 hours after 
administration (Figure 4.22).  Tissues were harvested 72 hours post-administration 
of the vectors and homogenates produced for quantification of luciferase transgene 
expression by luciferase assay normalised to total protein content.  DNA was also 
extracted from tissue homogenates and vector genomes (VG) were quantified by 
qPCR. 
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Figure 4.22 – Effect of FX on in vivo transduction by Ad5, Ad35 and 
chimeric Ad5/Ad35 vectors in CD46 transgenic and non-transgenic MF1 
mice. 
Luciferase expression visualised by whole-body bioluminescence imaging 48 hours 
after systemic administration of 5x1010 VP/mouse into CD46 transgenic or non-
transgenic MF1 mice in the presence or absence of a pre-injection of FX binding 
protein X-bp, 30 minutes before administration of the vector. 
Chapter 4 – Influence of FX on Ad35 
170 
4.2.12 Liver vector accumulation and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in MF1 mice 
Vector genome accumulation in liver homogenate samples from MF1 mice was 
determined by qPCR (Figure 4.23A).  Ad5 selectively targeted the liver as expected 
and Ad5 vector accumulation was significantly inhibited by 9.3-fold in the presence 
of X-bp (Figure 4.23A).  Liver accumulation by all other vectors was substantially 
lower than that for Ad5 and the presence of X-bp significantly further reduced liver 
vector accumulation by Ad5/p35/f35, Ad35 and Ad35/f5 (Figure 4.23A).  This 
suggests that FX binding to both Ad5 and Ad35 hexons mediates liver accumulation 
and that this can be, at least partially, reduced by inhibition of the virus:FX 
interaction by X-bp.  Additionally, it further reinforces the relative inefficiency of 
the CAR-dependent pathway for liver vector accumulation in vivo as vectors with 
the Ad5 fiber (Ad5 and Ad35/f5) produced low levels of transduction in the absence 
of FX.  However, the presence of X-bp enhanced liver vector accumulation by 
Ad5/f35 by 1.6-fold (Figure 4.23A). 
Luciferase assays were also performed to determine the level of liver transduction by 
each vector and to quantify the data obtained from the bioluminescent imaging 
(Figure 4.22, 4.23B).  Liver transduction by Ad5 was substantially decreased by 
89.1-fold after pre-injection of X-bp (Figure 4.23B).  Levels of transgene expression 
by the other vectors in the liver were not sufficient to be quantified by luciferase 
expression assay (Figure 4.23B). 
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Figure 4.23 – Liver vector accumulation and transduction by Ad5, Ad35 
and chimeric Ad5/Ad35 vectors in MF1 mice. 
(A) Viral and total genomic DNA was extracted from liver samples taken 72 hours 
post-administration of vectors in the presence or absence of X-bp pre-injection 30 
minutes before administration of each vector.  Vector genome accumulation was 
quantified by qPCR.  (B) Luciferase expression was quantified at 72 hours post-
infection and normalised to total protein content determined by BCA assay.  Error 
bars represent SEM (* p < 0.05, versus control). 
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4.2.13 Spleen vector accumulation and transduction by 
Ad5, Ad35 and chimeric Ad5/Ad35 vectors in MF1 
mice 
A similar level of vector genome accumulation was detected in the liver and spleen 
of the MF1 mice (Figures 4.23A, 4.24A).  Increased vector accumulation was 
detected in the spleen for vectors with the Ad5 fiber, Ad5 and Ad35/f5, compared to 
vectors with the Ad35 fiber (Figure 4.24A).  Additionally, vector accumulation by 
Ad5 and Ad35/f5 was not effected by the presence of X-bp (Figure 4.24A).  This 
suggests that although the interaction with neither HSPGs (in the presence of FX) 
nor CAR (in the presence of X-bp) was responsible for accumulation of these vectors 
in the spleen, the increased accumulation by Ad5 and Ad35/f5 was fiber-dependent.  
Pre-administration of X-bp significantly enhanced vector accumulation by 
Ad5/p35/f35 by 4.4-fold but collectively the level of vector accumulation by vectors 
with the Ad35 fiber in the spleen was low (Figure 4.24A). 
Transduction by Ad5 in the spleen was low in comparison to transduction by this 
vector in the liver (Figures 4.23B, 4.24B) and was substantially reduced in the 
presence of X-bp (Figure 4.24B).  The levels of transgene expression by the other 
vectors in the spleen were not sufficient for quantification (Figure 4.24B). 
4.2.14 Heart vector accumulation and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in MF1 mice 
Vector genome accumulation in the heart was low in MF1 mice, less than 2x104 
VG/50 ng DNA (Figure 4.25A).  Accumulation by Ad5 in the heart was significantly 
reduced in the presence of X-bp by 3.6-fold (Figure 4.25A), indicating that heart 
transduction may be FX mediated.  In contrast, pre-administration of X-bp 
significantly enhanced vector accumulation by Ad5/f35 and Ad35/f5 by 6.6- and 1.9-
fold, respectively (Figure 4.25A).  Ad5 produced the highest level of cardiac 
transduction in the MF1 mice (Figure 4.25B).  Transduction of the heart by the other 
vectors was low and X-bp had no effect on transduction of the heart by any of the 
vectors (Figure 4.25B). 
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Figure 4.24 – Spleen vector accumulation and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in MF1 mice. 
(A) Viral and total genomic DNA was extracted from spleen samples taken 72 hours 
post-administration of vectors in the presence or absence of X-bp pre-injection 30 
minutes before administration of each vector.  Vector genome accumulation was 
quantified by qPCR.  (B) Luciferase expression was quantified at 72 hours post-
infection and normalised to total protein content determined by BCA assay.  Error 
bars represent SEM (* p < 0.05, versus control). 
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Figure 4.25 – Heart vector accumulation and transduction by Ad5, Ad35 
and chimeric Ad5/Ad35 vectors in MF1 mice. 
(A) Viral and total genomic DNA was extracted from heart samples taken 72 hours 
post-administration of vectors in the presence or absence of X-bp pre-injection 30 
minutes before administration of each vector.  Vector genome accumulation was 
quantified by qPCR.  (B) Luciferase expression was quantified at 72 hours post-
infection and normalised to total protein content determined by BCA assay.  Error 
bars represent SEM (* p < 0.05, versus control). 
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4.2.15 Lung vector accumulation and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in MF1 mice 
Low levels of vector genome accumulation (less than 3x104 VG/50 ng DNA) were 
present in the lungs of MF1 mice (Figure 4.26A).  Ad5 vector accumulation was 
significantly reduced in the presence of X-bp (Figure 4.26A).  However, in the 
presence of X-bp, vector accumulation by Ad5/f35, Ad5/p35/f35 and Ad35/f5 was 
significantly enhanced by 3.5-, 3.1- and 2.3-fold, respectively (Figure 4.26A).  The 
level of lung transduction in the MF1 mice was also low (Figure 4.26B).  The 
addition of X-bp substantially reduced transduction by Ad5 and had no effect on 
transduction by the other vectors (Figure 4.26B), confirming that lung transduction 
in MF1 mice by Ad5 was dependent on FX. 
4.2.16 Liver vector accumulation and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in CD46 
transgenic mice 
The liver vector accumulation and transduction by each of the vectors in CD46 
transgenic mice demonstrated a very similar pattern to that observed in the MF1 
mice (Figures 4.23, 4.27).  Ad5 selectively targeted to the liver as expected in the 
CD46 transgenic mice, an effect that was significantly inhibited in the presence of 
X-bp by 5.6-fold (Figure 4.27A).  Liver accumulation by all other vectors was 
substantially lower than that for Ad5 and X-bp significantly further reduced the liver 
vector accumulation by Ad5/f35, Ad5/p35/f35, Ad35 and Ad35/f5 by 2.3-, 4.3-, 1.6- 
and 1.4-fold, respectively (Figure 4.27A).  This suggests that FX binding to both 
Ad5 and Ad35 hexon mediates liver accumulation in the CD46 transgenic mice as 
well as in MF1 mice and that accumulation can be, at least partially, reduced by 
inhibition of the virus:FX interaction by X-bp. 
Liver transduction by Ad5 was substantially decreased after pre-injection of X-bp by 
17.1-fold but the levels of transgene expression by the other vectors in the liver were 
not sufficient to be quantified by luciferase expression assay (Figure 4.27B). 
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Figure 4.26 – Lung vector accumulation and transduction by Ad5, Ad35 
and chimeric Ad5/Ad35 vectors in MF1 mice. 
(A) Viral and total genomic DNA was extracted from lung samples taken 72 hours 
post-administration of vectors in the presence or absence of X-bp pre-injection 30 
minutes before administration of each vector.  Vector genome accumulation was 
quantified by qPCR.  (B) Luciferase expression was quantified at 72 hours post-
infection and normalised to total protein content determined by BCA assay.  Error 
bars represent SEM (* p < 0.05, versus control). 
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Figure 4.27 – Liver vector accumulation and transduction by Ad5, Ad35 
and chimeric Ad5/Ad35 vectors in CD46 transgenic mice. 
(A) Viral and total genomic DNA was extracted from liver samples taken 72 hours 
post-administration of vectors in the presence or absence of X-bp pre-injection 30 
minutes before administration of each vector.  Vector genome accumulation was 
quantified by qPCR.  (B) Luciferase expression was quantified at 72 hours post-
infection and normalised to total protein content determined by BCA assay.  Error 
bars represent SEM (* p < 0.05, versus control). 
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4.2.17 Spleen vector accumulation and transduction by 
Ad5, Ad35 and chimeric Ad5/Ad35 vectors in CD46 
transgenic mice 
Vector genomes were detected in the spleen of the CD46 transgenic mice at a similar 
level to vector accumulation in the liver (Figures 4.27A, 4.28A).  The vector 
accumulation in the spleen was higher for vectors with the Ad5 hexon, compared to 
vectors with the Ad35 hexon (Figure 4.28A).  This suggests that vector accumulation 
in the spleen was enhanced by the presence of the Ad5 hexon.  Only accumulation 
by Ad5/f35 was significantly decreased in the presence of X-bp (Figure 4.28A).  
However, the reduced level of Ad5/f35 vector genomes detected in the spleen in the 
presence of X-bp remained greater than Ad35 and Ad35/f5 vector accumulation 
levels (Figure 4.28A).  This indicates that vector accumulation in the spleen was not 
dependent on FX and was more likely due to the innate action of splenic 
macrophages to clear the blood of pathogens. 
However, in the presence of FX, Ad5 efficiently transduced the cells of the spleen, 
an effect completely abolished in the presence of X-bp (Figure 4.28B), thus 
suggesting that FX mediates transduction in the spleen by Ad5.  Transduction by 
Ad5/f35, Ad5/p35/f35, Ad35 and Ad35/f5 in the spleen was very low (Figure 
4.28B).  The degree of transduction by the vectors did not correlate well with vector 
accumulation in the spleen (Figure 4.28), indicating the importance of the spleen to 
remove viruses from the circulation while preventing transduction of this organ. 
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Figure 4.28 – Spleen vector accumulation and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in CD46 transgenic mice. 
(A) Viral and total genomic DNA was extracted from spleen samples taken 72 hours 
post-administration of vectors in the presence or absence of X-bp pre-injection 30 
minutes before administration of each vector.  Vector genome accumulation was 
quantified by qPCR.  (B) Luciferase expression was quantified at 72 hours post-
infection and normalised to total protein content determined by BCA assay.  Error 
bars represent SEM (* p < 0.05, versus control). 
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4.2.18 Heart vector accumulation and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in CD46 
transgenic mice 
Unexpectedly, vector genomes were detected in the heart at similar levels detected in 
the spleen at approximately 1x105 VG/50 ng DNA (Figure 4.29A).  Vector 
accumulation by Ad5 in the heart was modestly, yet significantly inhibited in the 
presence of X-bp (Figure 4.29A).  However, transduction by Ad5 in the heart was 
significantly enhanced by 8.8-fold after the addition of X-bp (Figure 4.29B).  This 
suggests that in CD46 transgenic mice, FX either effects transduction directly by 
blocking a native infective pathway for Ad5 in the heart or indirectly by reducing 
bioavailability of the vector. 
Vector accumulation in the heart was higher for vectors with the Ad35 fiber, 
compared to vectors with the Ad5 fiber (Figure 4.29A).  In the presence of X-bp, 
vector accumulation by Ad5/f35 and Ad5/p35/f35 was significantly reduced by 2.7- 
and 4.9-fold, respectively (Figure 4.29A).  This suggests that the presence of FX 
enhances vector accumulation in the heart by these vectors.  Pre-administration of X-
bp significantly enhanced Ad35 vector accumulation by 2.3-fold in the heart (Figure 
4.29), suggesting that in the absence of the FX interaction, Ad35 can efficiently 
utilise the interaction of the Ad35 fiber with CD46 for vector accumulation in the 
heart.  However, Ad5/f35, Ad5/p35/f35, Ad35 and Ad35/f5 all produced extremely 
low levels of transduction in the heart (Figure 4.29B). 
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Figure 4.29 – Heart vector accumulation and transduction by Ad5, Ad35 
and chimeric Ad5/Ad35 vectors in CD46 transgenic mice. 
(A) Viral and total genomic DNA was extracted from heart samples taken 72 hours 
post-administration of vectors in the presence or absence of X-bp pre-injection 30 
minutes before administration of each vector.  Vector genome accumulation was 
quantified by qPCR.  (B) Luciferase expression was quantified at 72 hours post-
infection and normalised to total protein content determined by BCA assay.  Error 
bars represent SEM (* p < 0.05, versus control). 
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4.2.19 Lung vector accumulation and transduction by Ad5, 
Ad35 and chimeric Ad5/Ad35 vectors in CD46 
transgenic mice 
It has previously been reported that vectors containing the Ad35 fiber possess the 
capacity to transduce the lungs of CD46 transgenic mice (Sakurai et al., 2006a, 
Verhaagh et al., 2006, Stone et al., 2007a).  In vivo bioluminescent imaging 
appeared to confirm this finding (Figure 4.22).  Vectors with an Ad35 fiber, Ad5/f35 
and Ad5/p35/f35, exhibited significantly higher levels of lung vector accumulation 
compared to Ad5 with 5.6x105 and 5.7x105 VG/50 ng of total DNA isolated in the 
absence of X-bp, respectively (Figure 4.30A).  Pre-administration of X-bp 
significantly reduced genome accumulation in the lung by Ad5/f35 and Ad5/p35/f35 
1.9- and 6.6-fold, respectively (Figure 4.30A).  Lung transduction by Ad5/f35 and 
Ad5/p35/f35 exhibited the same pattern as vector genome accumulation in the lung, 
with high levels of transgene expression by these vectors being significantly reduced 
51.9- and 5.9-fold in the presence of X-bp, respectively (Figure 4.30B).  This 
suggests that FX enhances vector accumulation in the lung mediated by these 
vectors, potentially via additive effects of CD46:Ad35 fiber interactions and the high 
affinity Ad5 hexon:FX:HSPG interaction. 
Lung accumulation for Ad35 was lower than Ad5/f35 and Ad5/p35/f35 and 
modestly, but significantly enhanced by X-bp (Figure 4.30A).  Levels of transgene 
expression were modest yet detectable and selective for the lung in the presence of 
X-bp (Figure 4.22, 4.30B).  This suggests that Ad35 was efficient at utilising CD46 
for delivery in vivo and that targeting was most efficient and selective when FX 
binding to the Ad35 hexon was ablated by X-bp. 
In the presence or absence of X-bp, Ad5 showed low level vector accumulation in 
the lung (Figure 4.30A) and no luciferase transgene expression (Figure 4.30B).  
Similarly, Ad35/f5, which also possesses the Ad5 fiber showed negligible vector 
accumulation in the lung (Figure 4.30A).  However, transgene expression by 
Ad35/f5 was substantially enhanced in the presence of X-bp, in the same manner as 
transduction by Ad35 (Figure 4.30B). 
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Figure 4.30 – Lung vector accumulation and transduction by Ad5, Ad35 
and chimeric Ad5/Ad35 vectors in CD46 transgenic mice. 
(A) Viral and total genomic DNA was extracted from lung samples taken 72 hours 
post-administration of vectors in the presence or absence of X-bp pre-injection 30 
minutes before administration of each vector.  Vector genome accumulation was 
quantified by qPCR.  (B) Luciferase expression was quantified at 72 hours post-
infection and normalised to total protein content determined by BCA assay.  Error 
bars represent SEM (* p < 0.05, versus control). 
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4.2.20 Effect of FX on retargeting of Ad5, Ad35 and 
chimeric Ad5/Ad35 vectors in CD46 transgenic mice 
The lung:liver ratio of vector genome accumulation for each of the vectors in the 
CD46 transgenic mice was calculated to determine the degree of retargeting which 
occurred in the presence of X-bp (Figure 4.31).  The lung:liver ratio produced by 
Ad5/f35 was the same in the presence and absence of X-bp (Figure 4.31), indicating 
that the addition of X-bp had no effect on retargeting Ad5/f35.  Although the levels 
of vector accumulation in both the liver and lung were significantly reduced in the 
presence of X-bp (Figures 4.27, 4.30), the ratio of vector genomes present in these 
organs remains the same (Figure 4.31).  In contrast, Ad5/p35/f35 had a reduced 
lung:liver ratio in the presence of X-bp (Figure 4.31).  This suggests some level of 
retargeting away from the lung through the interaction of the Ad5 hexon with FX.  
Importantly, Ad35 had an increased lung:liver ratio in the presence of X-bp (Figure 
4.31), indicating retargeting of this vector to the lung after the addition of X-bp.  The 
vectors possessing an Ad5 fiber (Ad5 and Ad35/f5) both had a very low lung:liver 
ratio, further emphasising the degree of liver targeting possessed by these vectors 
(Figure 4.31). 
Chapter 4 – Influence of FX on Ad35 
185 
Ad5 Ad5/f35 Ad5/
p35/f35
Ad35 Ad35/f5
0
10
20
30
40
Lu
n
g:
Li
v
e
r
R
a
tio
Lu
n
g:
Li
v
e
r
R
a
tio
Control
+ X-bp
Lu
n
g:
Li
v
e
r
R
a
tio
Lu
n
g:
Li
v
e
r
R
a
tio
 
Figure 4.31 – Lung:liver ratio of vector genome accumulation in CD46 
transgenic mice. 
The lung:liver ratio of vector genome accumulation/50 ng DNA was calculated to 
determine the degree of retargeting by the vectors in CD46 transgenic mice after the 
addition of X-bp. 
 
 
4.2.21 Immunohistochemical analysis of transduction by 
Ad5, Ad5/f35 and Ad35 in CD46 transgenic mice 
To further investigate the selectivity of lung transduction by vectors possessing the 
Ad35 fiber in CD46 transgenic mice, the in vivo experiments were repeated with 
Ad5, Ad5/f35 and Ad35 vectors which expressed an enhanced green fluorescent 
protein (eGFP) transgene.  Mice were again injected intravenously with 5x1010 
VP/mouse in the absence or presence of a pre-injection of X-bp 30 minutes 
beforehand.  Tissues were harvested 72 hours post-administration of the vectors.  
Sections were analysed for native eGFP expression and by immunohistochemistry 
(IHC) using an anti-GFP antibody and images were taken by confocal microscopy. 
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Figure 4.32 – Immunohistochemistical analysis of liver transduction by 
Ad5, Ad5/f35 and Ad35 in CD46 transgenic mice. 
Anti-GFP antibody localisation and native eGFP expression on sections of liver 
tissue from CD46 transgenic mice injected with eGFP expressing Ad5, Ad5/f35 and 
Ad35 vectors.  Scale bar = 20 µm. 
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IHC on liver sections taken from CD46 transgenic mice administered with Ad5, 
Ad5/f35 and Ad35 demonstrated very similar results to the relative levels of vector 
genome accumulation and transduction by the vectors, as seen by qPCR and 
luciferase assay, respectively (Figures 4.27, 4.32).  Liver sections from animals 
injected with Ad5.eGFP showed high levels of native eGFP expression and anti-GFP 
staining (detected with an Alexa Fluor® 488 (green) secondary antibody) with 
individual hepatocytes depicted due to very high levels of transgene expression 
(Figure 4.32).  The staining was reduced in the presence of X-bp (Figure 4.32).  Very 
few hepatocytes showed eGFP transgene expression in animals administered with 
Ad5/f35 and Ad35 (Figure 4.32), similar to the low levels of vector genome 
accumulation and luciferase expression by these vectors (Figure 4.27). 
Due to the very high levels of lung accumulation and transduction by the Ad5/f35 
and Ad35 vectors, IHC was also performed on lung sections to investigate which 
cells were transduced by the vectors.  By examination of a whole lung taken from a 
CD46 transgenic mouse administered with Ad35.eGFP, it was observed that the 
majority of eGFP expression was in the outer surface of the lung (Figure 4.33A).  
When the lung was cross-sectioned, eGFP expression was around the periphery of 
the lung with no expression seen in the large airways (Figure 4.33B).  IHC on lung 
sections produced a level of green staining (due to a combination of native eGFP 
expression and the anti-GFP antibody) relative to the levels of lung vector 
accumulation and transduction for each of the vectors (Figures 4.30, 4.34).  Ad5/f35 
transduction was significantly inhibited in the presence of X-bp (Figure 4.34), as 
previously determined by vector genome accumulation and transgene expression 
quantification (Figure 4.30). 
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Figure 4.33 – Fluorescent imaging of lung transduction by Ad35 in 
CD46 transgenic mice. 
(A) eGFP expression on outer surface of the lung and (B) cross-section of lung taken 
from a CD46 transgenic mouse injected with an Ad35 vector containing the eGFP 
transgene. 
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Figure 4.34 – Immunohistochemistical analysis of lung transduction by 
Ad5, Ad5/f35 and Ad35 in CD46 transgenic mice. 
Anti-GFP antibody localisation and native eGFP expression on sections of lung 
tissue from CD46 transgenic mice injected with Ad5, Ad5/f35 and Ad35 vectors 
containing the eGFP transgene.  Scale bar = 20 µm. 
Chapter 4 – Influence of FX on Ad35 
190 
4.3 Discussion 
This study has utilised Ad35 and chimeric Ad5/Ad35 vectors to determine the 
importance of the interaction of these vectors with FX.  FX was shown to bind 
directly to the Ad35 hexon, in a similar manner to Ad5, by cryoEM and SPR.  In 
vitro, the presence of FX does not further enhance binding to cells by vectors 
containing the Ad35 fiber.  However, FX can enhance binding by vectors with an 
Ad5 fiber, independent of capsid.  Ad35 internalisation in CHO-CD46 cells was 
enhanced by FX but FX significantly inhibited transduction by all vectors with the 
Ad35 fiber.  In cells which did not express CD46, binding, internalisation and 
transduction by vectors containing the Ad35 fiber demonstrated a similar profile to 
vectors with the Ad5 fiber.  The presence of FX significantly enhanced binding, 
internalisation and transduction by all vectors in CHO-WTR cells. 
In control MF1 mice, vectors with either the Ad35 fiber or hexon proteins 
demonstrated significantly lower levels of liver and spleen vector accumulation and 
transduction compared to Ad5.  In the presence of X-bp, vector accumulation in the 
heart and lungs by the chimeric vectors was significantly enhanced in MF1 mice.  In 
CD46 transgenic mice, liver vector accumulation and transduction by Ad5/f35, 
Ad5/p35/f35, Ad35 and Ad35/f5 was significantly reduced compared to Ad5 and the 
presence of X-bp further significantly reduced accumulation in the liver.  
Accumulation of vector genomes in the spleen was detected at similar levels to 
accumulation in the liver of the CD46 transgenic mice but the levels of splenic 
transduction were very low for all vectors except Ad5.  Vector genome accumulation 
in the heart and lungs of the CD46 transgenic mice exhibited a very similar profile 
but transduction in the lung was significantly increased.  In the lung, vectors with the 
Ad35 fiber exhibited significantly higher levels of lung vector accumulation than 
Ad5.  The presence of X-bp significantly reduced vector accumulation in the lung by 
Ad5/f35 and Ad5/p35/f35 but enhanced Ad35 lung accumulation.  Calculation of the 
lung:liver ratio showed that in the presence of X-bp, Ad5/p35/f35 was retargeted 
away from the lung, whereas Ad35 was targeted to the lung. 
Contrary to previous reports (Kalyuzhniy et al., 2008) but consistent with our 
previous findings (Waddington et al., 2008), this study has demonstrated that FX 
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binds directly to Ad35.  Kalyuzhniy et al. used SPR to determine the affinity of the 
FX interaction with several human Ad serotypes and reported that Ad35 does not 
bind to FX (Kalyuzhniy et al., 2008).  However, SPR data presented here 
demonstrates that the Ad35:FX interaction fitted to a heterogenous ligand model 
with equilibrium dissociation constants of 5.4x10-8 M and 3.5x10-9 M, confirming 
that Ad35 binds to FX with approximately ten-fold lower affinity than the Ad5:FX 
interaction.  The Ad35 hexon was also shown to bind FX in the context of the 
pseudotype vector Ad35/f5, as has been previously shown for Ad5 pseudotype 
vectors (Parker et al., 2007).  By cryoEM, it was observed as Ad5, binding was via 
the hexon protein with FX density in the centre of the trimeric hexon proteins.  It 
remains to be determined which Ad35 HVRs and specific loops mediate this 
interaction in a similar manner to the reported interaction of FX with Ad5 HVRs 5 
and 7 (Waddington et al., 2008, Alba et al., 2009) as the crystal structure of Ad35 
has not yet been resolved. 
Although FX was shown to bind to the Ad35 hexon, FX had no effect on binding by 
Ad35 to CHO-CD46 cells in vitro.  The presence of FX had no effect on any of the 
vectors containing the Ad35 fiber (Ad5/f35, Ad5/p35/f35 and Ad35) due to the high 
affinity interaction between the Ad35 fiber and its primary cellular receptor, the 
membrane glycoprotein CD46 (Gaggar et al., 2003, Tuve et al., 2006).  However, in 
the CHO-WTR cell line, FX significantly increased binding by all vectors.  In the 
absence of CD46 expression in this cell line, Ad5/f35, Ad5/p35/f35 and Ad35 use a 
low affinity interaction with HSPGs for binding (Tuve et al., 2008).  Ad35 has been 
shown to interact with the sulphated regions of HSPGs but not via the fiber knob 
domain (Tuve et al., 2008).  In the presence of FX, binding was enhanced by all 
vectors possibly due to incorporation of the high affinity HSPG pathway used by 
vectors with the Ad5 hexon in the presence of FX (Waddington et al., 2008).  FX 
can significantly enhance binding by vectors with an Ad5 fiber, independent of 
capsid type, indicating the importance of both hexon and fiber in the cell binding 
process.  This has important implications in the design of future gene therapy 
vectors, as pseudotyping may not be sufficient to increase binding to a specific cell 
type due to interactions with blood coagulation factors following intravenous 
administration. 
Chapter 4 – Influence of FX on Ad35 
192 
Cell internalisation by all vectors was significantly enhanced in the presence of FX 
in the CHO-WTR cell line.  In the absence of FX, vectors have been shown to bind 
to HSPGs with low affinity (Tuve et al., 2008) and the addition of FX results in 
utilisation of a high affinity interaction with HSPGs (Waddington et al., 2008).  
Therefore, these data suggest that in the absence of the primary receptors for the Ad5 
and Ad35 fibers, vectors bind and internalise through a low affinity HSPG pathway 
and the addition of FX causes an increase in binding and internalisation through a 
high affinity HSPG pathway.  Cell internalisation by Ad5, Ad35 and Ad35/f5 was 
significantly enhanced by the presence of FX in CHO-CD46 cells.  This indicates 
that FX has the potential to increase cell entry by Ad35 due to the interaction with 
HSPGs, in addition to binding to CD46, in a similar manner to vectors with the Ad5 
fiber. 
In CHO-CD46 cells, the presence of FX significantly inhibited transduction by 
vectors possessing the Ad35 fiber; an effect which was reversed by the addition of 
X-bp.  However, the addition of FX enhanced transduction by all vectors in CHO-
WTR cells.  This suggests that the presence of FX, and the resulting recruitment of 
HSPGs for internalisation, possibly leads to inhibition of a post-internalisation 
intracellular trafficking pathway for vectors with the Ad35 fiber compared to 
transduction through the CD46-dependent pathway.  In the absence of the CD46-
dependent pathway in CHO-WTR cells, the conversion from the HSPG pathway 
used in the absence of FX to the high affinity HSPG pathway used in the presence of 
FX, results in significantly enhanced transduction. 
The interaction between Ad35 and the chimeric Ad5/Ad35 vectors and FX was also 
investigated in three human cancer cell lines as CD46 expression is up-regulated in 
many cancers (Kinugasa et al., 1999, Murray et al., 2000, Ni et al., 2006), making 
sub-species B Ads attractive candidates for cancer gene therapy applications.  The 
level of binding by vectors with the Ad35 fiber was high but resulted in much lower 
transduction levels in the cancer cell lines.  There was variability in the influence of 
FX on binding and transduction by Ad5/f35, Ad5/p35/f35 and Ad35 across the three 
cancer cell lines and the relative expression level of CD46 appeared to have no 
influence on the pattern of binding and transduction. 
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Binding by Ad5/f35 was high in the three cancer cell lines and varying effects were 
produced in the presence of FX; FX enhanced binding in the SKOV-3 cells, 
inhibited binding in T-47D cells and had no effect on binding by Ad5/f35 in MDA-
MD-435 cells.  In the three cancer cell lines, the high level of binding by Ad5/f35 
did not translate to high levels of transduction.  This suggests that Ad5/f35 vector 
inefficiently traffics to the nucleus of the cell, resulting in low transgene expression.  
However, Ad5/f35 has been previously shown to efficiently transduce MDA-MB-
435 cells but at a substantially increased concentration of vector was used 
(Shayakhmetov et al., 2002).  This inefficiency in transduction was not seen for 
Ad5/p35/f35, suggesting that transduction was enhanced by the presence of the 
Ad35 penton.  In contrast to Ad5/f35, Ad35 demonstrated moderate levels of binding 
to MDA-MB-435 and T-47D cells and high binding to SKOV-3 cells and this 
correlated into efficient transduction of the three cancer cell lines.  Ad35 was also 
influenced differentially by FX in MDA-MB-435 and SKOV-3 cells but the presence 
of FX had no effect on either binding or transduction in T-47D cells, possibly as 
binding and transduction could not be further enhanced in the T-47D cells by 
incorporation of the high affinity HSPG pathway due to the high expression of 
CD46.  Overall, the influence of FX on binding and transduction by Ad35 and the 
chimeric Ad5/Ad35 vectors varies greatly between the MDA-MB-435, SKOV-3 and 
T-47D cell lines.  This is likely due to the relative CAR and CD46 expression levels, 
which have been previously shown to correlate strongly with levels of transduction 
in primary cancer cells (Ni et al., 2006, Suominen et al., 2006, Brouwer et al., 2007). 
Ad5 and Ad35/f5 reproducibly demonstrated enhanced binding and transduction in 
the presence of FX in all three cancer cell lines.  Additionally, the degree of 
enhancement which occurred in the presence of FX correlated well with the level of 
CAR expression in the cancer cells; the presence of FX produced a substantial 
enhancement in binding and transduction in cells with low CAR expression due to 
recruitment of HSPGs, compared to cells with high CAR expression which resulted 
in a lesser enhancement in binding and transduction in the presence of FX.  The level 
of transduction produced by Ad35/f5 was very low in all cases, indicating that its 
gene transfer ability was diminished compared to either parent vector Ad5 or Ad35. 
Chapter 4 – Influence of FX on Ad35 
194 
The findings in vitro indicate the complexity of the FX interaction as the presence of 
FX can change the way in which binding, internalisation and intracellular trafficking 
by the vectors possessing the Ad35 fiber occurs.  In the absence of FX, vectors with 
an Ad35 fiber bind to CD46, which allows internalisation of the vectors.  The 
intracellular trafficking pathways of the sub-species B Ads have been previously 
studied (Miyazawa et al., 1999, Shayakhmetov et al., 2003).  Despite high levels of 
cellular binding by vectors with fibers from sub-species B Ads, these vectors take 
significantly longer than Ad5 to reach the nucleus of the cell in SKOV-3 cells 
despite no obvious difference in internalisation kinetics (Miyazawa et al., 1999).  
Sub-species B Ads remain in late endosomes or lysosomes for long periods after 
infection and use these intracellular organelles for localisation with the nucleus 
(Shayakhmetov et al., 2003).  However, this continued presence of vectors with the 
Ad35 fiber in late endosomes and lysosomes can lead to recycling of the vectors to 
the cell surface, resulting in reduced transduction by these vectors (Shayakhmetov et 
al., 2003).  This is in contrast to Ad5 which rapidly escapes from endosomes into the 
cytosol three to 15 minutes after internalisation, allowing efficient transduction 
(Greber et al., 1993, Greber et al., 1996, Leopold et al., 1998, Miyazawa et al., 
1999).  The presence of FX allows the utilisation of an alternative pathway for 
transduction by vectors with the Ad35 hexon.  In the absence of FX, Ad35 uses two 
pathways for transduction, the high affinity CD46 pathway and low affinity HSPG 
pathway (Tuve et al., 2008).  In the presence of FX, there are three pathways that can 
be used; the CD46-dependent pathway and high and low affinity HSPG pathways 
(Tuve et al., 2008, Waddington et al., 2008).  Therefore, as the addition of FX 
causes an inhibition of transduction by Ad35 hexon-containing vectors, this could 
possibly be due to a further hindrance in intracellular trafficking after internalisation 
through the high affinity HSPG pathway.  Taken together this suggests that the 
absolute levels of CAR, CD46 and HSPGs on the surface of target cells define the 
importance of FX in modulating cell binding and transduction mediated by Ad5, 
Ad35 and the chimeric Ad5/Ad35 vectors.  Therefore, heparinase I pre-treatment 
before administration of CD46 binding ablated vectors, in the presence and absence 
of FX, could be used to further dissect the role of each receptor and subsequent 
intracellular trafficking pathway for transduction. 
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Vectors with the Ad35 hexon demonstrated lower levels of liver vector genome 
accumulation in vivo, in both MF1 and CD46 transgenic mice, compared to vectors 
possessing the Ad5 hexon.  FX binding to the hexon of Ad5 results in increased liver 
vector accumulation, compared to in the presence of X-bp (Waddington et al., 2008).  
Therefore, liver accumulation by Ad35 hexon-containing vectors may be reduced 
due to the lower affinity interaction between the Ad35 hexon protein and FX.  Liver 
vector accumulation was significantly reduced by all vectors, indicating that FX 
binding was an important feature mediating liver uptake of Ad5- and Ad35-based 
vectors.  However, there was also a significant influence of the Ad35 fiber on liver 
vector accumulation as Ad5/f35 and Ad5/p35/f35 both have the Ad5 hexon but 
demonstrated significantly reduced liver accumulation than Ad5.  This reduced liver 
tropism by Ad5/f35 has been previously reported in non-CD46 transgenic mice 
(Shayakhmetov et al., 2002, Bernt et al., 2003, Sakurai et al., 2003b) and rats 
(Shinozaki et al., 2006).  As X-bp could further reduce liver accumulation by 
Ad5/f35 and Ad5/p35/f35, this suggests that the interaction with FX targets these 
vectors to the liver and removal of this interaction could allow retargeting of these 
vectors to other organs. 
Low level vector genome accumulation and transduction by Ad35 was detected in 
the liver of CD46 transgenic mice in this study, in comparison to a previous study 
which reported no detectable levels of Ad35 in the liver (Verhaagh et al., 2006).  
Additionally, vector accumulation and especially transduction in the spleen of CD46 
transgenic mice by Ad35 was very low compared to Ad5.  This is in contrast to 
another study performed in CD46 transgenic mice where Ad5 and Ad35 expressed 
similar levels of liver transduction and Ad35 produced significantly higher levels of 
transduction in the spleen (Stone et al., 2007a).  Vector accumulation and 
transduction in the spleen by Ad5/f35, Ad5/p35/f35 and Ad35 was increased in the 
CD46 transgenic mice, compared to the MF1 mice.  This suggests that accumulation 
and transduction in the spleen was, at least in part, mediated by the Ad35 fiber:CD46 
interaction.  Additionally, vectors with the Ad5 hexon showed increased vector 
accumulation and transduction of the spleen in the CD46 transgenic mice, in 
comparison to Ad35 hexon-containing vectors.  This indicates a possible 
involvement of the Ad5 hexon in splenic targeting. 
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Previously, Ad5/f35 showed no retargeting away from the liver in non-CD46 
transgenic mice (Shayakhmetov et al., 2002).  However, in this study pre-
administration of X-bp clearly retargeted Ad5/f35 and Ad35/f5 to the heart and 
Ad5/f35, Ad5/p35/f35 and Ad35/f5 to the lungs in MF1 mice as vector accumulation 
was significantly reduced in the liver and increased in the heart and lungs.  This 
suggests that this retargeting to specific organs by each of the vectors was not fiber-
dependent as the receptor for the Ad35 fiber, CD46, was not present in these organs 
of MF1 mice. 
It has previously been reported that vectors containing the Ad35 fiber transduce the 
lungs of CD46 transgenic mice (Sakurai et al., 2006a, Verhaagh et al., 2006, Stone 
et al., 2007a).  This study showed that levels of transduction in the lung by Ad35 
were significantly increased compared to Ad5, in agreement with Stone et al. (Stone 
et al., 2007a).  Interestingly, the data in this study is similar to a previous study of 
sub-species B Ad vectors in non-transgenic mice, where transduction in the spleen, 
heart and lung by Ad35 was lower than transduction by Ad5/f35 (Sakurai et al., 
2003b).  Therefore, the differences in the transduction efficiency by Ad5/f35 and 
Ad35 were due to the interaction of the Ad5 and Ad35 hexons, respectively, with FX 
as a similar pattern of transduction was seen in a study which did not involve the 
Ad35 fiber:CD46 interaction.  This suggests that FX binding to the Ad35 hexon 
inhibited an intracellular pathway leading to transduction in vivo, as well as 
previously seen in vitro.  The high affinity of the Ad35 fiber for CD46 partially 
overcomes the Ad5 hexon:FX interaction as the level of lung transduction in CD46 
transgenic mice administered with Ad5/f35 and Ad5/p35/f35 was significantly 
higher compared to Ad5.  However, both vector genome accumulation and 
transduction by Ad5/f35 and Ad5/p35/f35 was significantly inhibited in the presence 
of X-bp.  Determination of the lung:liver ratio of vector accumulation produced by 
Ad5/f35 and Ad5/p35/f35 found that pre-administration of X-bp had no effect on 
retargeting Ad5/f35 as the lung:liver ratio remained constant.  Conversely, the 
lung:liver ratio for Ad5/p35/f35 was significantly reduced in the presence of X-bp 
indicating retargeting away from the lung.  This suggests that a certain degree of 
lung targeting by Ad5/p35/f35 was determined by the interaction of this vector with 
FX.  Therefore, Ad5/f35 and Ad5/p35/f35 demonstrated the highest levels of 
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selective lung targeting in the presence of FX, causing them to be good candidates 
for development into gene therapy vectors. 
Lung vector genome accumulation and transduction by Ad35 was lower than that by 
Ad5/f35 and Ad5/p35/f35.  However, in contrast to the vectors containing the Ad5 
hexon, Ad35 produced increased lung accumulation and transduction in the presence 
of X-bp.  Additionally, in vivo Ad35 had an increased lung:liver ratio in the presence 
of X-bp, indicating enhanced accumulation of this vector in the lung after the 
removal of the FX interaction.  Therefore, due to its selective lung targeting ability 
and low seroprevalence development of a vector based on Ad35, which had been 
modified to ablate the interaction with FX, would be a highly useful tool to 
selectively target CD46 and tumours in vivo by intravascular administration. 
The addition of X-bp had very similar effects on vector genome accumulation by the 
vectors in the heart of CD46 transgenic mice as in the lung, suggesting that FX was 
involved in retargeting away from the liver and not targeting of the vectors to 
another specific organ.  However, no transduction by Ad5/f35, Ad5/p35/f35 and 
Ad35 was detected in the heart.  Pre-administration of X-bp significantly decreased 
vector accumulation in the heart of both MF1 and CD46 transgenic mice by Ad5.  
Surprisingly, the presence of X-bp substantially enhanced cardiac transduction in the 
absence of FX either by a direct effect on transduction by blockade of a native 
infective pathway for Ad5 in the heart or indirectly by reducing bioavailability of the 
vector. 
The use of a variety of in vitro techniques and in vivo administration of Ad35 and 
chimeric Ad35-based vectors has investigated the interaction between these vectors 
and the blood coagulation FX.  This study has increased understanding of the 
requirements needed for the generation of a successfully targeted Ad35 vector. 
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This thesis has focussed on identifying novel techniques which may impact on 
treatment of disease via targeting.  A novel in vivo targeting strategy was developed 
to enhance delivery of the anti-oxidant peptide gp91ds (Rey et al., 2001) to sites of 
oxidative stress in the vasculature, to reduce SO production and subsequent 
endothelial dysfunction.  By targeting defined cells in vivo, this anti-oxidant has 
increased potential efficacy compared to alternative anti-oxidant therapies.  
Additionally, administration of a variety of Ad35-based vectors has led to increased 
understanding of the requirements needed for the generation of a successfully 
targeted Ad35 vector, which has relevance primarily to the treatment of cancer as the 
primary cellular receptor for the Ad35 fiber is up-regulated in many cancers 
(Kinugasa et al., 1999, Murray et al., 2000, Ni et al., 2006). 
Previously, the gp91ds anti-oxidant peptide has been used in a non-targeted 
approach by linkage to the HIV-tat peptide to allow internalisation of the anti-
oxidant peptide into every cell (Rey et al., 2001, Jacobson et al., 2003, Zhou et al., 
2006).  Co-infusion of angiotensin II and gp91ds-tat significantly attenuated 
angiotensin II-induced hypertension in mice (Rey et al., 2001).  However, in vivo 
administration of gp91ds-tat into salt-induced hypertensive rats did not significantly 
reduced systolic BP (Zhou et al., 2006).  The gp91ds-tat did reduce the production of 
aortic SO and inhibited the development of endothelial dysfunction in the aorta of 
these inducibly-hypertensive animals but this was not sufficient to produce a 
reduction in systolic BP (Zhou et al., 2006).  Additionally, gp91ds-tat did not reduce 
systolic BP in the normotensive Sprague-Dawley rat (Jacobson et al., 2003), 
suggesting that the SO production in these animals was not excessive.  In this study, 
and similar to the previous studies in rats (Jacobson et al., 2003, Zhou et al., 2006), 
administration of the non-targeted HIV-tat-gp91ds in the SHRSP had no effect on 
systolic BP.  However, in contrast to the study performed in Dahl salt-sensitive rats 
(Zhou et al., 2006), HIV-tat-gp91ds did not have a significant effect on SO 
production in the aorta as determined by the reduced aortic response to the 
NAD(P)H oxidase inhibitor apocynin.  The HIV-tat-gp91ds peptide did produce a 
significant reduction in SO production in whole blood, indicating that the HIV-tat 
peptide was effective at delivering the anti-oxidant peptide.  However, the lack of 
targeting capacity by this peptide meant that it was not successful in conveying the 
Chapter 5 – General Discussion 
200 
anti-oxidant peptide to sites of oxidative stress, where it could produce significant 
effects on BP and endothelial function. 
Evaluation of a vascular targeting anti-oxidant therapy in the SHRSP, a model of 
human essential hypertension, has potential clinical implications.  As a significant 
reduction in systolic BP was achieved in animals treated with CRPPR-gp91ds, this 
indicates that selective inhibition of vascular NAD(P)H oxidase has potential as a 
future target for drug development.  Additionally, SHRSP administered with 
CRPPR-gp91ds demonstrated significantly improved NO bioavailability in 
functional studies by large vessel myography, indicating reduced endothelial 
dysfunction.  Endothelial dysfunction is an important risk factor for cardiovascular 
adverse events (Cai and Harrison, 2000, Schachinger et al., 2000, Suwaidi et al., 
2000, Halcox et al., 2002).  Indeed, the commonly prescribed family of drugs, the 
statins, partly exert their beneficial effects by inactivation of endothelial NAD(P)H 
oxidase and, thereby, maintenance of endothelial function (Wassmann et al., 2002, 
Liao and Laufs, 2005).  Therefore, selectively targeting vascular NAD(P)H oxidase 
has clinical relevance. 
Importantly, patients with auto-immune diseases and organ transplant recipients bear 
an increased risk of coronary vascular dysfunction (Frostegard, 2002).  Calcineurin 
inhibitors CsA and FK506 are immunosuppressive drugs which have been shown to 
increase endothelial SO production in HUVECs, an effect which could be selectively 
inhibited by gp91ds-tat (Krotz et al., 2007).  This suggests that these drugs are 
activating endothelial NAD(P)H oxidase, increasing production of SO, which could 
be contributing to endothelial dysfunction.  Therefore, immunosuppressive 
medications to enable treatment of one condition could be leading to the 
development of another serious condition.  However, the immunosuppressive drugs 
rapamycin and mycophenolate acid did not alter and attenuated endothelial SO 
release, respectively (Krotz et al., 2007).  Therefore, not only does this suggest the 
inhibition of vascular NAD(P)H oxidase by gp91ds is a viable treatment option but 
careful consideration is needed before the use of drugs which effect oxidative stress 
and endothelial function. 
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Administration of the vascular targeting anti-oxidant peptide to patients is not a 
viable treatment option as it would require vast quantities of peptides most likely 
delivered daily by subcutaneous injection, which would result in inflammation at the 
injection and possibly systemic immune reactions.  Therefore, an alternative method 
of delivering the anti-oxidant peptide to the vasculature would be required.  One 
possibility is intravenous administration of a vascular targeting Ad vector, which is 
capable of delivering the anti-oxidant peptide.  Previous studies have shown that 
insertion of a targeting peptide sequence into the HI loop in the fiber protein of the 
Ad5 capsid allows effective targeting by several Ad vectors to either ECs (Nicklin et 
al., 2001, Nicklin et al., 2004) or VSMCs (Work et al., 2004) in vitro.  However, 
after systemic administration, these vectors retained profound liver tropism (Nicklin 
et al., 2001), characteristic of Ad5 (Huard et al., 1995, Connelly, 1999, Parker et al., 
2006, Waddington et al., 2007, Kalyuzhniy et al., 2008, Waddington et al., 2008), 
due to the interaction with FX (Parker et al., 2006, Waddington et al., 2008).  By 
high resolution cryo-EM, it was determined that HVR 5 and 7 were crucial for FX 
binding (Kalyuzhniy et al., 2008, Waddington et al., 2008).  This enabled the 
development of vectors based on Ad5 with an ablated interaction with FX (Alba et 
al., 2009).  Therefore, there is now the potential to develop selectively vascular-
targeting vectors by insertion of the CRPPR peptide into the HI loop of a FX-binding 
ablated vector.  Ablation of the FX interaction should prevent the liver tropism seen 
in previous studies investigating targeting in vivo. 
Vectors containing the Ad35 fiber have become popular for gene therapy 
applications for use in cell types (for example, vascular cells and cancer cell lines) 
which are relatively refractory to infection by Ad5.  This thesis has shown that 
Ad5/f35, Ad5/p35/f35 and Ad35 selectively transduce the lungs in CD46 transgenic 
mice and the degree of lung targeting was dependent on the interaction with FX.  
Gene therapy vectors containing the Ad35 fiber may afford many benefits compared 
to Ad5.  There is a possibility that a reduced dose of gene therapy vectors based on 
Ad35 would be required for treatment, thus impacting on dose limiting toxicities.  
Vectors possessing the Ad35 shaft, but not the fiber knob, produced significantly 
impaired Kupffer cell depletion compared to Ad5 (Smith et al., 2008).  This was 
independent of vector clearance rate from the blood as Ad5 and pseudotype vectors 
have approximately similar clearance kinetics (Alemany et al., 2000, Kanerva et al., 
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2002, Koizumi et al., 2003, Sakurai et al., 2003b).  Studies have also shown 
significant differences in vector accumulation in Kupffer cells by Ad5 and Ad35 
fiber-containing vectors, although the reason for such differences is presently 
unclear.  Kupffer cell accumulation for Ad5 and vectors containing the Ad35 fiber 
were shown to be similar in two studies (Shayakhmetov et al., 2005b, Smith et al., 
2008).  However, other studies have shown reduced accumulation in Kupffer cells 
by Ad5/f35 (Bernt et al., 2003, Shayakhmetov et al., 2004).  As Ad5/f35 and Ad35 
have been shown to interact with platelets (Stone et al., 2007b), inhibition of Kupffer 
cell death by Ad35 fiber-containing vectors could result in reduced adverse effects of 
Ad35-based gene therapy, in comparison to Ad5, as Kupffer cells are required to 
clear aggregated platelets produced by interaction with blood-borne vectors.  Also 
reduced accumulation of these vectors in Kupffer cells would increase the 
bioavailability of the administered dose, enabling a lower dose of Ad35 fiber-
containing vectors with correspondingly reduced toxicity issues. 
The differences in Kupffer cell accumulation after administration of Ad5 or Ad35 
fiber-containing vectors was shown to be due to deficiencies in intracellular 
trafficking by vectors with the Ad35 fiber shaft (Smith et al., 2008).  Ad5 and 
vectors with the Ad35 fiber have been shown to use different intracellular trafficking 
pathways (Miyazawa et al., 1999, Shayakhmetov et al., 2003).  This was also seen in 
SKOV-3 cells in this study where Ad5/f35, Ad5/p35/f35 and Ad35 took 
substantially longer than Ad5 to reach the nucleus of the cell.  Studies into the 
interactions with vectors and Kupffer cells were performed in non-CD46 transgenic 
mice (Bernt et al., 2003, Shayakhmetov et al., 2004, Shayakhmetov et al., 2005b, 
Smith et al., 2008).  This suggests that the Kupffer cell interaction with Ad35 fiber-
containing vectors was not CD46-dependent.  It is possible that the inhibition of 
Kupffer cell depletion, seen with vectors possessing the Ad35 fiber shaft, is FX-
dependent as FX significantly inhibits a post-internalisation mechanism leading to 
transduction in vitro.  The inhibition of transduction by FX was seen in CD46 
expressing cells but could potentially occur in vivo in non-CD46 transgenic animals 
as Ads are internalised into Kupffer cells by endocytosis (Zsengeller et al., 2000) in 
large numbers (Manickan et al., 2006).  If FX was bound to the vector containing the 
Ad35 fiber before internalisation, the presence of FX could inhibit subsequent 
intracellular trafficking mechanisms.  Sub-species B Ads remain in late endosomes 
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or lysosomes for long periods after infection and use these intracellular organelles 
for localisation with the nucleus (Shayakhmetov et al., 2003), unlike Ad5 which 
rapidly lyses the endosomal membrane and escapes into the cytosol (Seth, 1994b, 
Miyazawa et al., 2001).  As membrane-lytic activity is also required for Kupffer cell 
death (Smith et al., 2008), it is possible that it is the ability to lyse membranes which 
is reduced in Ad35 fiber-containing vectors.  Time lapse trafficking experiments and 
co-localisation with antibodies directed against a variety of intracellular organelles 
are required to fully investigate the differences in intracellular trafficking by vectors 
possessing the Ad35 fiber, in both the presence and absence of FX.  Additionally, it 
is currently unknown how long FX remains bound to either the Ad5 or Ad35 hexon.  
Therefore, trafficking experiments should also be performed with labelled FX to 
determine whether FX is internalised with the vectors and, if so, where in the 
intracellular pathways FX dissociates. 
In this study and others, vectors possessing the Ad35 fiber (Ad5/f35, Ad5/p35/f35 
and Ad35) showed lung transduction in CD46 transgenic mice but at varying levels 
(Sakurai et al., 2006a, Verhaagh et al., 2006, Stone et al., 2007a).  The CD46 
transgenic mice expressed both BC and C isoforms of CD46 (Sakurai et al., 2006a, 
Verhaagh et al., 2006, Stone et al., 2007a).  Another study showed much lower 
levels of lung transduction by Ad5/f35 (Ni et al., 2006).  The CD46 transgenic mice 
used only expressed the C1 isoform of CD46 (Ni et al., 2006), possibly suggesting 
that the interaction between the Ad35 fiber and the BC1 isoform results in enhanced 
lung transduction.  However, the mechanism of lung infection by vectors with the 
Ad35 fiber remains unclear.  Human CD46 is primarily expressed on the basolateral 
surface of polarised epithelial cells (Ichida et al., 1994, Maisner et al., 1997).  
Therefore, vectors which use CD46 as their receptor need to surmount anatomical 
barriers, such as tight junctions between cells and the extracellular matrix.  Further 
investigation into the mechanism of Ad35 infection is required, in both the presence 
and absence of FX. 
Sub-species B Ads are primarily in development for cancer gene therapy as CD46 is 
up-regulated in many cancers (Kinugasa et al., 1999, Murray et al., 2000, Ni et al., 
2006).  Ad5/f35 has been previously shown to selectively target liver metastases in 
vivo (Bernt et al., 2003).  However, the complex structure of tumours provides 
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another anatomical barrier which limits the accessibility of vectors.  In particular, 
many tumours have a basement membrane which forms a network through the 
extracellular matrix.  Ad35-based vectors could provide a dual approach to cancer 
gene therapy as they have not only shown tumour targeting but the Ad35 knob 
protein also binds to ECs of tumour feeding blood vessels but not to blood vessels 
present in non-malignant tissues (Ni et al., 2006).  This can occur due to the 
expression of different surface markers in neoangiogenic vasculature compared to 
tissue blood vessels (Arap et al., 2002). 
The interaction with FX could play a significant role in the design of future gene 
therapy vectors.  This study suggests that a certain degree of lung targeting by 
Ad5/p35/f35 in CD46 transgenic mice was determined by the interaction of this 
vector with FX as the lung:liver ratio for Ad5/p35/f35 was reduced in the presence 
of X-bp.  Although the lung:liver ratio produced by Ad5/f35 was the same in the 
presence and absence of X-bp, indicating that the addition of X-bp had no effect on 
retargeting Ad5/f35.  Ad5/f35 and Ad5/p35/f35 demonstrated the highest levels of 
selective lung targeting in the presence of FX, causing them to be good candidates 
for development into gene therapy vectors.  However, as both Ad5/f35 and 
Ad5/p35/f35 possess the Ad5 hexon, these vectors will be susceptible to anti-Ad5 
antibodies which are present in a high percentage of the population (Christ et al., 
1997, Seshidhar Reddy et al., 2003, Sprangers et al., 2003, Vogels et al., 2003, 
Sumida et al., 2005, Abbink et al., 2007, Parker et al., 2009).  The resulting 
neutralisation of these vectors in vivo would lead to very low levels of transduction 
after systemic administration and hinder their use as gene therapy vectors. 
Importantly, Ad35 had an increased lung:liver ratio in the presence of X-bp, 
indicating retargeting of this vector to the lung in the absence of the interaction with 
FX.  X-bp could be replaced by a small molecule screen which is more 
pharmaceutically and therapeutically relevant.  Vectors based on Ad35 have the 
potential for reduced immune reactions.  Even though the sub-species B Ads have 
been isolated frequently from immunocompromised patients (De Jong et al., 1999) 
and though the immune system is suppressed in cancer patients, only 31% of Dutch 
cancer patients possessed neutralising antibodies against Ad35 (Brouwer et al., 
2007).  Other studies have shown that the typical seroprevalence of neutralising 
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antibodies to Ad35 is between zero (Vogels et al., 2003) and 17% (Abbink et al., 
2007).  This is significantly lower than the Ad5 seroprevalence, which ranges from 
66% of cancer patients having neutralising antibodies to Ad5 (Brouwer et al., 2007), 
to nearly 80% of healthy people (Vogels et al., 2003), to 100% of the population 
(Abbink et al., 2007).  This suggests that vectors based on the Ad35 hexon would 
induce fewer immune reactions after gene therapy.  To overcome the significant 
problem of the high seroprevalence of Ad neutralising antibodies, there are many 
Ads from other species (Jager and Ehrhardt, 2007).  These viruses could be 
developed into gene vectors which have relevance to human gene therapy and 
especially vaccine development. 
In summary, this thesis has shown that the selective targeting of an anti-oxidant 
peptide to the vasculature has led to a significant enhancement in the efficacy and 
verified that inhibition of vascular NAD(P)H oxidase is a clinically relevant target.  
Administration of a variety of Ad35-based vectors has led to increased 
understanding of the requirements needed for the generation of a successfully 
targeted vector based on Ad35, which has potential as a vector for cancer gene 
therapy.  Currently in the UK, there is an approved phase I clinical trial for cancer 
gene therapy using intravenous delivery of Ad5/f35 at high doses 
(http://www.dh.gov.uk/ab/GTAC/index.htm).  However, the work presented here 
suggests important issues which may impact on the effectiveness of this strategy. 
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